Lactams as CBL-B inhibitors selective against C-CBL

Compounds of formula (I) selectively inhibit Cbl-b, addressing the need for targeted immune regulation and enhancing antitumor responses by selectively inhibiting Cbl-b, thereby improving cancer immunotherapy.

JP2024542117APending Publication Date: 2024-11-13GENENTECH INC
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2024526722
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-05
Filing Date
2022-11-04
Publication Date
2024-11-13

AI Technical Summary

Technical Problem

There is a need for compounds that selectively inhibit Cbl-b while avoiding the non-selective inhibition of closely related family members like c-Cbl, which are crucial for regulating receptor signaling and immune activation, particularly in cancer immunotherapy.

Method used

Development of compounds represented by formula (I) that selectively inhibit Cbl-b by binding to specific domains, allowing for targeted regulation of immune activation and antitumor responses.

Benefits of technology

The compounds provide selective inhibition of Cbl-b, enhancing immune activation and antitumor immunity, offering potential therapeutic benefits for cancer treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024542117000001_ABST
    Figure 2024542117000001_ABST
Patent Text Reader

Abstract

A compound of formula (I): Compound TIFF2024542117000130.tif35170.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] Priority claims This application claims priority benefit of U.S. Provisional Patent Application No. 63 / 276,547, filed November 5, 2021, the entire contents of which are incorporated herein by reference.

[0002] TECHNICAL FIELD The technology described herein relates generally to inhibitors of Cbl-B that are selective over C-Cbl, and more particularly to methods of making and using the same. [Background technology]

[0003] The technology described herein generally relates to inhibitors of Cbl-B that are selective for C-Cbl. Casitas B-lineage lymphoma-b (Cbl-b) is a member of the Cbl family of RING E3 ubiquitin ligases. The general function of Cbl family proteins is negative regulation of receptor tyrosine kinase signaling. Because inhibition of Cbl-b leads to immune activation, it was predicted that Cbl-b inhibitors may be broadly active in multiple oncological indications.

[0004] Cbl proteins contain three major domains: a conserved N-terminal tyrosine kinase binding (TKB) domain, a short linker region, and a RING finger (RF) domain. The TKB domain, in turn, is composed of three subdomains: a four-helix bundle (4H), a calcium-binding domain with an EF handfold, and a variant Src homology region 2 (SH2) domain, all three of which are involved in phosphotyrosine binding. The TKB domain binds to substrates containing phosphotyrosine motifs, such as ZAP70.

[0005] The conserved RF domain, which has intrinsic E3 ligase activity, can recruit E2 ubiquitin-conjugating enzymes and mediate the transfer of ubiquitin to substrates.

[0006] Phosphorylation of Cbl-b at Y363 within the linker domain regulates its E3 ubiquitin ligase activity by unmasking the RF domain by the TKB domain.

[0007] In T cells, Cbl-b is a key tolerogenic factor that directly controls cell activation. Specifically, Cbl-b is highly expressed in mouse and human CD4+ and CD8+ T cells and functions as a potent negative regulator of T cell activation by controlling the activation threshold and the need for costimulation. Mechanistically, Cbl-b acts by ubiquitinating multiple substrates downstream of the T cell receptor (TCR), including ZAP70, leading to TCR internalization and termination of signaling. Loss of Cbl-b in T cells results in prolonged TCR surface expression, which, in combination with TCR stimulation, leads to the expression of activation markers such as CD25, increased cytokine production, and increased proliferation.

[0008] Mouse models surprisingly demonstrated that Cbl-b deficiency results in increased adaptive and innate antitumor immunity mediated by enhanced T cell effector function and increased natural killer (NK) cell activity. Cbl-b-deficient mice spontaneously reject a variety of cancer tumors, including spontaneous solid tumors and hematopoietic malignancies, in a CD8+ T cell-dependent manner. Adoptive transfer of Cbl-b- / - CD8+ T cells is sufficient to reject tumors, demonstrating that Cbl-b has a nonredundant role in regulating T cell-mediated antitumor activity.

[0009] As a result, developing small molecule approaches to inhibit Cbl-b is a promising but challenging goal for cancer immunotherapy.

[0010] Nevertheless, c-Cbl, a closely related family member of Cbl-b, shares high sequence homology with Cbl-b in the N-terminus, including the TKB and RING domains. c-Cbl negatively regulates the signaling of multiple growth factor receptors, including Flt3 and c-Kit. Among other defects, c-Cbl-deficient mice exhibit an expansion of hematopoietic stem cells and multipotent progenitor cells in the bone marrow. This defect is amplified in mice conditionally deficient in both c-Cbl and Cbl-b, and by approximately 8 weeks of age, the mice develop a rapidly progressive and fatal myeloproliferative disorder accompanied by splenomegaly. Given the broad range of functions of c-Cbl in growth factor receptor regulation and the potent amplification of dysregulation of these pathways in the absence of both c-Cbl and Cbl-b, compounds with selectivity for Cbl-b over c-Cbl are considered highly desirable as cancer immunotherapeutic agents.

[0011] Therefore, there is a need for compounds that inhibit Cbl-b and exhibit selectivity for binding to c-Cbl.

[0012] The background discussion herein is included to explain the context of the present technology and should not be construed as an admission that any of the material referred to was published, known, or part of the common general knowledge as of the priority date of any of the claims herein.

[0013] Throughout the description and claims of this application, the word "comprise" and its variations such as "comprising" and "comprises" are not intended to exclude other additives, components, integers or steps. Summary of the Invention

[0014] The present disclosure is directed to compounds for inhibiting Cbl-B receptors that are also selective for C-Cbl receptors. In particular, the present disclosure includes a number of such compounds and methods for their use.

[0015] The present disclosure provides a compound of formula (I): Provides the compound TIFF2024542117000002.tif35170.

[0016] In formula (I), Q is a 5-membered heteroaryl group optionally substituted with one or more alkyl, cycloalkyl, or haloalkyl groups.

[0017] In formula (I), Y1 and Y2 are independently CH, CF, or N.

[0018] In formula (I), J is C(R3)(R4), where R3 and R4 are independently H, halogen, CN, OH, amino, and LR. 2a L is O, NR, CHR, C(=O), or a bond; R is H or alkyl; and R 2a is selected from alkyl, alkenyl, alkynyl, alkylcarboxy, cyanoalkyl, aminoalkyl, hydroxyalkyl, haloalkyl, and a 3- to 14-membered ring moiety, and at least one of R3 and R4 is not H; or R3 and R4 together with the carbon atom to which they are both attached form a 3- to 14-membered ring moiety: When R3 or R4 is alkyl, haloalkyl, or hydroxyalkyl, R3 or R4 may be substituted with a 3- to 14-membered ring moiety; When R3 or R4 is or is substituted with a 3- to 14-membered ring moiety, R3 and R4 together are a 3- to 14-membered ring moiety, and the ring moiety is selected from monocyclic rings, fused bicyclic ring systems, bridged bicyclic ring systems, and spirocyclic ring systems; The ring part is: Halogen, CN, amino, oxo, carbenyl, OH, or L0R 2b and L is CH, C(=O), NH, O, S, S(=O), S(=O) or a bond; and R 2bis alkyl, cycloalkyl, heterocyclyl, alkenyl, alkoxy, hydroxyalkyl, haloalkyl, cyanoalkyl, and aminoalkyl; is saturated or contains 1 or 2 endocyclic double bonds or is aryl; is carbocyclic, heterocyclic, or heteroaryl; and The ring moiety, when heterocyclic or heteroaryl, contains 1, 2, or 3 ring atoms independently selected from O, N, and S; R5 is H, halo, or L1-R 10 and L1 is selected from -N(R 11 )-, -C(=O)N(R 11 )-, O, S, carbonyl, or a bond, and R 10 and R 11 are independently H, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl; R 10 and R 11 When either of these is not H, R 10 or R 11 is optionally substituted with one or more groups selected from halo, CN, amino, oxo, OH, alkoxy, alkyl, perhaloalkyl, haloalkyl, heterocyclyl, aryl, and heteroaryl, or R 10 and R 11 together form a cycloalkyl or heterocyclyl ring, a spirocyclic ring, a fused bicyclic ring, or a bridged bicyclic ring; R 10 and R 11 taken together to form a ring may be substituted with one or more groups selected from halo, CN, amino, oxo, carbenyl, OH, alkoxy, alkyl, perhaloalkyl, or haloalkyl; R1 is H, halo, haloalkyl, or cycloalkyl; Z is -L 2a NR7R8 or -L 2b CyN-R7: CyN is a 3-8 membered cycloaminoalkyl ring and R7 is attached to N; L 2a Ha-C(H)R 6a -, -C(=O)-, or a bond; L 2b is -O-, -N(R 6b )-, -C(H)R 6b -, -C(=O)-, or a bond; R 6a =H, alkyl, cycloalkyl, haloalkyl, or hydroxyalkyl; R 6b =H or alkyl; R7 and R8 are independently L3R9; L3=-(C(H)R 10 ) n -, -(C(H)R 10 ) n O- or a bond, and n=1 or 2; R 10 is selected from H and alkyl; R9 is selected from H, alkyl, haloalkyl, perhaloalkyl, hydroxyalkyl, aminoalkyl, cycloalkyl, hydroxyalkyl, alkoxyalkyl, alkylalkanoate, heterocyclyl, spirocyclyl ring systems, fused ring systems, bicyclic ring systems, 5- or 6-membered aromatic heterocycles, or 3-10 membered fused aromatic heterocycles, and bridged bicyclic rings; When Z=CyN-R7, or when R7 or R8 is a cycloalkyl, heterocyclyl, spirocyclyl, fused bicyclic, bridged bicyclic ring, 5- or 6-membered aromatic heterocycle, or 3-10-membered fused aromatic heterocyclic ring system, said ring or ring system or CyN may be optionally substituted with one or more groups selected from sulfonyl, halo, hydroxyl, alkoxy, alkyl, cycloalkyl, alkoxyalkyl, carbenyl, alkenyl, hydroxyalkyl, cyano, carboxyalkyl, or haloalkyl; or R7 and R8 together with the nitrogen atom to which they are both attached form a 3-8 membered ring moiety selected from monocyclic rings, fused bicyclic rings, bridged bicyclic rings, and spirocyclic rings, the ring moiety being: optionally substituted with one or more groups independently selected from sulfonyl, cyano, halo, hydroxyl, alkoxy, alkyl, cycloalkyl, alkoxyalkyl, alkenyl, hydroxyalkyl, oxo, carbenyl, carboxyalkyl, or haloalkyl; The ring moiety contains, in addition to the nitrogen atom to which R7 and R8 are attached, one or more ring atoms selected from N, O, and S; provided that when both Y1 and Y2 are CH, R5 = H, X = CF3, and Q is 2-methyltriazol-1-yl: When R7 and R8, together with the nitrogen atom to which they are both attached, form a 3-substituted-cyclohexaminyl, R3 and R4, together, are not cyclobutyl, oxetan-4-yl, spiro[2.3]hexan-5-yl, or 3-substituted cyclobutyl, or J is not C(H)(3-substituted cyclobutyl); When R7 and R8, together with the nitrogen atom to which they are both attached, form a 3-substituted morpholinyl, then R3 and R4, together, are not 3-substituted cyclobutyl or spiro[2.3]hexan-5-yl, or J is not C(H)(3-substituted cyclobutyl).

[0019] Also included are enantiomers, diastereomers, or pharmaceutically acceptable salts or solvates of the structures of formula (I).

[0020] The present disclosure includes methods for making compounds of formula (I), particularly according to any of the synthetic methods disclosed herein.

[0021] The present disclosure further includes methods of treatment comprising administering a compound of formula (I), optionally in combination with another agent, such as a checkpoint inhibitor, to a patient suffering from cancer.

[0022] The present disclosure further includes the use of compounds of formula (I), optionally in combination with another agent, such as a checkpoint inhibitor, for the treatment of cancer in individuals afflicted with certain cancers.

[0023] The present disclosure further includes the use of a compound of formula (I) for the manufacture of a medicament for treating certain cancers, said medicament may contain and / or be administered with one or more other active agents. [Brief explanation of the drawings]

[0024] [Figure 1] FIG. 1 shows a flow diagram of a method for synthesizing intermediate A used in the synthesis of compounds of formula (I), as further described herein. [Figure 2] FIG. 1 shows a flow diagram of a method for synthesizing intermediate A used in the synthesis of compounds of formula (I), as further described herein. [Figure 3] FIG. 1 shows a flow diagram of a method for synthesizing intermediate B used in the synthesis of compounds of formula (I), as further described herein. [Figure 4] FIG. 1 shows a flow diagram of a method for synthesizing intermediate C used in the synthesis of compounds of formula (I), as further described herein. [Figure 5] FIG. 1 shows a flow diagram of a method for synthesizing intermediate D used in the synthesis of compounds of formula (I), as further described herein. [Figure 6] 1 shows a flow diagram of a method for synthesizing intermediate D used in the synthesis of compounds of formula (I), as further described herein. [Figure 7] FIG. 1 shows a flow diagram of a method for synthesizing intermediate E used in the synthesis of compounds of formula (I), as further described herein. [Figure 8] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 9] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 10] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 11]1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 12] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 13] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 14] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 15] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 16] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 17] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 18] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 19] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 20] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 21] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 22] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 23] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 24]1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 25] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 26] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 27] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 28] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 29] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 30] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 31] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 32] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 33] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 34] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 35] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 36] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 37]1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 38] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 39] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 40] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 41] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 42] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 43] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 44] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 45] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 46] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 47] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 48] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 49] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 50]1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 51] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 52] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 53] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 54] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 55] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 56] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 57] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 58] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 59] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 60] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 61] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 62] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 63]1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 64] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 65] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 66] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 67] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 68] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 69] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 70] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 71] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 72] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 73] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 74] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 75] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 76]1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 77] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 78] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 79] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 80] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 81] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 82] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 83] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 84] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 85] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 86] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 87] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 88] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 89]1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 90] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 91] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 92] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 93] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 94] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 95] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 96] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 97] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 98] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 99] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 100] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 101] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 102]1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 103] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 104] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 105] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 106] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 107] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 108] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. [Figure 109] 1 shows a flow diagram of a method for synthesizing various exemplary compounds according to Formula (I), as further described herein. DETAILED DESCRIPTION OF THE INVENTION

[0025] The present disclosure is directed to compounds that bind to Cbl-b inhibitors and exhibit selectivity for C-Cbl. Methods for making such compounds, as well as assays for evaluating their potency and selectivity, as well as metabolic and permeability properties, are also described herein.

[0026] structure The present disclosure provides a compound of formula (I): Provides the compound TIFF2024542117000003.tif35170.

[0027] In the following description of substituents and variable positions in Formula (I), it is understood that at any position, any subset including all individual members of the list of possible substituents can be freely selected when describing preferred classes of compounds.

[0028] In formula (I), Q is a 5-membered heteroaryl group optionally substituted with one or more alkyl, cycloalkyl, or haloalkyl groups.

[0029] In formula (I), Y1 and Y2 are independently CH, CF, or N.

[0030] In formula (I), J is C(R3)(R4), where R3 and R4 are independently H, halogen, CN, OH, amino, and LR. 2a L is O, NR, CHR, C(=O), or a bond; R is H or alkyl; and R 2a is selected from alkyl, alkenyl, alkynyl, alkylcarboxy, cyanoalkyl, aminoalkyl, hydroxyalkyl, haloalkyl, and a 3- to 14-membered ring moiety, and at least one of R3 and R4 is not H.

[0031] In formula (I), R3 and R4 together with the carbon atom to which they are both attached form a 3- to 14-membered ring moiety: When R3 or R4 is alkyl, haloalkyl, or hydroxyalkyl, R3 or R4 may be substituted with a 3- to 14-membered ring moiety; When R3 or R4 is or is substituted with a 3- to 14-membered ring moiety, R3 and R4 together are a 3- to 14-membered ring moiety, and the ring moiety is selected from monocyclic rings, fused bicyclic ring systems, bridged bicyclic ring systems, and spirocyclic ring systems; The ring part is: Halogen, CN, amino, oxo, carbenyl, OH, or L0R 2band L is CH, C(=O), NH, O, S, S(=O), S(=O) or a bond; and R 2b is alkyl, cycloalkyl, heterocyclyl, alkenyl, alkoxy, hydroxyalkyl, haloalkyl, cyanoalkyl, and aminoalkyl; is saturated or contains 1 or 2 endocyclic double bonds or is aryl; is carbocyclic, heterocyclic, or heteroaryl; and When a ring moiety is heterocyclic or heteroaryl, it contains 1, 2, or 3 ring atoms independently selected from O, N, and S.

[0032] In formula (I), R5 is H, halo, or L1-R 10 and L1 is selected from -N(R 11 )-, -C(=O)N(R 11 )-, O, S, carbonyl, or a bond, and R 10 and R 11 are independently H, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl; R 10 and R 11 When either of these is not H, R 10 or R 11 is optionally substituted with one or more groups selected from halo, CN, amino, oxo, OH, alkoxy, alkyl, perhaloalkyl, haloalkyl, heterocyclyl, aryl, and heteroaryl, or R 10 and R 11 together form a cycloalkyl or heterocyclyl ring, a spirocyclic ring, a fused bicyclic ring, or a bridged bicyclic ring; R 10 and R 11 The ring formed by taking together may be substituted with one or more groups selected from halo, CN, amino, oxo, carbenyl, OH, alkoxy, alkyl, perhaloalkyl, or haloalkyl.

[0033] In formula (I), R1 is H, halo, haloalkyl, or cycloalkyl.

[0034] In formula (I), Z is -L 2a NR7R8 or -L 2b CyN-R7: CyN is a 3-8 membered cycloaminoalkyl ring and R7 is attached to N; L 2a Ha-C(H)R 6a -, -C(=O)-, or a bond; L 2b is -O-, -N(R 6b )-, -C(H)R 6b -, -C(=O)-, or a bond; R 6a =H, alkyl, cycloalkyl, haloalkyl, or hydroxyalkyl; R 6b =H or alkyl; R7 and R8 are independently L3R9; L3=-(C(H)R 10 ) n -, -(C(H)R 10 ) n O- or a bond, and n=1 or 2; R 10 is selected from H and alkyl; R9 is selected from H, alkyl, haloalkyl, perhaloalkyl, hydroxyalkyl, aminoalkyl, cycloalkyl, hydroxyalkyl, alkoxyalkyl, alkylalkanoate, heterocyclyl, spirocyclyl ring systems, fused ring systems, bicyclic ring systems, 5- or 6-membered aromatic heterocycles, or 3-10 membered fused aromatic heterocycles, and bridged bicyclic rings; When Z=CyN-R7, or when R7 or R8 is a cycloalkyl, heterocyclyl, spirocyclyl, fused bicyclic, bridged bicyclic ring, 5- or 6-membered aromatic heterocycle, or 3-10-membered fused aromatic heterocyclic ring system, said ring or ring system or CyN may be optionally substituted with one or more groups selected from sulfonyl, halo, hydroxyl, alkoxy, alkyl, cycloalkyl, alkoxyalkyl, carbenyl, alkenyl, hydroxyalkyl, cyano, carboxyalkyl, or haloalkyl; or R7 and R8 together with the nitrogen atom to which they are both attached form a 3-8 membered ring moiety selected from monocyclic rings, fused bicyclic rings, bridged bicyclic rings, and spirocyclic rings, the ring moiety being optionally substituted with one or more groups independently selected from sulfonyl, cyano, halo, hydroxyl, alkoxy, alkyl, cycloalkyl, alkoxyalkyl, alkenyl, hydroxyalkyl, oxo, carbenyl, carboxyalkyl, or haloalkyl; The ring moiety may include, in addition to the nitrogen atom to which R7 and R8 are attached, one or more ring atoms selected from N, O, and S; provided that when both Y1 and Y2 are CH, R5 = H, X = CF3, and Q is 2-methyltriazol-1-yl: When R7 and R8, together with the nitrogen atom to which they are both attached, form a 3-substituted-cyclohexaminyl, R3 and R4, together, are not cyclobutyl, oxetan-4-yl, spiro[2.3]hexan-5-yl, or 3-substituted cyclobutyl, or J is not C(H)(3-substituted cyclobutyl); When R7 and R8, together with the nitrogen atom to which they are both attached, form a trisubstituted morpholinyl, then R3 and R4, together, are not trisubstituted cyclobutyl or spiro[2.3]hexan-5-yl, or J is not C(H)(trisubstituted cyclobutyl).

[0035] Also included are enantiomers, diastereomers, or pharmaceutically acceptable salts or solvates of the structures of formula (I).

[0036] The present disclosure includes compounds of Formula (I) where R5 is H or halogen.

[0037] The present disclosure includes compounds of formula (I) where R5 is selected from alkyl, alkoxy, alkylamino, cycloalkylamino, cycloalkyl, and cycloalkyloxy, any of which may be substituted with one or more groups independently selected from halo, alkyl, cyano, hydroxyl, amino, and alkoxy.

[0038] The present disclosure provides 1-6 Alkyl, C 1-6 Cycloalkyl, C 1-6 Alkylamino, C 1-6 Cycloalkylamino, C 1-6 Cycloalkyloxy, or C 1-6 Includes compounds of formula (I) which are alkoxy.

[0039] The present disclosure includes compounds of Formula (I) where R5 is cyclopentylamino or cyclopentyloxy.

[0040] This disclosure provides that R5 is L1-R 10 where L1 is a bond and R 10 Includes compounds of formula (I) wherein is heterocyclyl.

[0041] The present disclosure includes compounds of formula (I) where Y1 = Y2 = CH.

[0042] The present disclosure includes compounds of Formula (I) where Y1 = N.

[0043] The present disclosure includes compounds of formula (I) where R1 = CF3.

[0044] The present disclosure includes compounds of formula (I) where R1 = Cl.

[0045] The present disclosure includes compounds of Formula (I) where Q is 2-methyltriazol-1-yl, tetrazolyl, or imidazolyl.

[0046] The present disclosure includes compounds of Formula (I) where Q is 2-methyltriazol-1-yl.

[0047] The present disclosure includes compounds of formula (I) where Z is —C(H)R 6 NR 7 R 8 .

[0048] The present disclosure includes compounds of formula (I) where Z is —C(H)R 6 NR 7 R 8 : R6 is H or methyl; R3 and R8 together with the carbon atom to which they are both attached form a saturated monocyclic ring selected from piperidinyl and piperazinyl; The saturated monocyclic ring may be substituted with alkyl.

[0049] The present disclosure includes compounds of formula (I) where Z is —C(H)R 6 NR 7 R 8 : R6 is H or methyl; R7 is H; R8 is cyclobutyl optionally substituted with alkyl.

[0050] The present disclosure includes compounds of Formula (I) where R6 and R7 are H and R8 is 1-methylcyclobutyl.

[0051] The present disclosure includes compounds of formula (I) where Z is -C(H)R6NR7R8, R6, R7 is H, and R8 is spirocyclyl.

[0052] The present disclosure includes compounds of formula (I) wherein Z is —C(H)R 6 NR 7 R 8 , R 6 , R 7 is H, and R 8 is selected from isobutyl, 1,1-difluorospiro[2.3]hexan-5-yl, and 6,6-difluorobicyclo[3.1.0]hexan-3-yl.

[0053] The present disclosure includes compounds of Formula (I) where R6 is H or methyl.

[0054] The present disclosure includes compounds of Formula (I) where R7 and R8 together form a piperidinyl or piperazinyl ring.

[0055] The present disclosure includes compounds of Formula (I) where both R7 and R8 are H and R6 is alkyl.

[0056] The present disclosure includes compounds of Formula (I) where R7 and R8 together form a piperidinyl or piperazinyl ring substituted with a 2-isopropyl group.

[0057] The present disclosure includes compounds of formula (I) where Z is H.

[0058] The present disclosure includes compounds of formula (I) where R3 is H or OH and R4 is selected from cyclobut-1-amino, 3-oxetanyl, cyclopropyloxy, cyclobutyloxy, cyclopropyl, cyclobutyl, and methoxy, and R4 is optionally substituted with one or more groups selected from halo, alkyl, hydroxyl, and alkoxyl.

[0059] The present disclosure includes compounds of Formula (I) where R3 is H or OH and R4 is cyclobutyl, where R4 is optionally substituted with one or more groups selected from fluoro, methyl, and methoxy.

[0060] The present disclosure provides that R3 and R4, together with the carbon atom to which they are both attached, Includes compounds of formula (I) that form a 3-8 membered ring moiety selected from cyclobutyl, oxetanyl, cyclobutenyl, spiro[3.3]hept-2-yl, and 2-oxaspiro[3.]hept-6-yl, wherein the ring moiety is optionally substituted with one or more groups independently selected from halo, carbenyl, oxo, hydroxyl, cyano, alkyl, and alkoxy.

[0061] The present disclosure includes compounds of Formula (I) in which R3 and R4, together with the carbon atom to which they are both attached, form an oxetan-3-yl ring.

[0062] The present disclosure includes compounds of formula (I) where R3 and R4, together with the carbon atom to which they are both attached, form an oxetan-3-yl ring substituted with one or more instances of fluoro.

[0063] The present disclosure includes compounds of Formula (I) where R3 and R4, together with the carbon atom to which they are both attached, form a cyclobutyl ring.

[0064] The present disclosure includes compounds of Formula (I) in which R3 and R4, together with the carbon atom to which they are both attached, form a spirocyclic ring moiety having from 5 to 8 ring atoms.

[0065] The present disclosure includes compounds of formula (I) where R and R, together with the carbon atom to which they are both attached, form 2-oxaspiro[3.3]heptan-6-yl, 1-oxaspiro[3.3]heptan-6-yl, or 6-oxospiro[3.3]heptan-2-yl.

[0066] The present disclosure includes compounds of Formula (I) in which R3 and R4, together with the carbon atoms to which they are both attached, form a ring moiety that is substituted twice with fluoro.

[0067] The present disclosure includes compounds of formula (I) where R and R, together with the carbon atom to which they are both attached, form a cycloalkyl ring substituted with one or more instances of methyl, ethyl, methoxy, acetyl, chloro, fluoro, fluoromethyl, difluoromethoxy, trifluoromethoxy, methoxy-d, cyanomethyl, or cyano.

[0068] The present disclosure provides a method for treating a compound in which one of R3 and R4 is C 1-6 and the other is H.

[0069] The present disclosure includes a list of compounds of formula (I) as follows: In the list, the numerical order is arbitrary but will be used consistently herein: 1) (R)-2-(3-(cyclobutyl(hydroxy)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 2) (S)-2-(3-(cyclobutyl(hydroxy)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 3) 2-(6-ethoxy-4-((1s,3s)-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-yl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 4) 2-(6-ethoxy-4-((1r,3r)-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-yl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 5) 2-(6-(ethylamino)-4-((1s,3s)-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-yl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 6) 2-(6-(ethylamino)-4-((1r,3r)-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-yl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 7) 2-(6-(ethylamino)-4-(6-(4-methyl-4H-1,2,4-triazol-3-yl)-2-oxaspiro[3.3]heptan-6-yl)pyridin-2-yl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 8) 2-(6-(cyclopentylamino)-4-((1s,3s)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-yl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 9) 2-(6-(cyclopentylamino)-4-((1r,3r)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-yl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 10) 6-(((S)-2-isopropyl-4-methylpiperazin-1-yl)methyl)-2-(3-((R)-(4-methyl-4H-1,2,4-triazol-3-yl)(oxetan-3-yl)methyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 11) 6-(((S)-2-isopropyl-4-methylpiperazin-1-yl)methyl)-2-(3-((S)-(4-methyl-4H-1,2,4-triazol-3-yl)(oxetan-3-yl)methyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 12) 6-(((S)-2-isopropyl-4-methylpiperazin-1-yl)methyl)-2-(3-((R)-((1r,3R)-3-methoxycyclobutyl)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 13) 6-(((S)-2-isopropyl-4-methylpiperazin-1-yl)methyl)-2-(3-((R)-((1s,3S)-3-methoxycyclobutyl)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 14) 6-(((S)-2-isopropyl-4-methylpiperazin-1-yl)methyl)-2-(3-((S)-((1s,3R)-3-methoxycyclobutyl)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 15) 6-(((S)-2-isopropyl-4-methylpiperazin-1-yl)methyl)-2-(3-((S)-((1r,3S)-3-methoxycyclobutyl)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 16) 2-(6-cyclopropyl-4-(3,3-difluoro-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-yl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 17) 2-(4-(3,3-difluoro-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)-6-(ethylamino)pyridin-2-yl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 18) 2-(3-(1-(4-methyl-4H-1,2,4-triazol-3-yl)-3-methylenecyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 19) 2-(3-(1-(4-methyl-4H-1,2,4-triazol-3-yl)-3-oxocyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 20) 2-(3-((1r,3r)-3-hydroxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 21) 2-(3-((1s,3s)-3-hydroxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 22) 2-(3-((1s,3s)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 23) 2-(3-((1r,3r)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 24) (1r,3r)-3-(4-methyl-4H-1,2,4-triazol-3-yl)-3-(3-(6-(((1-methylcyclobutyl)amino)methyl)-1-oxo-4-(trifluoromethyl)isoindolin-2-yl)phenyl)cyclobutanecarbonitrile; 25) (1s,3s)-3-(4-methyl-4H-1,2,4-triazol-3-yl)-3-(3-(6-(((1-methylcyclobutyl)amino)methyl)-1-oxo-4-(trifluoromethyl)isoindolin-2-yl)phenyl)cyclobutanecarbonitrile; 26) 2-(3-((1s,3s)-3-hydroxy-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 27) (2-(3-((1r,3r)-3-hydroxy-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 28) 2-(3-((1r,3r)-3-methoxy-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 29) (2-(3-((1s,3s)-3-hydroxy-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 30) 2-(3-((1s,3s)-3-fluoro-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 31) 2-(3-((1r,3r)-3-fluoro-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 32) (S)-2-(3-(azetidin-1-yl(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 33) (R)-2-(3-(azetidin-1-yl(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 34) 2-(3-((1s,3s)-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 35) 2-(3-((1r,3r)-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 36) 2-(3-((1r,3r)-3-fluoro-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 37) (S)-6-(1-(cyclobutylamino)ethyl)-2-(3-(3,3-difluoro-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 38) (R)-6-(1-(cyclobutylamino)ethyl)-2-(3-(3,3-difluoro-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 39) 2-(3-(3,3-dimethyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 40) 2-(3-(2-(4-methyl-4H-1,2,4-triazol-3-yl)spiro[3.3]heptan-2-yl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 41) (S)-6-((2-isopropyl-4-methylpiperazin-1-yl)methyl)-2-(3-(6-(4-methyl-4H-1,2,4-triazol-3-yl)-2-oxaspiro[3.3]heptan-6-yl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 42) (R)-2-(3-(methoxy(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 43) (S)-2-(3-(methoxy(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 44) (S)-2-(3-(cyclopropoxy(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 45) (R)-2-(3-(cyclopropoxy(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 46) (S)-2-(3-(cyclobutoxy(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 47) (R)-2-(3-(cyclobutoxy(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 48) 2-(6-((3,3-difluorocyclobutyl)amino)-4-((1r,3r)-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-yl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 49) 2-(6-((3,3-difluorocyclobutyl)amino)-4-((1s,3s)-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-yl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 50) 2-(6-(cyclohexylamino)-4-((1r,3r)-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-yl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 51) 2-(6-(cyclohexylamino)-4-((1s,3s)-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-yl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 52) 2-(6-(cyclopentylamino)-4-((1r,3r)-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-yl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 53) 2-(6-(cyclopentylamino)-4-((1s,3s)-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-yl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 54) 2-(6-(cyclopentyloxy)-4-((1s,3s)-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-yl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 55) 2-(6-(cyclopentyloxy)-4-((1r,3r)-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-yl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 56) (S)-2-(3-((3,3-difluoroazetidin-1-yl)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 57) (R)-2-(3-((3,3-difluoroazetidin-1-yl)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 58) 2-(3-(3-(4-methyl-4H-1,2,4-triazol-3-yl)oxetan-3-yl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 59) 2-(4-(3,3-difluoro-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)-6-ethylpyridin-2-yl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 60) 2-(4-(3,3-difluoro-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)-6-methylpyridin-2-yl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 61) 2-(3-(3,3-difluoro-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 62) 2-(4-(3,3-difluoro-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)-6-(ethylamino)pyridin-2-yl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 63) (1S,3r)-3-(3-(6-(((S)-2-isopropyl-4-methylpiperazin-1-yl)methyl)-1-oxo-4-(trifluoromethyl)isoindolin-2-yl)phenyl)-3-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutanecarbonitrile; 64) (1R,3s)-3-(3-(6-(((S)-2-isopropyl-4-methylpiperazin-1-yl)methyl)-1-oxo-4-(trifluoromethyl)isoindolin-2-yl)phenyl)-3-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutanecarbonitrile; 65) 2-(3-(6-(4-methyl-4H-1,2,4-triazol-3-yl)-2-oxaspiro[3.3]heptan-6-yl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 66) (S)-2-(3-(6-(4-methyl-4H-1,2,4-triazol-3-yl)-2-oxaspiro[3.3]heptan-6-yl)phenyl)-6-((3-methylpiperidin-1-yl)methyl)-4-(trifluoromethyl)isoindolin-1-one; 67) 2-(6-(cyclobutylamino)-4-((1S,3S)-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-yl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 68) 2-(6-(cyclobutylamino)-4-((1R,3R)-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-yl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 69) 2-(6-(cyclopentylamino)-4-((1S,3S)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-yl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 70) 2-(6-(cyclopentylamino)-4-((1R,3R)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-yl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 71) 2-(6-(cyclobutylamino)-4-((S)-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobut-2-en-1-yl)pyridin-2-yl)-6-(((S)-2-isopropyl-4-methylpiperazin-1-yl)methyl)-4-(trifluoromethyl)isoindolin-1-one; 72) 2-(6-(cyclopentyloxy)-4-((1S,3R)-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-yl)-6-(((S)-2-isopropyl-4-methylpiperazin-1-yl)methyl)-4-(trifluoromethyl)isoindolin-1-one; 73) 2-(6-(cyclopentyloxy)-4-((1R,3S)-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-yl)-6-(((S)-2-isopropyl-4-methylpiperazin-1-yl)methyl)-4-(trifluoromethyl)isoindolin-1-one; 74) 2-(6-(cyclopentylamino)-4-((1S,3R)-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-yl)-6-(((S)-2-isopropyl-4-methylpiperazin-1-yl)methyl)-4-(trifluoromethyl)isoindolin-1-one; 75) 2-(6-(cyclopentylamino)-4-((1R,3S)-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-yl)-6-(((S)-2-isopropyl-4-methylpiperazin-1-yl)methyl)-4-(trifluoromethyl)isoindolin-1-one; 76) 2-(6-ethoxy-4-((1S,3S)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-yl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 77) 2-(6-ethoxy-4-((1R,3R)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-yl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 78) 2-(6-(cyclopentyloxy)-4-((1S,3S)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-yl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 79) 2-(6-(cyclopentyloxy)-4-((1R,3R)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-yl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 80) 2-(6-(ethylamino)-4-((1S,3S)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-yl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 81) 2-(6-(ethylamino)-4-((1R,3R)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-yl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 82) 2-(6-(cyclopentyloxy)-4-((1S,3R)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-yl)-6-(((S)-2-isopropyl-4-methylpiperazin-1-yl)methyl)-4-(trifluoromethyl)isoindolin-1-one; 83) 2-(6-(cyclopentyloxy)-4-((1R,3S)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-yl)-6-(((S)-2-isopropyl-4-methylpiperazin-1-yl)methyl)-4-(trifluoromethyl)isoindolin-1-one; 84) 2-(6-(cyclopentylamino)-4-((1S,3R)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-yl)-6-(((S)-2-isopropyl-4-methylpiperazin-1-yl)methyl)-4-(trifluoromethyl)isoindolin-1-one; 85) 2-(6-(cyclopentylamino)-4-((1R,3S)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-yl)-6-(((S)-2-isopropyl-4-methylpiperazin-1-yl)methyl)-4-(trifluoromethyl)isoindolin-1-one; 86) 3-((4-((1S,3S)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)-6-(6-(((1-methylcyclobutyl)amino)methyl)-1-oxo-4-(trifluoromethyl)isoindolin-2-yl)pyridin-2-yl)amino)propanenitrile; 87) 3-((4-((1R,3R)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)-6-(6-(((1-methylcyclobutyl)amino)methyl)-1-oxo-4-(trifluoromethyl)isoindolin-2-yl)pyridin-2-yl)amino)propanenitrile; 88) 2-((1s,3s)-3-(4-methyl-4H-1,2,4-triazol-3-yl)-3-(3-(6-(((1-methylcyclobutyl)amino)methyl)-1-oxo-4-(trifluoromethyl)isoindolin-2-yl)phenyl)cyclobutyl)acetonitrile; 89) 2-((1r,3r)-3-(4-methyl-4H-1,2,4-triazol-3-yl)-3-(3-(6-(((1-methylcyclobutyl)amino)methyl)-1-oxo-4-(trifluoromethyl)isoindolin-2-yl)phenyl)cyclobutyl)acetonitrile; 90) 2-(3-(ethylamino)-5-((1r,3r)-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 91) 2-(3-(ethylamino)-5-((1s,3s)-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 92) 2-(3-(2-(4-methyl-4H-1,2,4-triazol-3-yl)-6-oxospiro[3.3]heptan-2-yl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 93) 2-(3-(6-hydroxy-2-(4-methyl-4H-1,2,4-triazol-3-yl)spiro[3.3]heptan-2-yl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 94) 2-(3-(6,6-difluoro-2-(4-methyl-4H-1,2,4-triazol-3-yl)spiro[3.3]heptan-2-yl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 95) 2-(3-((1s,3s)-3-fluoro-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 96) 2-(3-(6-(4-methyl-4H-1,2,4-triazol-3-yl)-2-(2,2,2-trifluoroethyl)-2-azaspiro[3.3]heptan-6-yl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 97) 2-(3-(2-acetyl-6-(4-methyl-4H-1,2,4-triazol-3-yl)-2-azaspiro[3.3]heptan-6-yl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 98) 2-(3-(6-(4-methyl-4H-1,2,4-triazol-3-yl)-2-(methylsulfonyl)-2-azaspiro[3.3]heptan-6-yl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 99) 2-(3-((1s,3s)-3-(hydroxymethyl)-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one formate; 100) 2-(3-((1r,3r)-3-(hydroxymethyl)-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one formate; 101) 2-(3-((1r,3r)-3-(fluoromethyl)-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 102) 2-(3-((1s,3s)-3-(fluoromethyl)-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 103) 2-(3-((1s,3s)-3-(methoxymethyl)-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 104) 2-(3-((1r,3r)-3-(methoxymethyl)-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 105) 2-(3-((1r,3r)-3-fluoro-3-(fluoromethyl)-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 106) (S)-2-(3-(3,3-difluoro-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclopentyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 107) (R)-2-(3-(3,3-difluoro-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclopentyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 108) 2-(3-((4r,6r)-6-(4-methyl-4H-1,2,4-triazol-3-yl)-1-oxaspiro[3.3]heptan-6-yl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 109) 2-(3-((4s,6s)-6-(4-methyl-4H-1,2,4-triazol-3-yl)-1-oxaspiro[3.3]heptan-6-yl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 110) 2-(3-(3-(4-methyl-4H-1,2,4-triazol-3-yl)-1-(2,2,2-trifluoroethyl)azetidin-3-yl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 111) 2-(3-(3-(4-methyl-4H-1,2,4-triazol-3-yl)-1-(oxetan-3-yl)azetidin-3-yl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 112) 2-(3-(1-acetyl-3-(4-methyl-4H-1,2,4-triazol-3-yl)azetidin-3-yl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 113) 2-(3-(3-(4-methyl-4H-1,2,4-triazol-3-yl)-1-(methylsulfonyl)azetidin-3-yl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 114) (R)-2-(3-((4-methyl-4H-1,2,4-triazol-3-yl)(3-oxocyclobutyl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 115) (S)-2-(3-((4-methyl-4H-1,2,4-triazol-3-yl)(3-oxocyclobutyl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 116) 4-(difluoromethyl)-2-(3-((1s,3s)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)isoindolin-1-one; 117) 4-(difluoromethyl)-2-(3-((1r,3r)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)isoindolin-1-one; 118) (S)-2-(3-(cyclobutyl(methoxy)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 119) (R)-2-(3-(cyclobutyl(methoxy)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 120) 2-(3-((1s,3s)-3-hydroxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)-3-(trifluoromethyl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 121) (S)-2-(3-((4-methyl-4H-1,2,4-triazol-3-yl)(2-oxaspiro[3.3]heptan-6-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 122) (R)-2-(3-((4-methyl-4H-1,2,4-triazol-3-yl)(2-oxaspiro[3.3]heptan-6-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 123) 2-(3-((2R,4S)-4-methyl-2-(4-methyl-4H-1,2,4-triazol-3-yl)oxetan-2-yl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 124) 2-(3-((2R,4R)-4-methyl-2-(4-methyl-4H-1,2,4-triazol-3-yl)oxetan-2-yl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 125) 2-(3-((2S,4S)-4-methyl-2-(4-methyl-4H-1,2,4-triazol-3-yl)oxetan-2-yl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 126) 2-(3-((2S,4R)-4-methyl-2-(4-methyl-4H-1,2,4-triazol-3-yl)oxetan-2-yl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 127) 2-(3-((S)-((1r,3S)-3-fluorocyclobutyl)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 128) 2-(3-((S)-((1s,3R)-3-fluorocyclobutyl)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 129) 2-(3-((R)-((1r,3R)-3-fluorocyclobutyl)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 130) 2-(3-((R)-((1s,3S)-3-fluorocyclobutyl)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 131) 2-(3-((R)-((1r,3R)-3-methoxycyclobutyl)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 132) 2-(3-((R)-((1s,3S)-3-methoxycyclobutyl)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 133) 2-(3-((S)-((1r,3S)-3-methoxycyclobutyl)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 134) 2-(3-((S)-((1s,3R)-3-methoxycyclobutyl)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 135) (R)-2-(3-((5-methyl-1H-1,2,3-triazol-1-yl)(oxetan-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 136) (S)-2-(3-((5-methyl-1H-1,2,3-triazol-1-yl)(oxetan-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 137) 2-(3-((1r,3r)-3-chloro-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one hydrochloride; 138) 2-(3-((1s,3s)-3-chloro-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 139) (1R,3r)-3-((R)-(4-methyl-4H-1,2,4-triazol-3-yl)(3-(6-(((1-methylcyclobutyl)amino)methyl)-1-oxo-4-(trifluoromethyl)isoindolin-2-yl)phenyl)methyl)cyclobutane-1-carbonitrile; 140) (1S,3s)-3-((R)-(4-methyl-4H-1,2,4-triazol-3-yl)(3-(6-(((1-methylcyclobutyl)amino)methyl)-1-oxo-4-(trifluoromethyl)isoindolin-2-yl)phenyl)methyl)cyclobutane-1-carbonitrile; 141) (1R,3s)-3-((S)-(4-methyl-4H-1,2,4-triazol-3-yl)(3-(6-(((1-methylcyclobutyl)amino)methyl)-1-oxo-4-(trifluoromethyl)isoindolin-2-yl)phenyl)methyl)cyclobutane-1-carbonitrile; 142) (1S,3r)-3-((S)-(4-methyl-4H-1,2,4-triazol-3-yl)(3-(6-(((1-methylcyclobutyl)amino)methyl)-1-oxo-4-(trifluoromethyl)isoindolin-2-yl)phenyl)methyl)cyclobutane-1-carbonitrile; 143) (S)-2-(3-(hydroxy(4-methyl-4H-1,2,4-triazol-3-yl)(oxetan-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 144) (R)-2-(3-(hydroxy(4-methyl-4H-1,2,4-triazol-3-yl)(oxetan-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 145) 2-(3-((3,3-difluorocyclobutyl)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 146) (R)-2-(3-((3-hydroxyoxetan-3-yl)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 147) (S)-2-(3-((3-hydroxyoxetan-3-yl)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 148) (R)-6-(2-hydroxy-1-((1-methylcyclobutyl)amino)ethyl)-2-(3-(1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 149) (S)-6-(2-hydroxy-1-((1-methylcyclobutyl)amino)ethyl)-2-(3-(1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 150) (R)-2-(3-(fluoro(4-methyl-4H-1,2,4-triazol-3-yl)(oxetan-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 151) (S)-2-(3-(fluoro(4-methyl-4H-1,2,4-triazol-3-yl)(oxetan-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 152) (R)-2-(3-fluoro-5-((4-methyl-4H-1,2,4-triazol-3-yl)(oxetan-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 153) (S)-2-(3-fluoro-5-((4-methyl-4H-1,2,4-triazol-3-yl)(oxetan-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 154) (S)-2-(3-(hydroxy(4-methyl-4H-1,2,4-triazol-3-yl)(phenyl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 155) (R)-2-(3-(hydroxy(4-methyl-4H-1,2,4-triazol-3-yl)(phenyl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 156) (S)-2-(3-(fluoro(4-methyl-4H-1,2,4-triazol-3-yl)(phenyl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 157) (R)-2-(3-(fluoro(4-methyl-4H-1,2,4-triazol-3-yl)(phenyl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 158) (R)-4-chloro-2-(3-((4-methyl-4H-1,2,4-triazol-3-yl)(phenyl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)isoindolin-1-one; 159) (S)-4-chloro-2-(3-((4-methyl-4H-1,2,4-triazol-3-yl)(phenyl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)isoindolin-1-one; 160) 2-(3-((1S,3r)-1-(4-methyl-4H-1,2,4-triazol-3-yl)-3-((S)-methylsulfinyl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 161) 2-(3-((1S,3s)-1-(4-methyl-4H-1,2,4-triazol-3-yl)-3-((R)-methylsulfinyl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 162) 2-(3-((1R,3s)-1-(4-methyl-4H-1,2,4-triazol-3-yl)-3-((S)-methylsulfinyl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 163) 2-(3-((1R,3r)-1-(4-methyl-4H-1,2,4-triazol-3-yl)-3-((R)-methylsulfinyl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 164) (R)-2-(3-((4-methyl-4H-1,2,4-triazol-3-yl)(oxetan-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 165) (S)-2-(3-((4-methyl-4H-1,2,4-triazol-3-yl)(oxetan-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 166) 2-(3-((2R)-2-(methoxymethyl)-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclopropyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 167) 2-(3-((2S)-2-(methoxymethyl)-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclopropyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 168) 2-(3-((R)-(4-methyl-4H-1,2,4-triazol-3-yl)((S)-tetrahydrofuran-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 169) 2-(3-((S)-(4-methyl-4H-1,2,4-triazol-3-yl)((R)-tetrahydrofuran-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 170) (R)-2-(3-(1-(4-methyl-4H-1,2,4-triazol-3-yl)ethyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 171) 2-(3-(1-(4-methyl-4H-1,2,4-triazol-3-yl)ethyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 172) 6-(((S)-2-Isopropyl-4-methylpiperazin-1-yl)methyl)-2-(3-((1s,3R)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 173) (S)-2-(3-(3,3-difluoro-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(1-((1-methylcyclobutyl)amino)ethyl)-4-(trifluoromethyl)isoindolin-1-one; 174) (R)-2-(3-(3,3-difluoro-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(1-((1-methylcyclobutyl)amino)ethyl)-4-(trifluoromethyl)isoindolin-1-one; 175) 2-(3-((1s,3S)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-((R)-1-((1-methylcyclobutyl)amino)ethyl)-4-(trifluoromethyl)isoindolin-1-one; 176) 2-(3-((1s,3R)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-((S)-1-((1-methylcyclobutyl)amino)ethyl)-4-(trifluoromethyl)isoindolin-1-one; 177) 2-(3-(cyclopentylamino)-5-((1s,3s)-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 178) 2-(3-((1s,3s)-3-ethoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 179) 2-(3-((1r,3r)-3-ethoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 180) 6-(((S)-2-isopropyl-4-methylpiperazin-1-yl)methyl)-2-(3-((1r,3S)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 181) 2-(3-ethoxy-5-((1s,3s)-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 182) 2-(4-(3,3-difluoro-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)-6-ethoxypyridin-2-yl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 183) 2-(3-(cyclopentylamino)-5-((1r,3r)-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 184) 2-(3-((1r,3R)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-((R)-1-((1-methylcyclobutyl)amino)ethyl)-4-(trifluoromethyl)isoindolin-1-one; 185) 2-(3-((1r,3S)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-((S)-1-((1-methylcyclobutyl)amino)ethyl)-4-(trifluoromethyl)isoindolin-1-one; 186) 2-(3-(cyclopentyloxy)-5-((1s,3s)-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 187) 3-((4-(6-(4-methyl-4H-1,2,4-triazol-3-yl)-2-oxaspiro[3.3]heptan-6-yl)-6-(6-(((1-methylcyclobutyl)amino)methyl)-1-oxo-4-(trifluoromethyl)isoindolin-2-yl)pyridin-2-yl)amino)propanenitrile; 188) 2-(6-(cyclopentylamino)-4-(6-(4-methyl-4H-1,2,4-triazol-3-yl)-2-oxaspiro[3.3]heptan-6-yl)pyridin-2-yl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 189) 2-(3-ethoxy-5-((1r,3r)-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 190) 2-(3-((1s,3s)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 191) 2-(3-(6-(4-methyl-4H-1,2,4-triazol-3-yl)-2-oxaspiro[3.3]heptan-6-yl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 192) (R)-3-((4-(6-(4-methyl-4H-1,2,4-triazol-3-yl)-2-oxaspiro[3.3]heptan-6-yl)-6-(6-(((1-methylcyclobutyl)amino)methyl)-1-oxo-4-(trifluoromethyl)isoindolin-2-yl)pyridin-2-yl)amino)butanenitrile; 193) (R)-3-((4-(6-(4-methyl-4H-1,2,4-triazol-3-yl)-2-oxaspiro[3.3]heptan-6-yl)-6-(6-(((1-methylcyclobutyl)amino)methyl)-1-oxo-4-(trifluoromethyl)isoindolin-2-yl)pyridin-2-yl)amino)butanenitrile; 194) (S)-3-((4-(6-(4-methyl-4H-1,2,4-triazol-3-yl)-2-oxaspiro[3.3]heptan-6-yl)-6-(6-(((1-methylcyclobutyl)amino)methyl)-1-oxo-4-(trifluoromethyl)isoindolin-2-yl)pyridin-2-yl)amino)butanenitrile; 195) 2-(3-(cyclopentyloxy)-5-((1r,3r)-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 196) 2-(3-((1r,3r)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 197) 4-(difluoromethyl)-2-(3-(6-(4-methyl-4H-1,2,4-triazol-3-yl)-2-oxaspiro[3.3]heptan-6-yl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)isoindolin-1-one; 198) (S)-4-(Difluoromethyl)-6-((2-isopropyl-4-methylpiperazin-1-yl)methyl)-2-(3-(6-(4-methyl-4H-1,2,4-triazol-3-yl)-2-oxaspiro[3.3]heptan-6-yl)phenyl)isoindolin-1-one formate; 199) 2-(3-(6-(4-methyl-4H-1,2,4-triazol-3-yl)-2-(oxetan-3-yl)-2-azaspiro[3.3]heptan-6-yl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 200) 2-(3-methoxy-5-((1s,3s)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 201) 2-(3-methoxy-5-((1r,3r)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 202) 2-(3-ethoxy-5-((1r,3r)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 203) 2-(3-ethoxy-5-((1s,3s)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 204) (S)-4-chloro-6-((2-isopropyl-4-methylpiperazin-1-yl)methyl)-2-(3-(6-(4-methyl-4H-1,2,4-triazol-3-yl)-2-oxaspiro[3.3]heptan-6-yl)phenyl)isoindolin-1-one; 205) 2-(3-(allyloxy)-5-((1s,3s)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 206) 2-(3-isopropoxy-5-((1s,3s)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 207) 2-(3-isopropoxy-5-((1r,3r)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 208) 2-(3-(cyclopentyloxy)-5-((1s,3s)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 209) 2-(3-(cyclopentylamino)-5-((1r,3r)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 210) 2-(3-(ethylamino)-5-((1r,3r)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 211) 2-(3-(cyclobutylamino)-5-((1r,3r)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 212) 2-(3-(cyclopentyloxy)-5-((1r,3r)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 213) 2-(3-((R)-but-3-en-2-yloxy)-5-((1s,3S)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 214) 2-(3-(cyclopropylamino)-5-((1r,3r)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 215) 2-(3-(isopropylamino)-5-((1r,3r)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 216) 3-((3-((1r,3r)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)-5-(6-(((1-methylcyclobutyl)amino)methyl)-1-oxo-4-(trifluoromethyl)isoindolin-2-yl)phenyl)amino)propanenitrile; 217) 2-(3-(cyclobutylamino)-5-((1s,3s)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 218) 2-(3-(cyclopentylamino)-5-((1s,3s)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 219) 2-(3-((R)-but-3-en-2-ylamino)-5-((1r,3R)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 220) 2-(3-((S)-but-3-en-2-ylamino)-5-((1r,3S)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 221) (R)-3-((3-((1r,3R)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)-5-(6-(((1-methylcyclobutyl)amino)methyl)-1-oxo-4-(trifluoromethyl)isoindolin-2-yl)phenyl)amino)butanenitrile; 222) 2-(3-((1s,3s)-3-isopropoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 223) 2-(3-(isopropylamino)-5-((1s,3s)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 224) 3-((3-((1s,3s)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)-5-(6-(((1-methylcyclobutyl)amino)methyl)-1-oxo-4-(trifluoromethyl)isoindolin-2-yl)phenyl)amino)propanenitrile; 225) (S)-3-((3-((1r,3S)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)-5-(6-(((1-methylcyclobutyl)amino)methyl)-1-oxo-4-(trifluoromethyl)isoindolin-2-yl)phenyl)amino)butanenitrile; 226) 2-(3-cyclopropyl-5-((1r,3r)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 227) 2-(3-(ethylamino)-5-((1s,3s)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 228) (R)-3-((3-((1s,3S)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)-5-(6-(((1-methyl-cyclobutyl)amino)methyl)-1-oxo-4-(trifluoromethyl)isoindolin-2-yl)phenyl)amino)butanenitrile; 229) 2-(3-(6-methoxy-2-(4-methyl-4H-1,2,4-triazol-3-yl)spiro[3.3]heptan-2-yl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 230) 2-(3-((1r,3r)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)-5-methylphenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 231) 2-(3-(cyclopropylamino)-5-((1s,3s)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 232) 2-(3-(allylamino)-5-((1r,3r)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 233) (S)-3-((3-((1s,3R)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)-5-(6-(((1-methylcyclobutyl)amino)methyl)-1-oxo-4-(trifluoromethyl)isoindolin-2-yl)phenyl)amino)butanenitrile; 234) 2-(3-((1r,3r)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)-5-(oxetan-3-ylamino)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 235) 2-(3-ethyl-5-((1s,3s)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 236) 2-(3-ethyl-5-((1r,3r)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 237) 2-(3-((1s,3s)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)-5-methylphenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 238) 2-(3-((1s,3s)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)-5-(methylamino)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 239) 2-(3-((1r,3r)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)-5-(methylamino)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 240) 2-(3-(allylamino)-5-((1s,3s)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 241) 2-(3-((1s,3s)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)-5-(oxetan-3-yloxy)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 242) 2-(3-((1r,3r)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)-5-(oxetan-3-yloxy)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 243) 2-(3-((1s,3s)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)-5-(oxetan-3-ylamino)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 244) (S)-2-(3-(1-(4-methyl-4H-1,2,4-triazol-3-yl)-2-(oxetan-3-yl)ethyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 245) (R)-2-(3-(1-(4-methyl-4H-1,2,4-triazol-3-yl)-2-(oxetan-3-yl)ethyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 246) 4-chloro-2-(3-((1s,3s)-3-fluoro-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)isoindolin-1-one; 247) 4-(difluoromethyl)-2-(3-((1s,3s)-3-fluoro-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)isoindolin-1-one; 248) (S)-2-(3-(2-cyclopentyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)ethyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 249) (R)-2-(3-(2-cyclopentyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)ethyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 250) (R)-2-(3-(cyclohexyl(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 251) (S)-2-(3-(cyclohexyl(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 252) (R)-2-(3-(1-(4-methyl-4H-1,2,4-triazol-3-yl)-2-(tetrahydro-2H-pyran-4-yl)ethyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 253) (S)-2-(3-(1-(4-methyl-4H-1,2,4-triazol-3-yl)-2-(tetrahydro-2H-pyran-4-yl)ethyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 254) (R)-2-(3-(1-(4-methyl-4H-1,2,4-triazol-3-yl)-2-(3-methyloxetan-3-yl)ethyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 255) (S)-2-(3-(1-(4-methyl-4H-1,2,4-triazol-3-yl)-2-(3-methyloxetan-3-yl)ethyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 256) (R)-2-(3-(cyclopentyl(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 257) (S)-2-(3-(cyclopentyl(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 258) (R)-2-(3-(cyclobutyl(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 259) (S)-2-(3-(cyclobutyl(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 260) 2-(3-((R)-((1r,3R)-3-(2,2-difluoroethoxy)cyclobutyl)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 261) 2-(3-((R)-((1s,3S)-3-(2,2-difluoroethoxy)cyclobutyl)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 262) 2-(3-((S)-((1s,3R)-3-(2,2-difluoroethoxy)cyclobutyl)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 263) 2-(3-((S)-((1r,3S)-3-(2,2-difluoroethoxy)cyclobutyl)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 264) 2-(3-((R)-((1r,3R)-3-ethoxycyclobutyl)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 265) 2-(3-((R)-((1s,3S)-3-ethoxycyclobutyl)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 266) 2-(3-((S)-((1s,3R)-3-ethoxycyclobutyl)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 267) 2-(3-((S)-((1r,3S)-3-ethoxycyclobutyl)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 268) (R)-2-(3-(2-cyclobutyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)ethyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 269) (S)-2-(3-(2-cyclobutyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)ethyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 270) (R)-4-chloro-2-(3-((4-methyl-4H-1,2,4-triazol-3-yl)(oxetan-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)isoindolin-1-one; 271) (S)-4-chloro-2-(3-((4-methyl-4H-1,2,4-triazol-3-yl)(oxetan-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)isoindolin-1-one; 272) 4-(difluoromethyl)-2-(3-((1r,3r)-3-fluoro-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)isoindolin-1-one; 273) 4-chloro-2-(3-((1r,3r)-3-fluoro-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)isoindolin-1-one; 274) 4-(difluoromethyl)-2-(6-(ethylamino)-4-((1s,3s)-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-yl)-6-(((1-methylcyclobutyl)amino)methyl)isoindolin-1-one; 275) 2-(3-((R)-1-(4-methyl-4H-1,2,4-triazol-3-yl)-2-((R)-tetrahydrofuran-3-yl)ethyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 276) 2-(3-((S)-1-(4-methyl-4H-1,2,4-triazol-3-yl)-2-((R)-tetrahydrofuran-3-yl)ethyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 277) 2-(3-((S)-1-(4-methyl-4H-1,2,4-triazol-3-yl)-2-((S)-tetrahydrofuran-3-yl)ethyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 278) 2-(3-((R)-1-(4-methyl-4H-1,2,4-triazol-3-yl)-2-((S)-tetrahydrofuran-3-yl)ethyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 279) 2-(3-(1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 280) 2-((1s,3s)-3-(4-methyl-4H-1,2,4-triazol-3-yl)-3-(3-(6-(((1-methylcyclobutyl)amino)methyl)-1-oxo-4-(trifluoromethyl)isoindolin-2-yl)phenyl)cyclobutoxy)acetonitrile; 281) 2-((1r,3r)-3-(4-methyl-4H-1,2,4-triazol-3-yl)-3-(3-(6-(((1-methylcyclobutyl)amino)methyl)-1-oxo-4-(trifluoromethyl)isoindolin-2-yl)phenyl)cyclobutoxy)acetonitrile; 282) 2-(3-(4-(4-methyl-4H-1,2,4-triazol-3-yl)tetrahydro-2H-pyran-4-yl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 283) 2-(3-(1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclopropyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 284) 2-(3-((4-methyl-4H-1,2,4-triazol-3-yl)(oxetan-3-yl)methyl)phenyl)-6-((R)-1-((1-methylcyclobutyl)amino)ethyl)-4-(trifluoromethyl)isoindolin-1-one; 285) 2-(3-((4-methyl-4H-1,2,4-triazol-3-yl)(oxetan-3-yl)methyl)phenyl)-6-((S)-1-((1-methylcyclobutyl)amino)ethyl)-4-(trifluoromethyl)isoindolin-1-one; 286) (R)-2-(3-(2-(1,1-dioxidetetrahydro-2H-thiopyran-4-yl)-1-(4-methyl-4H-1,2,4-triazol-3-yl)ethyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 287) (S)-2-(3-(2-(1,1-dioxidetetrahydro-2H-thiopyran-4-yl)-1-(4-methyl-4H-1,2,4-triazol-3-yl)ethyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 288) 4-chloro-2-(3-((1s,3S)-3-fluoro-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-((R)-1-((1-methylcyclobutyl)amino)ethyl)isoindolin-1-one; 289) 4-chloro-2-(3-((1s,3R)-3-fluoro-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-((S)-1-((1-methylcyclobutyl)amino)ethyl)isoindolin-1-one; 290) (R)-2-(3-((4-methyl-4H-1,2,4-triazol-3-yl)(tetrahydro-2H-pyran-4-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 291) (S)-2-(3-((4-methyl-4H-1,2,4-triazol-3-yl)(tetrahydro-2H-pyran-4-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one formate; 292) 2-(3-(1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclopentyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 293) 2-(3-(2-(4-methyl-4H-1,2,4-triazol-3-yl)-5,8-dioxaspiro[3.4]octan-2-yl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 294) 2-(3-((R)-2-((S)-1,4-dioxan-2-yl)-1-(4-methyl-4H-1,2,4-triazol-3-yl)ethyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 295) 2-(3-((S)-2-((S)-1,4-dioxan-2-yl)-1-(4-methyl-4H-1,2,4-triazol-3-yl)ethyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 296) 2-(3-((S)-2-((R)-1,4-dioxan-2-yl)-1-(4-methyl-4H-1,2,4-triazol-3-yl)ethyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 297) 2-(3-((R)-2-((R)-1,4-dioxan-2-yl)-1-(4-methyl-4H-1,2,4-triazol-3-yl)ethyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 298) 2-(3-(1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclohexyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 299) (R)-2-(3-((1,1-dioxidetetrahydro-2H-thiopyran-4-yl)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 300) (S)-2-(3-((1,1-dioxidetetrahydro-2H-thiopyran-4-yl)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 301) (R)-6-(1,2-dihydroxyethyl)-2-(3-(1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 302) (S)-6-(1,2-dihydroxyethyl)-2-(3-(1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 303) (R)-4-(difluoromethyl)-2-(3-((4-methyl-4H-1,2,4-triazol-3-yl)(oxetan-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)isoindolin-1-one; 304) (S)-4-(Difluoromethyl)-2-(3-((4-methyl-4H-1,2,4-triazol-3-yl)(oxetan-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)isoindolin-1-one; 305) (R)-2-(3-(1-hydroxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)ethyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 306) (S)-2-(3-(1-hydroxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)ethyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 307) (R)-6-(((1-methylcyclobutyl)amino)methyl)-2-(3-(2,2,2-trifluoro-1-hydroxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)ethyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 308) (S)-6-(((1-methylcyclobutyl)amino)methyl)-2-(3-(2,2,2-trifluoro-1-hydroxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)ethyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 309) (R)-2-(3-(1-hydroxy-2-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)propyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 310) (S)-2-(3-(1-hydroxy-2-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)propyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 311) 4-chloro-2-(3-((1r,3R)-3-fluoro-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-((R)-1-((1-methylcyclobutyl)amino)ethyl)isoindolin-1-one; 312) 4-chloro-2-(3-((1r,3S)-3-fluoro-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-((S)-1-((1-methylcyclobutyl)amino)ethyl)isoindolin-1-one; 313) 2-(3-((R)-(4-methyl-4H-1,2,4-triazol-3-yl)(oxetan-3-yl)methyl)phenyl)-6-((S)-1-((1-methylcyclobutyl)amino)propyl)-4-(trifluoromethyl)isoindolin-1-one; 314) 2-(3-((R)-(4-methyl-4H-1,2,4-triazol-3-yl)(oxetan-3-yl)methyl)phenyl)-6-((R)-1-((1-methylcyclobutyl)amino)propyl)-4-(trifluoromethyl)isoindolin-1-one; 315) 2-(3-((S)-(4-methyl-4H-1,2,4-triazol-3-yl)(oxetan-3-yl)methyl)phenyl)-6-((S)-1-((1-methylcyclobutyl)amino)propyl)-4-(trifluoromethyl)isoindolin-1-one; 316) 2-(3-((S)-(4-methyl-4H-1,2,4-triazol-3-yl)(oxetan-3-yl)methyl)phenyl)-6-((R)-1-((1-methylcyclobutyl)amino)propyl)-4-(trifluoromethyl)isoindolin-1-one; 317) 4-chloro-2-(3-((R)-((1s,3S)-3-fluorocyclobutyl)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)isoindolin-1-one; 318) 4-chloro-2-(3-((R)-((1r,3R)-3-fluorocyclobutyl)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)isoindolin-1-one; 319) 4-chloro-2-(3-((S)-((1s,3R)-3-fluorocyclobutyl)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)isoindolin-1-one; 320) 4-chloro-2-(3-((S)-((1r,3S)-3-fluorocyclobutyl)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)isoindolin-1-one; 321) (S)-4-chloro-2-(3-(fluoro(4-methyl-4H-1,2,4-triazol-3-yl)(phenyl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)isoindolin-1-one; 322) (R)-4-chloro-2-(3-(fluoro(4-methyl-4H-1,2,4-triazol-3-yl)(phenyl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)isoindolin-1-one; 323) 2-(3-((1r,3r)-1-(4-methyl-4H-1,2,4-triazol-3-yl)-3-(methylthio)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 324) 2-(3-((1s,3s)-1-(4-methyl-4H-1,2,4-triazol-3-yl)-3-(methylthio)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 325) 2-(3-((1r,3r)-1-(4-methyl-4H-1,2,4-triazol-3-yl)-3-(methylsulfonyl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 326) 2-(3-((1s,3s)-1-(4-methyl-4H-1,2,4-triazol-3-yl)-3-(methylsulfonyl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 327) 2-(3-(1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-3-oxo-7-(trifluoromethyl)isoindoline-5-carboxamide; 328) 2-(3-(3-(4-methyl-4H-1,2,4-triazol-3-yl)-1,1-dioxidothietan-3-yl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 329) 2-(3-(3-(4-methyl-4H-1,2,4-triazol-3-yl)thietan-3-yl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one formate; 330) 2-(3-(3-(4-methyl-4H-1,2,4-triazol-3-yl)-1-oxidothietan-3-yl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 331) 2-(3-(3-(4-methyl-4H-1,2,4-triazol-3-yl)-1-oxidothietan-3-yl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 332) (R)-2-(3-methyl-5-((4-methyl-4H-1,2,4-triazol-3-yl)(oxetan-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 333) (S)-2-(3-methyl-5-((4-methyl-4H-1,2,4-triazol-3-yl)(oxetan-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 334) 2-(3-((1r,3r)-3-(difluoromethoxy)-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 335) 2-(3-((1s,3s)-3-(difluoromethoxy)-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 336) 2-(3-(ethylamino)-2-fluoro-5-((1r,3r)-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 337) 2-(3-(ethylamino)-2-fluoro-5-((1s,3s)-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 338) (R)-2-(3-methoxy-5-((4-methyl-4H-1,2,4-triazol-3-yl)(oxetan-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 339) (S)-2-(3-methoxy-5-((4-methyl-4H-1,2,4-triazol-3-yl)(oxetan-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 340) 2-(3-((2s,4r)-2-(4-methyl-4H-1,2,4-triazol-3-yl)-5-oxaspiro[3.4]octan-2-yl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 341) 2-(3-((2r,4s)-2-(4-methyl-4H-1,2,4-triazol-3-yl)-5-oxaspiro[3.4]octan-2-yl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 342) (R)-2-(3-(cyclopropyl(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 343) (S)-2-(3-(cyclopropyl(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 344) (R)-2-(3-((1H-imidazol-1-yl)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 345) (S)-2-(3-((1H-imidazol-1-yl)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 346) 2-(3-((1s,3s)-3-acetyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 347) 2-(3-((1r,3r)-3-acetyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 348) (R)-2-(3-((1-methyl-1H-tetrazol-5-yl)(oxetan-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 349) (S)-2-(3-((1-methyl-1H-tetrazol-5-yl)(oxetan-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 350) 2-(3-((1s,3s)-1-(4-methyl-4H-1,2,4-triazol-3-yl)-3-(trifluoromethoxy)cyclobutyl)phenyl)-6-(((1 methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 351) 2-(3-((1r,3r)-1-(4-methyl-4H-1,2,4-triazol-3-yl)-3-(trifluoromethoxy)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 352) (R)-2-(3-((1-methyl-1H-imidazol-2-yl)(oxetan-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 353) (S)-2-(3-((1-methyl-1H-imidazol-2-yl)(oxetan-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 354) 2-(3-((S)-((1s,3R)-3-chlorocyclobutyl)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 355) 2-(3-((S)-((1r,3S)-3-chlorocyclobutyl)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 356) 2-(3-((R)-((1r,3R)-3-chlorocyclobutyl)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 357) 2-(3-((R)-((1s,3S)-3-chlorocyclobutyl)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 358) (R)-4-chloro-2-(3-(1-(4-methyl-4H-1,2,4-triazol-3-yl)propyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)isoindolin-1-one; 359) (S)-4-chloro-2-(3-(1-(4-methyl-4H-1,2,4-triazol-3-yl)propyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)isoindolin-1-one; 360) 6-((R)-1-amino-2,2-dimethylpropyl)-2-(3-((1r,3R)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 361) 6-((S)-1-amino-2,2-dimethylpropyl)-2-(3-((1r,3S)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 362) 2-((1R,3s)-3-((S)-(4-methyl-4H-1,2,4-triazol-3-yl)(3-(6-(((1-methylcyclobutyl)amino)methyl)-1-oxo-4-(trifluoromethyl)isoindolin-2-yl)phenyl)methyl)cyclobutyl)acetonitrile; 363) 2-((1S,3r)-3-((S)-(4-methyl-4H-1,2,4-triazol-3-yl)(3-(6-(((1-methylcyclobutyl)amino)methyl)-1-oxo-4-(trifluoromethyl)isoindolin-2-yl)phenyl)methyl)cyclobutyl)acetonitrile; 364) 2-((1R,3r)-3-((R)-(4-methyl-4H-1,2,4-triazol-3-yl)(3-(6-(((1-methylcyclobutyl)amino)methyl)-1-oxo-4-(trifluoromethyl)isoindolin-2-yl)phenyl)methyl)cyclobutyl)acetonitrile; 365) 2-((1S,3s)-3-((R)-(4-methyl-4H-1,2,4-triazol-3-yl)(3-(6-(((1-methylcyclobutyl)amino)methyl)-1-oxo-4-(trifluoromethyl)isoindolin-2-yl)phenyl)methyl)cyclobutyl)acetonitrile; 366) 2-(3-((S)-((1r,3S)-1-hydroxy-3-methoxycyclobutyl)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 367) 2-(3-((S)-((1s,3R)-1-hydroxy-3-methoxycyclobutyl)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 368) 2-(3-((R)-((1s,3S)-1-hydroxy-3-methoxycyclobutyl)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 369) 2-(3-((R)-((1r,3R)-1-hydroxy-3-methoxycyclobutyl)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 370) 2-(3-((1s,3s)-3-(fluoromethoxy)-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 371) 2-(3-((1r,3r)-3-(fluoromethoxy)-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 372) 2-(3-((1S,3S)-3-(methoxy-d3)-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 373) 2-(3-((1R,3R)-3-(methoxy-d3)-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 374) 4-chloro-2-(3-((1r,3s)-3-ethyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)isoindolin-1-one; 375) 4-chloro-2-(3-((1s,3r)-3-ethyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)isoindolin-1-one; 376) 2-(3-((S)-(4-methyl-4H-1,2,4-triazol-3-yl)((1r,3S)-3-methylcyclobutyl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 377) 2-(3-((S)-(4-methyl-4H-1,2,4-triazol-3-yl)((1s,3R)-3-methylcyclobutyl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 378) 2-(3-((R)-(4-methyl-4H-1,2,4-triazol-3-yl)((1r,3R)-3-methylcyclobutyl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 379) 2-(3-((R)-(4-methyl-4H-1,2,4-triazol-3-yl)((1s,3S)-3-methylcyclobutyl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 380) (R)-2-(3-((3-fluorooxetan-3-yl)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 381) (S)-2-(3-((3-fluorooxetan-3-yl)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 382) 2-(3-((R)-((1r,3R)-3-acetylcyclobutyl)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 383) 2-(3-((S)-((1s,3R)-3-acetylcyclobutyl)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 384) 2-(3-((S)-((1r,3S)-3-acetylcyclobutyl)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 385) 2-(3-((R)-((1s,3S)-3-acetylcyclobutyl)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 386) (R)-2-(3-((4-methyl-4H-1,2,4-triazol-3-yl)(oxetan-3-yl)methyl)phenyl)-6-(1-propylazetidin-3-yl)-4-(trifluoromethyl)isoindolin-1-one; 387) 2-(3-((R)-((1r,3R)-3-(difluoromethoxy)cyclobutyl)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 388) 2-(3-((R)-((1s,3S)-3-(difluoromethoxy)cyclobutyl)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 389) 2-(3-((S)-((1r,3S)-3-(difluoromethoxy)cyclobutyl)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 390) 2-(3-((S)-((1s,3R)-3-(difluoromethoxy)cyclobutyl)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 391) (S)-2-(3-(1-hydroxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)propyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 392) (R)-2-(3-(1-hydroxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)propyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 393) (S)-2-(3-(1-fluoro-1-(4-methyl-4H-1,2,4-triazol-3-yl)propyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 394) (R)-2-(3-(1-fluoro-1-(4-methyl-4H-1,2,4-triazol-3-yl)propyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 395) 2-(3-((R)-(4-methyl-4H-1,2,4-triazol-3-yl)((1r,3R)-3-(trifluoromethoxy)cyclobutyl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 396) 2-(3-((S)-(4-methyl-4H-1,2,4-triazol-3-yl)((1s,3R)-3-(trifluoromethoxy)cyclobutyl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 397) 2-(3-((R)-(4-methyl-4H-1,2,4-triazol-3-yl)((1s,3S)-3-(trifluoromethoxy)cyclobutyl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 398) 2-(3-((S)-(4-methyl-4H-1,2,4-triazol-3-yl)((1r,3S)-3-(trifluoromethoxy)cyclobutyl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 399) (R)-N-methyl-N-((4-methyl-4H-1,2,4-triazol-3-yl)(3-(6-(((1-methylcyclobutyl)amino)methyl)-1-oxo-4-(trifluoromethyl)isoindolin-2-yl)phenyl)methyl)acetamide; 400) (S)-N-methyl-N-((4-methyl-4H-1,2,4-triazol-3-yl)(3-(6-(((1-methylcyclobutyl)amino)methyl)-1-oxo-4-(trifluoromethyl)isoindolin-2-yl)phenyl)methyl)acetamide; 401) (R)-2-(3-((1-acetylazetidin-3-yl)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 402) (S)-2-(3-((1-acetylazetidin-3-yl)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 403) (S)-2-(3-(fluoro(3-fluorooxetan-3-yl)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 404) (R)-2-(3-(fluoro(3-fluorooxetan-3-yl)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 405) 2-(3-((1s,3s)-3-(difluoromethyl)-3-hydroxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 406) 4-(difluoromethyl)-2-(3-((S)-(4-methyl-4H-1,2,4-triazol-3-yl)(oxetan-3-yl)methyl)phenyl)-6-((R)-1-((1-methylcyclobutyl)amino)ethyl)isoindolin-1-one; 407) 4-(difluoromethyl)-2-(3-((S)-(4-methyl-4H-1,2,4-triazol-3-yl)(oxetan-3-yl)methyl)phenyl)-6-((S)-1-((1-methylcyclobutyl)amino)ethyl)isoindolin-1-one; 408) (R)-2-(3-chloro-5-((4-methyl-4H-1,2,4-triazol-3-yl)(oxetan-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 409) (S)-2-(3-chloro-5-((4-methyl-4H-1,2,4-triazol-3-yl)(oxetan-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 410) (R)-4-chloro-2-(3-(hydroxy(4-methyl-4H-1,2,4-triazol-3-yl)(phenyl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)isoindolin-1-one; 411) (S)-4-chloro-2-(3-(hydroxy(4-methyl-4H-1,2,4-triazol-3-yl)(phenyl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)isoindolin-1-one; 412) 4-(difluoromethyl)-2-(3-((R)-(4-methyl-4H-1,2,4-triazol-3-yl)(oxetan-3-yl)methyl)phenyl)-6-((R)-1-((1-methylcyclobutyl)amino)ethyl)isoindolin-1-one; 413) 4-(difluoromethyl)-2-(3-((R)-(4-methyl-4H-1,2,4-triazol-3-yl)(oxetan-3-yl)methyl)phenyl)-6-((S)-1-((1-methylcyclobutyl)amino)ethyl)isoindolin-1-one; 414) 6-((cyclobutylamino)methyl)-2-(3-((1r,3r)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 415) 6-(((cyclopropylmethyl)amino)methyl)-2-(3-((1r,3r)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 416) 6-(((cyclobutylmethyl)amino)methyl)-2-(3-((1r,3r)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 417) 2-(3-((1r,3r)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(morpholinomethyl)-4-(trifluoromethyl)isoindolin-1-one; 418) 2-(3-((1r,3r)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(pyrrolidin-1-ylmethyl)-4-(trifluoromethyl)isoindolin-1-one; 419) 6-((isopropylamino)methyl)-2-(3-((1r,3r)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 420) 2-(3-((1r,3r)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(piperidin-1-ylmethyl)-4-(trifluoromethyl)isoindolin-1-one; 421) 6-((isobutylamino)methyl)-2-(3-((1r,3r)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 422) 6-((3-hydroxyazetidin-1-yl)methyl)-2-(3-((1r,3r)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 423) 6-(5-azaspiro[2.3]hexan-5-ylmethyl)-2-(3-((1r,3r)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 424) 6-((2-hydroxy-7-azaspiro[3.5]nonan-7-yl)methyl)-2-(3-((1r,3r)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 425) Methyl 2-(((2-(3-((1r,3r)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)amino)butanoate; 426) 6-(((1,1-difluorospiro[2.3]hexan-5-yl)amino)methyl)-2-(3-((1r,3r)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 427) 6-(((6,6-difluorobicyclo[3.1.0]hexan-3-yl)amino)methyl)-2-(3-((1r,3r)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 428) (S)-2-(3-((1-hydroxycyclobutyl)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 429) (R)-2-(3-((1-hydroxycyclobutyl)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 430) 6-((S)-cyclopropyl((1-methylcyclobutyl)amino)methyl)-2-(3-((R)-(4-methyl-4H-1,2,4-triazol-3-yl)(oxetan-3-yl)methyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 431) 6-((R)-cyclopropyl((1-methylcyclobutyl)amino)methyl)-2-(3-((R)-(4-methyl-4H-1,2,4-triazol-3-yl)(oxetan-3-yl)methyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 432) 6-((R)-cyclobutyl((1-methylcyclobutyl)amino)methyl)-2-(3-((R)-(4-methyl-4H-1,2,4-triazol-3-yl)(oxetan-3-yl)methyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 433) 6-((S)-cyclobutyl((1-methylcyclobutyl)amino)methyl)-2-(3-((R)-(4-methyl-4H-1,2,4-triazol-3-yl)(oxetan-3-yl)methyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 434) 6-((R)-cyclobutyl((1-methylcyclobutyl)amino)methyl)-2-(3-((S)-(4-methyl-4H-1,2,4-triazol-3-yl)(oxetan-3-yl)methyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 435) 6-((S)-cyclobutyl((1-methylcyclobutyl)amino)methyl)-2-(3-((S)-(4-methyl-4H-1,2,4-triazol-3-yl)(oxetan-3-yl)methyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 436) (R)-6-(((1-methylcyclobutyl)amino)methyl)-2-(3-(oxetan-3-yl(1H-1,2,3-triazol-1-yl)methyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 437) (S)-6-(((1-methylcyclobutyl)amino)methyl)-2-(3-(oxetan-3-yl(1H-1,2,3-triazol-1-yl)methyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 438) 2-(3-((R)-((S)-1,1-dioxidetetrahydrothiophen-3-yl)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 439) 2-(3-((S)-((S)-1,1-dioxidetetrahydrothiophen-3-yl)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 440) (R)-6-(((1-methylcyclobutyl)amino)methyl)-2-(3-(oxetan-3-yl(4H-1,2,4-triazol-3-yl)methyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 441) (S)-6-(((1-methylcyclobutyl)amino)methyl)-2-(3-(oxetan-3-yl(4H-1,2,4-triazol-3-yl)methyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 442) 2-(3-((S)-(4-methyl-4H-1,2,4-triazol-3-yl)(oxetan-3-yl)methyl)phenyl)-6-((S)-1-((1-methylcyclobutyl)amino)ethyl)-4-(trifluoromethyl)isoindolin-1-one; 443) 2-(3-((S)-(4-methyl-4H-1,2,4-triazol-3-yl)(oxetan-3-yl)methyl)phenyl)-6-((R)-1-((1-methylcyclobutyl)amino)ethyl)-4-(trifluoromethyl)isoindolin-1-one; 444) 2-(3-((R)-(4-methyl-4H-1,2,4-triazol-3-yl)(oxetan-3-yl)methyl)phenyl)-6-((R)-1-((1-methylcyclobutyl)amino)ethyl)-4-(trifluoromethyl)isoindolin-1-one; 445) 2-(3-((R)-(4-methyl-4H-1,2,4-triazol-3-yl)(oxetan-3-yl)methyl)phenyl)-6-((S)-1-((1-methylcyclobutyl)amino)ethyl)-4-(trifluoromethyl)isoindolin-1-one; 446) 2-(3-((1s,3s)-3-chloro-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-4-(difluoromethyl)-6-(((1-methylcyclobutyl)amino)methyl)isoindolin-1-one; 447) 2-(3-((1r,3r)-3-chloro-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-4-(difluoromethyl)-6-(((1-methylcyclobutyl)amino)methyl)isoindolin-1-one; 448) 2-(3-((1s,3s)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)isoindolin-1-one; 449) 2-(3-((1r,3r)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)isoindolin-1-one; 450) 2-(3-((1r,3r)-3-cyclopropoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 451) 4-chloro-2-(3-((1r,3r)-3-chloro-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)isoindolin-1-one; 452) 4-chloro-2-(3-((1s,3s)-3-chloro-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)isoindolin-1-one; 453) 6-(2-fluoro-1-((1-methylcyclobutyl)amino)ethyl)-2-(3-(1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 454) 2-(3-((1r,3s)-3-ethyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 455) 2-(3-((1s,3r)-3-ethyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 456) 6-((R)-cyclopropyl((1-methylcyclobutyl)amino)methyl)-2-(3-((S)-(4-methyl-4H-1,2,4-triazol-3-yl)(oxetan-3-yl)methyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 457) 6-((S)-cyclopropyl((1-methylcyclobutyl)amino)methyl)-2-(3-((S)-(4-methyl-4H-1,2,4-triazol-3-yl)(oxetan-3-yl)methyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 458) 4-(difluoromethyl)-2-(3-((R)-((1r,3R)-3-fluorocyclobutyl)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)isoindolin-1-one; 459) 4-(difluoromethyl)-2-(3-((R)-((1s,3S)-3-fluorocyclobutyl)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)isoindolin-1-one; 460) 4-(difluoromethyl)-2-(3-((S)-((1r,3S)-3-fluorocyclobutyl)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)isoindolin-1-one; 461) 4-(difluoromethyl)-2-(3-((S)-((1s,3R)-3-fluorocyclobutyl)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)isoindolin-1-one; 462) 2-(3-((3-fluorothietan-3-yl)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 463) (R)-6-(((2-fluoro-2-methylpropyl)amino)methyl)-2-(3-((4-methyl-4H-1,2,4-triazol-3-yl)(oxetan-3-yl)methyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 464) (R)-6-((isobutylamino)methyl)-2-(3-((4-methyl-4H-1,2,4-triazol-3-yl)(oxetan-3-yl)methyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 465) (R)-2-(3-((4-methyl-4H-1,2,4-triazol-3-yl)(oxetan-3-yl)methyl)phenyl)-6-((((1-methylcyclopropyl)methyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 466) (R)-2-(3-((4-methyl-4H-1,2,4-triazol-3-yl)(oxetan-3-yl)methyl)phenyl)-6-(((1-methylcyclopropyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 467) 6-((((R)-1-cyclobutylethyl)amino)methyl)-2-(3-((1r,3R)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 468) (R)-2-(3-((4-methyl-4H-1,2,4-triazol-3-yl)(oxetan-3-yl)methyl)phenyl)-6-((neopentylamino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 469) 6-(((1R,3r,5S)-bicyclo[3.1.0]hexan-3-ylamino)methyl)-2-(3-((R)-(4-methyl-4H-1,2,4-triazol-3-yl)(oxetan-3-yl)methyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 470) 6-((((S)-1-cyclobutylethyl)amino)methyl)-2-(3-((1r,3S)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 471) 6-(((3,3-difluoro-1-methylcyclobutyl)amino)methyl)-2-(3-((1r,3r)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 472) 6-(((1R,5S,6r)-3-oxabicyclo[3.1.0]hexan-6-ylamino)methyl)-2-(3-((R)-(4-methyl-4H-1,2,4-triazol-3-yl)(oxetan-3-yl)methyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 473) 6-((((1-hydroxycyclopropyl)methyl)amino)methyl)-2-(3-((1r,3r)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 474) 2-(3-((1r,3r)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-((((1-methylcyclopropyl)methyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 475) 2-(3-((1r,3r)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclopropyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 476) 2-(3-((1r,3r)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-((oxetan-3-ylamino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 477) 6-((cyclopropylamino)methyl)-2-(3-((1r,3r)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 478) 6-((3-hydroxy-3-methylazetidin-1-yl)methyl)-2-(3-((1r,3r)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 479) 2-(3-((1r,3r)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((3-methyloxetan-3-yl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 480) 6-(azetidin-1-ylmethyl)-2-(3-((1r,3r)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 481) 2-(3-((1r,3r)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-((neopentylamino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 482) 6-((((2,2-difluorocyclopropyl)methyl)amino)methyl)-2-(3-((1r,3r)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 483) 6-(((2-fluoro-2-methylpropyl)amino)methyl)-2-(3-((1r,3r)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 484) 6-((((1s,3S)-3-hydroxy-1-methylcyclobutyl)amino)methyl)-2-(3-((1r,3R)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 485) 6-((bicyclo[1.1.1]pentan-1-ylamino)methyl)-2-(3-((1r,3r)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 486) 6-((((1-fluorocyclopropyl)methyl)amino)methyl)-2-(3-((1r,3r)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 487) 2-(3-((1r,3r)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-(methoxymethyl)cyclopropyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 488) 6-(((3,3-dimethylcyclobutyl)amino)methyl)-2-(3-((1r,3r)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 489) 6-((((1-(hydroxymethyl)cyclobutyl)methyl)amino)methyl)-2-(3-((1r,3r)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 490) 6-(azepan-1-ylmethyl)-2-(3-((1r,3r)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 491) 6-(((2-(difluoromethoxy)ethyl)amino)methyl)-2-(3-((1r,3r)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 492) 6-(((1R,5S,6r)-3-oxabicyclo[3.1.0]hexan-6-ylamino)methyl)-2-(3-((1r,3R)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 493) 2-(3-((1r,3r)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-(2-methoxyethyl)cyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 494) 6-(((3-(difluoromethyl)cyclobutyl)amino)methyl)-2-(3-((1r,3r)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 495) 2-(3-((1r,3r)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-(methoxymethyl)cyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 496) 6-((((1-(fluoromethyl)cyclopropyl)methyl)amino)methyl)-2-(3-((1r,3r)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 497) 6-(((3-fluoro-3-methylcyclobutyl)amino)methyl)-2-(3-((1r,3r)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 498) 6-((bicyclo[3.1.0]hexan-3-ylamino)methyl)-2-(3-((1r,3r)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 499) 6-(((2-(2,2-difluorocyclobutyl)ethyl)amino)methyl)-2-(3-((1r,3r)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 500) 6-((2-oxabicyclo[2.2.1]heptan-5-ylamino)methyl)-2-(3-((1r,3r)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 501) 6-((((2,2-difluoro-1-methylcyclopropyl)methyl)amino)methyl)-2-(3-((1r,3r)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 502) 2-(3-((1r,3R)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-((((1R,2R)-2-methylcyclopropyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one; 503) 6-(((((1S,3R)-2,2-difluoro-3-methylcyclopropyl)methyl)amino)methyl)-2-(3-((1r,3S)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 504) 6-(((1-fluorospiro[2.3]hexan-5-yl)amino)methyl)-2-(3-((1r,3r)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 505) 3-(((2-(3-((1r,3r)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)amino)cyclobutanecarbonitrile; 506) 6-((((1R,2R)-2-(1,1-difluoroethyl)cyclopropyl)amino)methyl)-2-(3-((1r,3R)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 507) 6-((((1-(fluoromethyl)cyclobutyl)methyl)amino)methyl)-2-(3-((1r,3r)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 508) 6-(((1R,5R)-bicyclo[3.1.0]hexan-1-ylamino)methyl)-2-(3-((1r,3R)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 509) 6-((((3-(hydroxymethyl)bicyclo[3.1.0]hexan-3-yl)methyl)amino)methyl)-2-(3-((1r,3r)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; 510) 6-((((4,4-difluorospiro[2.2]pentan-1-yl)methyl)amino)methyl)-2-(3-((1r,3r)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one; and 511) 2-(3-((1r,3r)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-((propylamino)methyl)-4-(trifluoromethyl)isoindolin-1-one.

[0070] The present disclosure further includes a method of treating cancer, comprising administering to a subject in need thereof a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof.

[0071] definition It should be noted that "a" or "an" before an object may refer to one or more of that object. Thus, the terms "a" (or "an"), "one or more," and "at least one" can be used interchangeably herein.

[0072] All technical and scientific terms used herein have the same meaning as understood by one of ordinary skill in the art, unless otherwise specified herein. Efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperatures, etc.), but some experimental error and deviation should be accounted for when reading this disclosure.

[0073] Throughout this specification and the claims, the words "comprise" (comprises) and "comprising" are used in a non-exclusive sense unless the context indicates otherwise. It should be understood that the embodiments described herein include "consisting of" and / or "consisting essentially of" embodiments, and refer to some aspects that are defined exclusively.

[0074] As used herein, the term "about" when referring to a value encompasses variations from the particular amount of, in some embodiments, ±50%, in some embodiments, ±20%, in some embodiments, ±10%, in some embodiments, ±5%, in some embodiments, ±1%, in some embodiments, ±0.5%, and in some embodiments, ±0.1%, and thus means that such variations are appropriate for practicing the disclosed methods or using the disclosed compositions.

[0075] Where a range of values ​​is provided, unless the context dictates otherwise, each intervening value, to the tenth of the unit of the lower limit, between the upper and lower limit of the range is also disclosed, and it is understood that any other stated or intervening value in that stated range is also included within the invention. The upper and lower limits of these smaller ranges, which may independently be included in smaller ranges, are also encompassed within the invention, subject to any specifically excluded limit in the stated range. When the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the invention.

[0076] "Geminal" refers to the relationship between two moieties attached to the same atom. For example, the moiety -CH2-CR x R y -In R x and R y are geminal with respect to each other, and R x is R y It is sometimes called a geminal R group.

[0077] "Vicinal" refers to the relationship between two moieties attached to adjacent atoms, e.g., residue -CHR x -CHR y -In R x and R y are close together, and R x is R y is sometimes referred to as the proximal R group.

[0078] Unless otherwise specified, "optionally substituted" means that the group can be unsubstituted or substituted with one or more (e.g., 1, 2, 3, 4, or 5) non-hydrogen atoms or monovalent groups, where the substituents can be the same or different. In one embodiment, the optionally substituted group has one substituent. In another embodiment, the optionally substituted group has two substituents. In another embodiment, the optionally substituted group has three substituents. In another embodiment, the optionally substituted group has four substituents. In some embodiments, the optionally substituted group has 1 to 2, 1 to 3, 1 to 4, or 1 to 5 substituents. In any embodiment in which a group is substituted with two or more substituents, any two such substituents can be centrally located relative to each other, for example, 3,3-difluoro-cyclobutyl.

[0079] The structures of molecules herein are typically represented by 2D structural diagrams that embody numerous labeling and layout conventions well understood by synthetic and medicinal chemists. Hydrogen atoms bonded to carbon atoms are usually not shown (primarily to reduce clutter), and any carbon shown is assumed to have a valence of four, with all bonds not explicitly shown being satisfied by bonds to as many hydrogen atoms as necessary to satisfy the valence of four. Correspondingly, when structures are shown in "Markush" format and substituents are presented as a list, any "missing" valences are assumed to be completed by hydrogen atoms, in the absence of any specific direction to the contrary.

[0080] Heteroatom refers to any atom other than carbon or hydrogen. Typical heteroatoms found in small organic molecules are selected from nitrogen, oxygen, fluorine, phosphorus, sulfur, chlorine, and bromine. Those skilled in the art will understand that when the term heteroatom is used to refer to a member of a ring (e.g., an aromatic heterocycle), monovalent heteroatoms such as halogens are excluded.

[0081] As used herein, "alkyl" refers to a saturated straight-chain (i.e., unbranched) or branched monovalent hydrocarbon functional group obtained by removing one hydrogen atom from one carbon atom of a parent alkane. An alkyl group having n carbon atoms, as a radical, has the formula C n H 2n+1 Alkyl groups having a given number of carbon atoms can be designated as follows: C, which denotes any alkyl radical having n carbon atoms. n -C representing an alkyl or any alkyl radical having n1 to n2 carbon atoms n1-n2 -alkyl. Therefore, C 1-10 means any alkyl radical having from 1 to 10 carbon atoms. Particular alkyl groups of interest herein are those having from 1 to 20 carbon atoms ("C 1-20 -alkyl"), those having 1 to 12 carbon atoms ("C 1-12 -alkyl"), those having 1 to 6 carbon atoms ("C 1-6 -alkyl"), those having 2 to 6 carbon atoms ("C 2-6 -alkyl"), or those having 1 to 4 carbon atoms ("C 1-4 -alkyl"). Examples of alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, and sec-butyl. It is to be understood that an alkyl group can be attached to another group or moiety at any carbon atom within its structure. Thus, for example, butan-1-yl (n-butyl) and butan-2-yl (sec-butyl) are contemplated by the definitions herein.

[0082] As used herein, "alkenyl" refers to an unsaturated straight-chain (i.e., unbranched) or branched monovalent hydrocarbon functional group having at least one site of olefinic unsaturation, i.e., at least one instance of a carbon-carbon double bond (represented by the formula C=C), and having the specified number of carbon atoms. An alkenyl group having n carbon atoms and a single double bond as a radical has the formula C n H 2n-1and are obtained by removing one hydrogen atom from one carbon atom of the parent alkene. Alkenyl groups having a given number of carbon atoms can be designated as follows: C, which denotes any alkenyl radical having n carbon atoms. n -alkenyl or any alkenyl radical having n1 to n2 carbon atoms n1-n2 -alkenyl. Therefore, C 2-10 -Alkenyl refers to an alkenyl group having from 2 to 10 carbon atoms. Alkenyl groups can include constituent carbon atoms in the "cis" or "trans" configuration, or in the "E" or "Z" configuration about a given double bond. Particular alkenyl groups are those having from 2 to 20 carbon atoms ("C2- 20 -alkenyl"), those having 2 to 8 carbon atoms ("C 2-8 -alkenyl"), those having 2 to 6 carbon atoms ("C 2-6 -alkenyl"), or those having 2 to 4 carbon atoms ("C 2-4 Preferred alkenyl groups have one double bond. Other alkenyl groups may have two double bonds (and may be called dienyls). In alkenyl groups having more than one double bond, a pair of double bonds may be separated by one carbon-carbon single bond, in which case the arrangement is called a "conjugate," or they may be separated by more than one carbon-carbon single bond. Examples of alkenyl groups include, but are not limited to, groups such as ethenyl (or vinyl), prop-1-enyl, prop-2-enyl (or allyl), 2-methylprop-1-enyl, but-1-enyl, but-2-enyl, but-3-enyl, buta-1,3-dienyl, 2-methylbuta-1,3-dienyl, homologs and isomers thereof.

[0083] As used herein, "alkynyl" refers to an unsaturated straight-chain (i.e., unbranched) or branched monovalent hydrocarbon having at least one site of acetylenic unsaturation, i.e., at least one instance of a carbon-carbon triple bond (represented by the formula C≡C), and having the specified number of carbon atoms. An alkynyl group having n carbon atoms and one triple bond as a radical has the formula C n H 2n-3 and is obtained by removing one hydrogen atom from one carbon atom of the parent alkyne. Alkynyl groups having a given number of carbon atoms can be designated as follows: C, which denotes any alkynyl radical having n carbon atoms. n -alkynyl or any alkynyl radical having n1 to n2 carbon atoms n1-n2 -alkynyl. Particular alkynyl groups are those having 2 to 20 carbon atoms ("C 2-20 -alkynyl"), those having 2 to 8 carbon atoms ("C 2-8 -alkynyl"), those having 2 to 6 carbon atoms ("C 2-6 -alkynyl"), or those having 2 to 4 carbon atoms ("C 2-4 Examples of alkynyl groups include, but are not limited to, groups such as ethynyl (or acetylenyl), prop-1-ynyl, prop-2-ynyl (or propargyl), but-1-ynyl, but-2-ynyl, but-3-ynyl, homologs and isomers thereof.

[0084] As used herein, "alkylene" refers to a saturated straight-chain (i.e., unbranched) or branched divalent hydrocarbon group having the specified number of carbon atoms. An alkylene group having n carbon atoms, as a radical, has the formula -C n H 2n Particular alkylene groups are those having 1 to 6 carbon atoms ("C 1-6 -alkylene"), those having 1 to 5 carbon atoms ("C 1-5 -alkylene"), those having 1 to 4 carbon atoms ("C 1-4 -alkylene"), or those having 2 to 3 carbon atoms ("C 2-3Examples of alkylene radicals include, but are not limited to, methylene (-CH-), ethylene (-CH-CH-), propylene (-CH-CH-CH-), butylene (-CH-CH-CH-CH-), sec-butylene (-CH(CH)-CH-CH-), and the like.

[0085] A cyclic (ring-containing) moiety includes atoms bonded together in a ring, with one or more substituents other than hydrogen atoms bonded to one or more ring atoms, and the atoms in the ring define vertices of a polygon.

[0086] Two ring atoms are adjacent if they are bonded to each other within the ring. In rings with four or more ring atoms, adjacent atoms are bonded to each other but not to other atoms within the ring. In three-membered rings, each atom is necessarily bonded to every other atom within the ring. Two adjacent ring atoms define one "edge" of the ring.

[0087] Two or more cyclic moieties may be joined to each other in one of several ways to form a ring system containing more than one ring.

[0088] Two rings are fused to each other if two ring atoms are adjacent to each other in both rings and are shared by both rings. Such rings are said to share an "edge."

[0089] Spirocyclic ring systems contain a pair of rings that share a single vertex. Such systems contain a ring junction where the two rings share a single ring atom.

[0090] A bridged ring system contains at least one pair of rings in which two or more non-adjacent ring atoms are shared by two or more rings. The two non-adjacent ring atoms in question are called "bridgehead" atoms, and the pair of bridgehead atoms are members of three different rings. Examples of carbocyclic radicals containing bridged bicyclic rings are norbornyl and adamantyl.

[0091] A chained ring system contains two rings that are bonded to each other but do not share a common ring atom: one ring is a substituent of the other, and vice versa. Biphenyl is an example of a chained ring system.

[0092] The ring system may comprise pairs of rings that are fused or linked together, spiro-linked or bridged, or, in the case of three or more rings, joined by combinations of these methods.

[0093] As used herein, "carbocycle" refers to an aromatic, saturated or unsaturated, cyclic monovalent hydrocarbon group having a specified number of cyclic (i.e., ring) carbon atoms (i.e., C3- 10 means 3 to 10 ring carbon atoms). A carbocyclic group has one ring ("monocyclic") or more than one ring ("bicyclic," "tricyclic," or more commonly, polycyclic). Two or more carbocyclic rings can be joined together by fused, spiro, bridged, or cyclic connections, as further described elsewhere herein.

[0094] As used herein, the term carbocycle is intended to encompass radicals having one or more pairs of adjacent ring atoms with a double bond between them, and that if more than one such double bond is present, the double bond may or may not form a conjugated system within the ring. Thus, carbocycles may be more specifically designated according to whether they are fully saturated ("cycloalkyl"), at least partially unsaturated ("cycloalkenyl"), or fully conjugated ("aromatic" or "aryl"). Cycloalkyl groups are fully saturated radicals, derived by removing one hydrogen atom from one carbon atom of a parent cycloalkane. Particular cycloalkyl groups are those having 3 to 12 ring carbon atoms (C 3-12 -cycloalkyl). Preferred cycloalkyls are monocyclic hydrocarbons having 3 to 8 ring carbon atoms ("C 3-8 -cycloalkyl"), or a monocyclic hydrocarbon having 3 to 6 carbon atoms ("C 3-6 -cycloalkyl"). A monocyclic cycloalkyl radical is of the formula Cn H 2n-1 Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl. Cycloalkenyl groups have one or more double bonds between adjacent ring carbon atoms. Examples of cycloalkenyl groups include 1-cyclohex-1-enyl and 1-cyclohex-3-enyl.

[0095] As used herein, "aryl" refers to a carbocyclic group having a single aromatic ring (e.g., phenyl) or multiple aromatic rings fused together (e.g., naphthyl). Preferably, aryl groups contain from 6 to 20 carbon atoms, more preferably from 6 to 12 carbon atoms. Particularly preferred aryl groups are those having from 6 to 14 ring carbon atoms ("C 6-14 The term aromatic is used herein as typically used in organic chemistry to refer, with few understood exceptions, to rings and ring systems whose ring atoms contribute a total of (4n+2) pi electrons (n ​​is a positive, non-zero integer) to the set of delocalized molecular orbitals.

[0096] Exemplary aryl groups include, but are not limited to, groups derived from fused or conjugated ring systems containing one or more aromatic rings, such as, but not limited to, aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, coronene, fluoranthene, heptaphene, hexacene, hexaphene, as-indacene, s-indacene, indene, naphthalene (hexalene), octacene, octaphene, octalene, ovalene, pentacene, pentalene, pentaphene, perylene, phenalene, phenanthrene, picene, pleiadene, pyrene, pyranthrene, rubicene, tetraphenylene, triphenylene, and trinaphthalene.

[0097] As used herein, a "heterocyclic" or "heterocyclyl" group refers to a saturated or unsaturated, but non-aromatic, cyclic group having one or more rings containing at least one carbon atom and one or more heteroatoms. Typically, such groups have 1 to 14 ring carbon atoms and 1 to 6 ring heteroatoms, which may be the same or different from one another. Such groups are typically derived by removing one hydrogen atom from one ring atom of a parent heterocycle. As used herein, the term heterocyclyl is intended to encompass radicals having one or more double bonds between one or more respective pairs of adjacent ring atoms, and when more than one such double bond is present, the double bonds do not form a conjugated system within the ring.

[0098] Particularly preferred heterocyclyl groups are 3- to 14-membered rings having 1 to 13 ring carbon atoms and 1 to 6 ring heteroatoms independently selected from nitrogen, phosphorus, oxygen, and sulfur; 3- to 12-membered rings having 1 to 11 ring carbon atoms and 1 to 6 ring heteroatoms independently selected from nitrogen, phosphorus, oxygen, and sulfur; 3- to 10-membered rings having 1 to 9 ring carbon atoms and 1 to 4 ring heteroatoms independently selected from nitrogen, phosphorus, oxygen, and sulfur; 3- to 8-membered rings having 1 to 7 ring carbon atoms and 1 to 4 ring heteroatoms independently selected from nitrogen, phosphorus, oxygen, and sulfur; and 3- to 6-membered rings having 1 to 5 ring carbon atoms and 1 to 4 ring heteroatoms independently selected from nitrogen, phosphorus, oxygen, and sulfur. In one variation, heterocyclyl includes a monocyclic 3-, 4-, 5-, 6-, or 7-membered ring having 1 to 2, 1 to 3, 1 to 4, 1 to 5, or 1 to 6 ring carbon atoms and 1 to 2, 1 to 3, or 1 to 4 ring heteroatoms independently selected from nitrogen, phosphorus, oxygen, and sulfur. In another variation, heterocyclyl includes a polycyclic non-aromatic ring having 1 to 12 ring carbon atoms and 1 to 6 ring heteroatoms independently selected from nitrogen, phosphorus, oxygen, and sulfur. Exemplary heterocyclic rings include oxirane, aziridine, azetidine, pyrrolidine, piperazine, piperidine, oxetane, tetrahydrofuran, and morpholine.

[0099] Heterocyclic rings may form fused, spiro or bridged connections, or any combination of such connections to one or more other rings.

[0100] As used herein, "heteroaryl" or "heteroaromatic" refers to an aromatic cyclic group having 1 to 14 ring carbon atoms and at least one ring heteroatom (including, but not limited to, heteroatoms such as nitrogen, phosphorus, oxygen, and sulfur). The term refers to a monovalent heteroaromatic radical obtained by removing one hydrogen atom from a single ring atom of a parent heteroaromatic ring system. Heteroaryl groups can have a single ring (e.g., pyridyl, furyl) or multiple condensed rings (e.g., indolizinyl, benzothienyl). Particular heteroaryl groups are 5- to 14-membered rings having 1 to 12 cyclic (i.e., ring) carbon atoms and 1 to 6 cyclic (i.e., ring) heteroatoms independently selected from nitrogen, phosphorus, oxygen, and sulfur; 5- to 10-membered rings having 1 to 8 cyclic carbon atoms and 1 to 4 cyclic heteroatoms independently selected from nitrogen, phosphorus, oxygen, and sulfur; and 5-, 6-, or 7-membered rings having 1 to 5 cyclic carbon atoms and 1 to 4 cyclic heteroatoms independently selected from nitrogen, oxygen, and sulfur. In one variation, heteroaryl includes monocyclic aromatic 5-, 6-, or 7-membered rings having 1 to 6 cyclic carbon atoms and 1 to 4 cyclic heteroatoms independently selected from nitrogen, oxygen, and sulfur. In another variation, heteroaryl includes polycyclic aromatic rings having 1 to 12 cyclic carbon atoms and 1 to 6 cyclic heteroatoms independently selected from nitrogen, phosphorus, oxygen, and sulfur.

[0101] Typical heteroaryl groups include, but are not limited to, acridine, arsindole, carbazole, carboline, chroman, chromene, cinnoline, furan, imidazole, indazole, indole, indoline, indolizine, isobenzofuran, isochromene, isoindole, isoindoline, isoquinoline, isothiazole, isoxazole, naphthyridine, oxadiazole, oxazole, perimidine, phenanthridine, phenanthroline, phenazine, phthalazine, pteridine, purine, pyran, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolidine, quinazoline, quinoline, quinolizine, quinoxaline, tetrazole, thiadiazole, thiazole, thiophene, triazole, xanthene, etc. Preferred heteroaryl groups are thiophene, pyrrole, benzothiophene, benzofuran, indole, pyridine, quinoline, imidazole, oxazole, and pyrazine, and those derived therefrom.

[0102] Rings of different categories may be connected to each other by fused, spiro or bridged, connected, or combinations thereof, etc. Such ring systems may be referred to as "mixed" ring systems.

[0103] For example, at least one ring of a polycyclic ring system may itself be aromatic, while one or more of the remaining fused rings may not be aromatic. Examples of fused ring systems containing at least one aromatic ring and at least one partially saturated ring include fluorene, indane, and biphenylene.

[0104] Mixed ring systems having more than one ring, where at least one ring is aromatic and at least one ring is non-aromatic, can be connected to another structure by bonding to either an aromatic ring atom or a non-aromatic ring atom.

[0105] Heteroaryl groups having more than one ring, where at least one ring is non-aromatic, may be attached to another structure at an aromatic ring position or at a non-aromatic ring position.

[0106] Similarly, carbocyclic and heterocyclic groups may be joined to each other in one of several ways to form ring systems containing more than one ring.

[0107] "Halo" or "halogen" refers to fluoro, chloro, bromo, and / or iodo. An alkyl group in which one or more hydrogen atoms are replaced by halogen is referred to as a "haloalkyl," e.g., "C 1-6

[0023] When a moiety is substituted with more than one halogen, it may be preferable to refer to an aryl group substituted with two ("di") or three ("tri") halo groups by using a prefix corresponding to the number of halogen moieties attached, e.g., dihaloaryl, trihaloaryl, respectively. It is understood that when multiple halo groups are present, they are not necessarily the same as each other. Thus, 4-chloro-3-fluorophenyl is within the scope of dihaloaryl. An alkyl group in which all hydrogen atoms are replaced with halogen atoms is referred to as a "perhaloalkyl." Thus, the term haloalkyl includes perhaloalkyl unless the context specifically excludes perhaloalkyl. A preferred perhaloalkyl group is trifluoromethyl (-CF3). Similarly, "perhaloalkoxy" refers to an alkoxy group replacing each H in the hydrocarbon occupying the alkyl portion of the alkoxy group. An example of a perhaloalkoxy group is trifluoromethoxy (-OCF3).

[0108] "Carbonyl" refers to the group C=O.

[0109] "Carbenyl," when used as a ring substituent, refers to the moiety =C, i.e., a carbon atom double-bonded to a carbon atom within the ring. It means that a single carbon atom replaces two hydrogen (or other monovalent) atoms bonded to the ring carbon atoms, and is thus bonded to the ring carbon atoms through a double bond. Generally, carbenyl is a group consisting of R c R d C can be expressed as R c R c is independently hydrogen or alkyl.

[0110] "Thiocarbonyl" refers to the group C=S.

[0111] "Oxo" refers to the moiety =O, i.e., an oxygen atom double bonded to a second atom other than oxygen. When used as a ring substituent, it means that a ring atom, such as a carbon atom, is attached to an oxygen atom other than a ring atom through a double bond.

[0112] "Prodrug" refers to a pharmacologically inactive derivative of a drug molecule that requires a transformation, usually a metabolic transformation, within the body to release the active drug.

[0113] A "promoiety" refers to a form of protecting group that, when used to mask a functional group within a drug molecule, converts the drug into a prodrug. Typically, a promoiety is attached to the drug via one or more bonds that are cleaved in vivo by enzymatic or non-enzymatic means. Ideally, the promoiety is rapidly eliminated from the body upon cleavage from the prodrug.

[0114] A "protecting group" refers to a class of atoms that, when attached to a reactive group in a molecule, masks, reduces, or prevents that reactivity. Examples of protecting groups can be found in Green et al., "Protective Groups in Organic Chemistry," (Wiley, 2nd ed. 1991) and Harrison et al., "Compendium of Synthetic Organic Methods," Vols. 1-8 (John Wiley and Sons, 1971-1996). Representative amino-protecting groups include, but are not limited to, formyl, acetyl, trifluoroacetyl, benzyl, benzyloxycarbonyl ("CBZ"), tert-butoxycarbonyl ("Boc"), trimethylsilyl ("TMS"), 2-trimethylsilyl-ethanesulfonyl ("SES"), trityl and substituted trityl groups, allyloxycarbonyl, 9-fluorenylmethyloxycarbonyl ("FMOC"), and nitro-veratryloxycarbonyl ("NVOC"). Representative hydroxy protecting groups include, but are not limited to, those in which the hydroxy group is acylated or alkylated, for example, benzyl and trityl ethers, as well as alkyl ethers, tetrahydropyranyl ethers, trialkylsilyl ethers and allyl ethers.

[0115] The compounds of formula (I) described herein, or salts or solvates thereof, can exist in stereoisomeric forms (e.g., such compounds contain one or more asymmetric carbon atoms). Individual stereoisomers (such as purified enantiomers and diastereomers) and mixtures or enantiomerically / diastereomerically enriched mixtures thereof are included within the scope of the subject matter disclosed herein. The stereochemistry shown in the examples has been arbitrarily assigned.

[0116] Furthermore, it is understood that compounds or salts of formula (I) may exist in tautomeric forms other than that shown in the formula and these are also included within the scope of the presently disclosed subject matter.

[0117] The subject matter disclosed herein also includes isotopically labeled forms of the compounds described herein, i.e., compounds having the formulas set forth herein, but due to the fact that one or more constituent atoms have been replaced by an atom having an atomic mass or mass number that is different from the atomic mass or mass number of the atom normally found in nature and / or found in an abundance not normally found in nature. Examples of such isotopes that may be incorporated into the compounds described herein and their pharmaceutically acceptable salts at levels that differ from the natural distribution of isotopes include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, iodine, and chlorine, e.g., 2 H (denoted as D), 3 H, 11 C. 13 C. 14 C. 15 N, 17 O. 18 O. 31 P, 32 P, 35 S, 18 F, 36 Cl, 123 I, 125 I, and 131 I. In most cases, any hydrogen atom in the molecules disclosed herein can be replaced by a deuterium atom. A given isotopically substituted molecule can contain deuterium atoms at multiple positions. In particular, methyl groups in a molecule can be perdeuterated, designated CD3. For deuterated molecules, the molecule preferably has an isotopic enrichment factor of at least 3500 (~52.5% deuterium incorporation) at a given position, with an isotopic enrichment factor of 6633 representing 99.5% incorporation.

[0118] The presently disclosed subject matter further includes prodrugs, metabolites, and pharmaceutically acceptable salts of compounds of Formula (I). Metabolites of compounds of Formula (I) include compounds produced by a process comprising contacting a compound of Formula (I) with a mammal for a period of time sufficient to yield a metabolic product thereof.

[0119] In some embodiments, the salts of the compounds of the present invention are pharmaceutically acceptable salts. A "pharmaceutically acceptable salt" is a salt that retains at least some of the biological activity of the free (non-salt) compound and can be administered to a subject as a drug or pharmaceutical. Such salts include, for example, (1) acid addition salts; (2) salts formed when an acidic proton is replaced by a metal ion; or (3) acidic proton coordinates with an organic base. Pharmaceutically acceptable salts can be prepared in situ during a manufacturing process or by separately reacting a purified compound of the present invention in its free acid or base form with a suitable organic or inorganic base or acid, respectively, and then isolating the salt thus formed during purification.

[0120] If the compound of formula (I) is a base, the desired pharmaceutically acceptable salt may be prepared as an acid addition salt by any suitable method available in the art, such as treatment of the free base with an inorganic acid such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, methanesulfonic acid, phosphoric acid, and others with similar properties, or an organic acid such as acetic acid, maleic acid, succinic acid, mandelic acid, fumaric acid, propionic acid, malonic acid, pyruvic acid, oxalic acid, glycolic acid, salicylic acid, a pyranosidyl acid such as glucuronic acid or galacturonic acid, an alpha hydroxy acid such as citric acid or tartaric acid, an amino acid such as aspartic acid or glutamic acid, an aromatic acid such as benzoic acid or cinnamic acid, a sulfonic acid such as p-toluenesulfonic acid or ethanesulfonic acid, and others with similar properties.

[0121] When the compound of formula (I) is an acid, one or more acidic protons present may be replaced by a metal ion, such as an alkali metal ion, alkaline earth ion, or aluminum ion. The desired pharmaceutically acceptable salt can then be prepared by any suitable method, for example, by treating the free acid with an inorganic or organic base, such as an amine (primary, secondary, or tertiary), an alkali metal hydroxide, or an alkaline earth metal hydroxide. Examples of suitable salts include, but are not limited to, organic salts derived from amino acids such as glycine and arginine, ammonia, and cyclic amines such as piperidine, morpholine, and piperazine, alcohol amines such as ethanolamine, diethanolamine, and triethanolamine, and inorganic salts derived from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum, and lithium. Acceptable inorganic bases include aluminum hydroxide, calcium hydroxide, potassium hydroxide, sodium carbonate, sodium hydroxide, and the like.

[0122] The compounds herein may also exist as solvates, ie, crystallized with a corresponding amount of solvent molecules in a ratio that may or may not be stoichiometric.

[0123] The compounds of formula (I) may be in the form of "prodrugs," including compounds having moieties that can be metabolized in vivo. Generally, prodrugs are metabolized in vivo by esterases or other mechanisms to form active drugs in the patient's body. Examples of prodrugs and their uses are well known in the art (e.g., Berge et al. (1977) "Pharmaceutical Salts," J. Pharm. Sci., 66:1-19). Prodrugs can be prepared by separately reacting purified compounds in their free acid form or hydroxyls with an appropriate esterifying agent, or in situ during the final isolation and purification of the compounds. Hydroxyl groups can be converted to esters via treatment with a carboxylic acid. Examples of prodrug moieties include substituted and unsubstituted, branched or unbranched lower alkyl ester moieties (e.g., propionate ester), lower alkenyl ester, di-lower alkylamino lower alkyl ester (e.g., dimethylaminoethyl ester), acylamino lower alkyl ester (e.g., acetyloxymethyl ester), acyloxy lower alkyl ester (e.g., pivaloyloxymethyl ester), aryl ester (phenyl ester), aryl lower alkyl ester (e.g., benzyl ester), substituted (e.g., with methyl, halo, or methoxy substituents) aryl and aryl lower alkyl ester, amide, lower alkyl amide, di-lower alkyl amide, and hydroxyamide. Prodrugs that are converted to active forms in vivo through other mechanisms are also included. In some embodiments, the compounds of the present invention are prodrugs of any of the formulas herein.

[0124] It is also understood that the subject matter disclosed herein includes combinations and subsets of the particular categories (e.g., salt forms, tautomers, stereoisomeric forms) described herein.

[0125] The terms "treat" and "treatment" refer to therapeutic treatment, the purpose of which is to slow, reduce, or attenuate an undesirable physiological change or disorder, such as the onset or spread of arthritis or cancer. For purposes of this disclosure, beneficial or desired clinical results include, but are not limited to, alleviation of one or more symptoms, whether detectable or undetectable, reduction in the extent of the disease, stabilization of the disease state (i.e., not worsening), slowing or reducing the rate of disease progression, improvement or palliation of the disease state, and remission (partial or total). "Treatment" can also mean prolonging survival compared to the patient's expected survival if not receiving treatment. Those in need of treatment include those with a condition or disorder, and further include those experiencing only the early stages of the disorder or disease, where one or more typical symptoms may not yet be present.

[0126] The term "therapeutically effective amount" refers to an amount of a compound of the present invention (or a salt thereof) that produces a desired therapeutic result, such as: (i) treating a particular disease, condition, or disorder; (ii) attenuating, ameliorating, or eliminating one or more symptoms of a particular disease, condition, or disorder; or (iii) preventing or delaying the onset of one or more symptoms of a particular disease, condition, or disorder described herein. In the case of cancer, a therapeutically effective amount of a drug may reduce the severity or duration of, stabilize the severity of, or eliminate one or more symptoms of, cancer. This may be done by reducing the number of cancer cells; reducing tumor size or checking its growth rate; inhibiting (i.e., slowing to some extent, and preferably stopping) the invasion of cancer cells into peripheral organs; inhibiting (i.e., slowing to some extent, and preferably stopping) tumor metastasis; inhibiting to some extent tumor growth; and / or alleviating to some extent one or more symptoms associated with cancer. To the extent that they may prevent growth and / or kill existing cancer cells, drugs may be cytostatic and / or cytotoxic. For cancer treatment, efficacy can be measured, for example, by assessing the time to progression (TTP) and / or determining the response rate (RR). In other therapeutic fields, to be referred to as therapeutic use, beneficial or desired results include, for example, reducing one or more symptoms resulting from the disease (biochemical, histological, and / or behavioral), including its complications and intermediate pathological phenotypes exhibited during the development of the disease, improving the quality of life of those affected by the disease, reducing the dose of other medications required to treat the disease, enhancing the effectiveness of another medication, delaying the progression of the disease, and / or prolonging patient survival.

[0127] The term "cancer" refers to or describes a physiological condition in mammals that is typically characterized by uncontrolled cell growth and invasiveness, with cancerous cells capable of local invasion and / or metastasis to non-adjacent sites. As used herein, "cancer cell," "cancerous cell," or "tumor cell" refers to a cell characterized by such uncontrolled cell growth and invasive properties. A "tumor" comprises more than one cancerous cell. Cancers can be further divided into liquid and solid forms. The term "cancer," as used herein, generally encompasses all types of cancer according to the specific context. Examples of cancer include, but are not limited to, carcinoma, melanoma, lymphoma, blastoma, sarcoma, and leukemia or lymphoid malignancies. Specific examples of such cancers include squamous cell carcinoma (e.g., epithelial squamous cell carcinoma), lung cancer, including small cell lung cancer, non-small cell lung cancer ("NSCLC"), adenocarcinoma of the lung, and squamous cell carcinoma of the lung, cancer of the peritoneum, hepatocellular carcinoma, gastric (or stomach) cancer, including gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, liver cancer, breast cancer, colon cancer, rectal cancer, colorectal cancer, esophageal cancer, endometrial or uterine cancer, salivary gland cancer, kidney or renal cancer, prostate cancer, vulvar cancer, thyroid cancer, liver cancer, anal cancer, penile cancer, Ewing's sarcoma, medulloblastoma, and head and neck cancer.

[0128] A "chemotherapeutic agent" is a chemical compound or biological agent useful in the treatment of cancer. A chemotherapeutic agent can be an immunotherapeutic agent. As used herein, an "immunotherapeutic agent" is a compound that enhances the immune system to specifically or nonspecifically help fight cancer. Immunotherapies include monoclonal antibodies that enhance the immune system and nonspecific immunotherapies.

[0129] As used herein, a "combination therapy" refers to a therapy comprising two or more different compounds administered simultaneously or together. Typically, each of the two or more different compounds has a different mechanism of action. Thus, in one aspect, a combination therapy comprising a compound detailed herein and another compound is provided. In some variations, the combination therapy optionally comprises one or more pharmaceutically acceptable carriers or additives, non-pharmacologically active compounds, and / or inactive substances. The combination therapy can comprise two or more compounds in a single delivery vehicle, such as a tablet, or can comprise doses in separate formulations, for example, in different tablets, or in one tablet and an injectable solution.

[0130] As used herein, the term "effective amount" refers to the amount of a compound of the present invention that should be effective in a given dosage form, in combination with efficacy and toxicity parameters. As understood in the art, an effective amount may be contained in one or more doses, i.e., a single dose or multiple doses may be required to achieve a desired therapeutic endpoint. An effective amount is considered in the context of administering one or more therapeutic agents; a single agent may be considered to be given in an effective amount if, in conjunction with one or more other agents, a desired or beneficial result can be or is achieved. The appropriate dose of any co-administered compound may be reduced, as necessary, due to the combined effects (e.g., additive or synergistic) of the compounds. In various embodiments, an effective amount of a composition or treatment may (i) reduce the number of cancer cells; (ii) reduce tumor size; (iii) inhibit, delay, slow to some extent, and preferably stop, cancer cell invasion into peripheral organs; (iv) inhibit (e.g., slow to some extent, and preferably stop) tumor metastasis; (v) inhibit tumor growth; (vi) prevent or delay tumor onset and / or recurrence; and / or (vii) alleviate to some extent one or more symptoms associated with cancer. In various embodiments, the amount is sufficient to ameliorate, alleviate, relieve, and / or delay one or more symptoms of cancer.

[0131] A "prophylactically effective amount" refers to the amount of a compound or a pharmaceutically acceptable salt thereof that, when administered to a subject susceptible and / or susceptible to developing a disease or disorder, is sufficient to prevent or reduce the severity of one or more future symptoms of the disease or disorder. With respect to prophylactic use, beneficial or desired results include, for example, eliminating or reducing the risk, reducing the severity of future disease, or delaying the onset of disease (e.g., delaying the biochemical, histological, and / or behavioral symptoms of the disease, its complications, and intermediate pathological phenotypes manifested during future development of the disease).

[0132] It is understood that an effective amount of a compound disclosed herein or a pharmaceutically acceptable salt thereof, including a prophylactically effective amount, can be administered to a subject in adjuvant therapy, which refers to a clinical setting in which the subject has a history of a disease or disorder and has generally (but not necessarily) responded to treatment, including, but not limited to, surgery (e.g., surgical resection), radiation therapy, and chemotherapy. However, due to the patient's or the patient's family's history of a disease or disorder, these subjects are considered to be at risk of developing such a disease or disorder. Treatment or administration in the "adjuvant setting" refers to a subsequent mode of treatment.

[0133] As used herein, "unit dosage form" refers to physically discrete units suitable as unit dosages, each unit containing a predetermined quantity of active ingredient(s) calculated to produce a desired therapeutic effect in combination with the required pharmaceutical carriers or excipients. Unit dosage forms may contain a single compound or a combination therapy.

[0134] The term "controlled release" as used herein refers to a formulation or portion thereof containing an active pharmaceutical ingredient in which the release of the pharmaceutical agent is not immediate. Thus, in a "controlled release" formulation, administration to a subject does not result in the immediate release of the drug into the subject's circulation. This term encompasses depot formulations designed to gradually release a drug compound over an extended period of time. Controlled release formulations generally include a wide variety of drug delivery systems, including mixing a drug compound with a carrier, polymer, or other compound having desired release characteristics (e.g., pH-dependent or pH-independent solubility, and varying degrees of water solubility) and formulating the mixture according to the desired delivery route (e.g., coated capsules, implantable reservoirs, injectable solutions containing biodegradable capsules, etc.).

[0135] As used herein, "pharmaceutically acceptable" or "pharmacologically acceptable" means a material that is not biologically or otherwise undesirable; e.g., the material may be incorporated into a pharmaceutical composition administered to a patient without producing any significant undesirable biological effects or interacting in a deleterious manner with any of the other components of the composition in which it is contained. Pharmaceutically acceptable carriers or excipients preferably meet the required standards of toxicology and manufacturing testing and / or are included in the Inactive Ingredients Guides developed and updated by the U.S. Food and Drug Administration.

[0136] As used herein, the term "excipient" refers to an inactive or non-active substance that may be used in the manufacture of a drug or pharmaceutical product, such as a tablet, containing a compound of the present invention as an active ingredient. A variety of substances are encompassed by the term excipient, including, but not limited to, any substance used as a binder, disintegrant, coating, compression / encapsulation aid, cream or lotion, lubricant, parenteral solution, chewable tablet material, sweetener or flavoring agent, suspending / gelling agent, or wet granulation agent. Binders include, for example, carbomer, povidone, or xanthan gum. Coatings include, for example, cellulose acetate phthalate, ethyl cellulose, gellan gum, maltodextrin, and enteric coatings. Compression / encapsulation aids include, for example, calcium carbonate, dextrose, fructose dc (dc means "directly compressible"), honey dc, lactose (anhydrous or monohydrate; optionally in combination with aspartame, cellulose, or microcrystalline cellulose), starch dc, and sucrose. Disintegrants include, for example, croscarmellose sodium, gellan gum, and sodium starch glycolate. Creams or lotions include, for example, maltodextrin and carrageenan. Lubricants include, for example, magnesium stearate, stearic acid, and sodium stearyl fumarate. Chewable tablet materials include, for example, dextrose, fructose dc, and lactose (monohydrate, optionally in combination with aspartame or cellulose). Suspending / gelling agents include, for example, carrageenan, sodium starch glycolate, and xanthan gum. Sweeteners include, for example, aspartame, dextrose, fructose dc, sorbitol, sucrose dc, etc.; wet granulating agents include, for example, calcium carbonate, maltodextrin, microcrystalline cellulose, etc. In some cases, the terms "excipient" and "carrier" are used interchangeably.

[0137] The term "subject" or "patient" refers to humans, whether adult, juvenile, or infant, but can also encompass other higher animals, such as mammals, in which case the term can include, but is not limited to, primates, cows, sheep, goats, horses, dogs, cats, rabbits, rats, and mice.

[0138] The terms "abnormal cell growth," "uncontrolled cell growth," and "hyperproliferative disorder" are used interchangeably in this application. As used herein, unless otherwise indicated, "abnormal cell growth" refers to cell growth that is independent of normal control mechanisms (e.g., loss of contact inhibition).

[0139] Representative lactam (isoindolin-1-one) compounds according to Formula (I) are set forth in Table 1. It is understood that individual enantiomers and diastereomers are included in the following tables, where applicable. Furthermore, it is understood that the inclusion of a single particular enantiomer or diastereomer of a particular molecule does not exclude its partner enantiomer, or other stereoisomers thereof, from being encompassed by the present disclosure. Table 1 TIFF2024542117000004.tif255170TIFF2024542117000005.tif249170TIFF2024542117000006.tif250170TIFF2024542117000007.tif237170TIFF2024542117000008.tif255170TIFF2024542117000009.tif237170TIFF2024542117000010.tif249170TIFF2024542117000011.tif227170TIFF2024542117000012.tif241170TIFF2024542117000013.tif232170TIFF2024542117000014.tif239170TIFF2024542117000015.tif240170TIFF2024542117000016.tif230170TIFF2024542117000017.tif255170TIFF2024542117000018.tif238170TIFF2024542117000019.tif241170TIFF2024542117000020.tif236170TIFF2024542117000021.tif255170TIFF2024542117000022.tif255170TIFF2024542117000023.tif247170TIFF2024542117000024.tif240170TIFF2024542117000025.tif255170TIFF2024542117000026.tif253170TIFF2024542117000027.tif235170TIFF2024542117000028.tif250170TIFF2024542117000029.tif246170TIFF2024542117000030.tif238170TIFF2024542117000031.tif235170TIFF2024542117000032.tif238170TIFF2024542117000033.tif244170TIFF2024542117000034.tif241170TIFF2024542117000035.tif240170TIFF2024542117000036.tif242170TIFF2024542117000037.tif240170TIFF2024542117000038.tif251170TIFF2024542117000039.tif24 6170TIFF2024542117000040.tif235170TIFF2024542117000041.tif239170TIFF2024542117000042.tif243170T IFF2024542117000043.tif234170TIFF2024542117000044.tif230170TIFF2024542117000045.tif233170TIFF20 24542117000046.tif245170TIFF2024542117000047.tif252170TIFF2024542117000048.tif245170TIFF2024542 117000049.tif230170TIFF2024542117000050.tif234170TIFF2024542117000051.tif249170TIFF202454211700 0052.tif240170TIFF2024542117000053.tif255170TIFF2024542117000054.tif244170TIFF2024542117000055. tif255170TIFF2024542117000056.tif244170TIFF2024542117000057.tif255170TIFF2024542117000058.tif23 9170TIFF2024542117000059.tif237170TIFF2024542117000060.tif235170TIFF2024542117000061.tif206170.

[0140] Pharmaceutical Compositions and Formulations The compounds disclosed by the present invention can be formulated into pharmaceutical compositions together with pharmaceutically acceptable carriers or excipients.

[0141] The compounds of formula (I) may be formulated as pharmaceutical compositions in accordance with standard pharmaceutical practice. According to this aspect, there is provided a pharmaceutical composition comprising a compound of formula (I) together with a pharmaceutically acceptable excipient, diluent or carrier.

[0142] A typical formulation is prepared by mixing a compound of Formula (I) with a carrier, diluent, or additive. Suitable carriers, diluents, and additives are well known to those skilled in the art and include materials such as carbohydrates, waxes, water-soluble and / or swellable polymers, hydrophilic or hydrophobic materials, gelatin, oils, solvents, and water. The specific carrier, diluent, or additive used will depend on the means and purpose for which the compound of Formula (I) is being applied. Solvents are typically selected based on solvents recognized by those skilled in the art as safe (GRAS) for administration to mammals. Generally, safe solvents are non-toxic aqueous solvents, such as water and other non-toxic solvents that are soluble or miscible in water. Suitable aqueous solvents include water, ethanol, propylene glycol, polyethylene glycols (e.g., PEG400, PEG300), and the like, and mixtures thereof. The formulation may also include one or more buffers, stabilizers, surfactants, wetting agents, lubricants, emulsifiers, suspending agents, preservatives, antioxidants, opacifying agents, glidants, processing aids, colorants, sweeteners, flavors, flavoring agents, and other known additives to present the drug (i.e., compound of formula (I) or pharmaceutical composition thereof) in an attractive manner or to aid in the manufacture of the pharmaceutical product (i.e., medicament).

[0143] The formulations may be prepared using conventional dissolution and mixing procedures. For example, the bulk drug substance (i.e., the compound of formula (I), or a stabilized form of the compound of formula (I), such as a complex with a cyclodextrin derivative or other known complexing agent, is dissolved in a suitable solvent in the presence of one or more of the above-mentioned additives. The compound of formula (I) is typically formulated into a pharmaceutical dosage form to provide an easily controllable dosage of the drug and to enable patient compliance with the prescribed regimen.

[0144] Pharmaceutical compositions (or formulations) for application can be packaged in a variety of ways depending on the method used to administer the drug. Generally, an article for distribution includes a container having disposed therein the pharmaceutical formulation in an appropriate form. Suitable containers are well known to those skilled in the art and include materials such as bottles (plastic and glass), sachets, ampoules, plastic bags, and metal cylinders. The container may also include a tamper-evident assembly to prevent unintentional access to the contents of the package. In addition, the container has disposed thereon a label that describes the contents of the container. The label may include appropriate warnings.

[0145] Pharmaceutical preparations can be prepared for various routes and types of administration. For example, the compound of formula (I) having the desired purity can be optionally mixed with a pharmaceutically acceptable diluent, carrier, excipient, or stabilizer in the form of a lyophilized preparation, a crushed powder, or an aqueous solution (Remington's Pharmaceutical Sciences (1980) 16). th (Osol, A. Ed., ed.). Formulation is carried out by mixing with physiologically acceptable additives or carriers (i.e., additives or carriers that are nontoxic to recipients at the dosages and concentrations employed) at ambient temperature, at an appropriate pH, and at the desired purity. The pH of the formulation depends primarily on the specific application and concentration of compound, but can range from about 3 to about 8. Formulation in acetate buffer at pH 5 is a suitable embodiment.

[0146] The compounds of formula (I) can be sterile. In particular, formulations to be used for in vivo administration must be sterile. Such sterilization is readily accomplished by filtration through sterile filtration membranes.

[0147] The compounds of formula (I) may generally be stored as a solid composition, a lyophilized formulation or an aqueous solution.

[0148] Pharmaceutical compositions containing compounds of Formula (I) can be formulated, dosed, and administered in a manner consistent with good medical practice, i.e., amount, concentration, schedule, course, vehicle, and route of administration. Factors to consider in this context include the particular disorder being treated, the particular mammal being treated, the clinical condition of the individual patient, the cause of the disorder, the site of drug delivery, the method of administration, the administration scheduling, and other factors known to medical practitioners. The "therapeutically effective amount" of the compound administered will depend on such considerations and is the minimum amount necessary to prevent, ameliorate, or treat a coagulation factor-mediated disorder. In some embodiments, the amount is below an amount that is toxic to the host or renders the host more susceptible to bleeding.

[0149] Acceptable diluents, carriers, additives, and stabilizers are non-toxic to recipients at the dosages and concentrations employed and include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (e.g., octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride; benzethonium chloride; phenol, butyl, or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low polypeptides of molecular weight (less than about 10 residues); proteins such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose, or sorbitol; salt-forming counterions such as sodium; metal complexes (e.g., Zn-protein complexes), and / or TWEEN TM , PLURONICS TMor polyethylene glycol (PEG). The active pharmaceutical ingredient may also be incorporated into microcapsules prepared, for example, by coacervation techniques or interfacial polymerization, such as hydroxymethylcellulose or gelatin-microcapsules and poly-(methylmethylate) microcapsules, respectively, into colloidal drug delivery systems (e.g., liposomes, albumin microspheres, microemulsions, nanoparticles, and nanocapsules), or into macroemulsions. Such techniques are described in Remington's Pharmaceutical Sciences 16 th edition, Osol, A. Ed. (1980).

[0150] Sustained-release preparations of the compounds of formula (I) may be prepared. Suitable examples of sustained-release preparations include semipermeable matrices of solid hydrophobic polymers containing the compounds of formula (I), which matrices are in the form of shaped articles, e.g., films or microcapsules. Examples of sustained-release matrices include polyesters, hydrogels (e.g., poly(2-hydroxyethyl-methacrylate) or poly(vinyl alcohol)), polylactic acid (U.S. Pat. No. 3,773,919), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate, non-degradable ethylene-vinyl acetate, LUPRON DEPOT TM These include degradable lactic acid-co-glycolic acid polymers and poly-D-(-)-3-hydroxybutyrate, such as (injectable microspheres composed of lactic acid-co-glycolic acid polymer and leuprolide acetate).

[0151] Formulations include those suitable for routes of administration detailed herein. Formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. Techniques and formulations are generally found in Remington's Pharmaceutical Sciences (Mack Publishing Co., Easton, PA). Such methods include the step of bringing into association the active ingredient with the excipient or carrier, which constitutes one or more accessory ingredients. In general, formulations are prepared by uniformly and intimately bringing into association the active ingredient with liquid excipients or carriers, or finely divided solid excipients or carriers, or both, and then, if necessary, shaping the product.

[0152] Formulations of a compound of formula (I) suitable for oral administration may be prepared as discrete units such as pills, capsules, cachets or tablets, each containing a predetermined amount of a compound of formula (I).

[0153] Compressed tablets may be prepared by compressing in a suitable machine the active ingredient in a free-flowing form such as a powder or granules, optionally mixed with a binder, lubricant, inert diluent, preservative, surface-active agent, or dispersing agent. Molded tablets may be made by molding in a suitable machine a mixture of moistened powdered active ingredient and an inert liquid diluent. The tablets may optionally be coated or grooved, and optionally formulated so as to provide slow or controlled release of the active ingredient therefrom.

[0154] Tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, such as gelatin capsules, syrups, or elixirs may be prepared for oral use. Formulations of a compound of formula (I) intended for oral use may be prepared according to any method known in the art for the manufacture of pharmaceutical compositions, and such compositions may contain one or more agents, including sweeteners, flavoring agents, coloring agents, and preservatives, to provide a palatable preparation. Tablets containing the active ingredient mixed with non-toxic pharmaceutically acceptable additives suitable for the manufacture of tablets are acceptable. Such additives may be, for example, inert diluents such as calcium carbonate or sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents such as corn starch or alginic acid; binders such as starch, gelatin, or acacia; and lubricants such as magnesium stearate, stearic acid, or talc. Tablets may be uncoated or they may be coated by known techniques including microencapsulation to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period, for example, a time delay material such as glyceryl monostearate or glyceryl distearate alone or with a wax may be employed.

[0155] For treatments of the eye or other external tissues, for example mouth and skin, the formulations are preferably applied as a topical ointment or cream containing the active ingredient in an amount of from 0.075 to 20% w / w. When formulated in an ointment, the active ingredient may be employed with either a paraffinic or a water-miscible ointment base. Alternatively, the active ingredient may be formulated in a cream with an oil-in-water cream base.

[0156] If desired, the aqueous phase of the cream base may contain a polyhydric alcohol, i.e., an alcohol having two or more hydroxyl groups, such as propylene glycol, butane 1,3-diol, mannitol, sorbitol, glycerol, polyethylene glycol (including PEG 400), and mixtures thereof. Topical formulations may desirably contain a compound that enhances absorption or penetration of the active ingredient through the skin or other affected areas. Examples of such skin penetration enhancers include dimethyl sulfoxide and related analogs.

[0157] The oil phase of the emulsion can be composed of known ingredients in a known manner. This phase can contain only an emulsifier, but can also contain a mixture of at least one emulsifier with a fat or oil, or both. A hydrophilic emulsifier included with a lipophilic emulsifier can act as a stabilizer. Taken together, one or more emulsifiers, with or without one or more stabilizers, constitute the so-called emulsifying wax, which, together with oils and fats, forms the oily dispersed phase of the cream formulation, the so-called emulsifying ointment base. Emulsifiers and emulsion stabilizers suitable for use in this formulation include Tween® 60, Span® 80, cetostearyl alcohol, benzyl alcohol, myristyl alcohol, glyceryl monostearate, and sodium lauryl sulfate.

[0158] Aqueous suspensions of a compound of Formula (I) contain the active substance in admixture with additives suitable for the manufacture of aqueous suspensions. Such additives include suspending agents such as sodium carboxymethylcellulose, croscarmellose, povidone, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth, and gum acacia, as well as dispersing or wetting agents such as naturally occurring phosphatides (e.g., lecithin), condensation products of alkylene oxides with fatty acids (e.g., polyoxyethylene stearates), condensation products of ethylene oxide with long-chain aliphatic alcohols (e.g., heptadecaethyleneoxycetanol), and condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides (e.g., polyethylene sorbitan monooleate). Aqueous suspensions may also contain one or more preservatives, such as ethyl or n-propyl p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweeteners, such as sucrose or saccharin.

[0159] The pharmaceutical composition of the compound of formula (I) may be in the form of a sterile injectable preparation, such as a sterile injectable aqueous or oleaginous suspension. This suspension can be formulated according to known techniques using suitable dispersing or wetting agents and suspending agents as described above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, such as 1,3-butanediol. The sterile injectable preparation can also be prepared as a lyophilized powder. Acceptable vehicles and solvents that can be used include water, Ringer's solution, and isotonic sodium chloride solution. Additionally, sterile, fixed oils are commonly used as solvents or suspending media. For this purpose, any sterile, fixed oil, including synthetic monoglycerides or diglycerides, can also be used. Additionally, fatty acids such as oleic acid can also be used in the preparation of injectables.

[0160] The amount of active ingredient that can be combined with additives or carrier materials to produce a single dosage form will vary depending on the host treated and the particular mode of administration. For example, a sustained-release formulation intended for oral administration to humans may contain about 1 to 1000 mg of active agent, mixed with appropriate and convenient amounts of additives or carrier materials, which may vary from about 5 to about 95% (weight:weight) of the total composition. Pharmaceutical compositions can be prepared to provide easily measurable amounts for administration. For example, an aqueous solution for intravenous infusion may contain about 3 to 500 μg of active ingredient per milliliter of solution to allow infusion of a suitable volume at a rate of about 30 mL / hour.

[0161] Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain antioxidants, buffers, bacteriostats, and solutes which render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.

[0162] Formulations suitable for topical administration to the eye also include eye drops in which the active ingredient is dissolved or suspended in a suitable excipient or carrier, particularly an aqueous solvent for the active ingredient. The active ingredient is preferably present in such formulations in a concentration of about 0.5 to 20 w / w%, e.g., about 0.5 to 10 w / w%, e.g., about 1.5 w / w%.

[0163] Formulations suitable for topical administration in the mouth include lozenges comprising the active ingredient in a flavored base, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert base such as gelatin and glycerin or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.

[0164] Formulations for rectal administration may be presented as a suppository with a suitable base comprising, for example, cocoa butter or a salicylate.

[0165] Formulations suitable for pulmonary or nasal administration have, for example, particle sizes in the range of 0.1 to 500 microns (including particle sizes in the range of 0.1 to 500 microns in increments of microns, such as 0.5, 1, 30 microns, 35 microns, etc.), which are administered by rapid inhalation through the nostrils to reach the alveolar sacs, or by inhalation through the mouth. Suitable formulations include aqueous or oily solutions of the active ingredient. Formulations suitable for aerosol or dry powder administration may be prepared according to conventional methods and may be delivered together with other therapeutic agents, such as compounds previously used in the treatment or prevention of the disorders described below.

[0166] Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing, in addition to the active ingredient, such excipients or carriers as are known in the art to be appropriate.

[0167] The formulations may be packaged in unit-dose or multi-dose containers, for example, sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of a sterile liquid additive or carrier, such as water, for injection immediately prior to use. Extemporaneous injection solutions and suspensions are prepared from sterile powders, granules, and tablets of the kind described above. Preferred unit dosage formulations are those containing a daily dose or daily unit sub-dose, as herein above recited, of the active ingredient, or an appropriate fraction thereof.

[0168] The subject of the present invention further provides veterinary compositions comprising at least one active ingredient as defined above, together with a veterinary additive or carrier therefor. The veterinary additive or carrier is a substance useful for the purpose of administering the composition and may be a solid, liquid or gaseous substance that is otherwise inert or acceptable in the veterinary field and compatible with the active ingredient. These veterinary compositions may be administered parenterally, orally or by any other route.

[0169] The compound may be administered by any desired route. In certain embodiments, a pharmaceutical composition comprising a compound disclosed herein further comprises a chemotherapeutic agent. In some of these embodiments, the chemotherapeutic agent is an immunotherapeutic agent.

[0170] kit Further provided are kits for carrying out the methods detailed herein, which kits include one or more compounds described herein or pharmaceutical compositions containing the compounds described herein. The kits may utilize any of the compounds disclosed herein. In one variation, the kits utilize compounds described herein or pharmaceutically acceptable salts thereof. The kits may be used for any one or more of the methods described herein and therefore may include instructions for use in treating disorders such as cancer. In some embodiments, the kits include instructions for use in treating cancer.

[0171] The kit generally includes suitable packaging. The kit may include one or more containers containing any of the compounds described herein. Each component (if more than one component is present) may be packaged in a separate container, or multiple components may be combined in one container if cross-reactivity and shelf life permit. One or more components of the kit may be sterile and / or may be contained within sterile packaging.

[0172] The kit may be in unit dosage form, bulk package (e.g., multi-dose package), or subunit dose. For example, a kit may be provided that includes a sufficient dose (e.g., a therapeutically effective amount) of a compound disclosed herein and / or a second pharmaceutically active compound useful for a disorder (e.g., cancer) to provide effective treatment of an individual for an extended period of time, such as 1 week, 2 weeks, 3 weeks, 4 weeks, 6 weeks, 8 weeks, 3 months, 4 months, 5 months, 7 months, 8 months, 9 months, or longer. The kit may also include multiple unit doses of the compound and instructions for use, and may be packaged in an amount sufficient for storage and use in a pharmacy (e.g., hospital pharmacy and compounding pharmacy).

[0173] The kit may optionally include a set of instructions, typically written instructions, although electronic storage media (e.g., magnetic diskette or optical disk) containing instructions for use of one or more components of the methods of the invention are also acceptable. The instructions included in the kit generally include information about the components and their administration to a subject.

[0174] How to use The compounds disclosed herein find use in inhibiting the activity of Cbl-B. Moreover, the compounds inhibit the activity of Cbl-B with a greater inhibitory effect than they do C-cbl.

[0175] In one embodiment, the presently disclosed subject matter is directed to a method for inhibiting Cbl-B, the method comprising contacting one or more cells containing active Cbl-B protein with an effective amount of a compound of Formula (I) or a pharmaceutical composition described herein. "Contacting" refers to bringing the compound into sufficient proximity with an isolated Cbl-B enzyme or a cell expressing Cbl-B (e.g., a T cell, a B cell, a dendritic cell) so that the compound can bind to Cbl-B and inhibit its activity. The compound can be contacted with Cbl-B in vitro or in vivo via administration of the compound to a subject.

[0176] In one embodiment, the presently disclosed subject matter is directed to a method for enhancing an immune response in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of Formula (I), or a variant thereof, e.g., Formula (I), or a pharmaceutical composition described herein. In some aspects of this embodiment, the subject's T cells exhibit enhanced at least one of priming, activation, migration, proliferation, survival, and cytolytic response compared to before administration of the compound or pharmaceutical composition. In some aspects of this embodiment, T cell activation is characterized by an increased frequency of y-IFN+ CDS T cells, an increased frequency of y-IFN+ CD4 T cells, or an increased level of IL-2 or granzyme B production by the T cells compared to before administration of the compound or pharmaceutical composition. In some aspects of this embodiment, the number of T cells is increased compared to before administration of the compound or pharmaceutical composition. In some aspects of this embodiment, the T cells are antigen-specific CDS T cells. In some aspects of this embodiment, the T cells are antigen-specific CD4 T cells. In some aspects of this embodiment, the subject's antigen-presenting cells undergo enhanced maturation and activation compared to before administration of the compound or pharmaceutical composition. In some aspects of this embodiment, the antigen-presenting cells are dendritic cells. In some aspects of this embodiment, the maturation of the antigen-presenting cells is characterized by an increase in the frequency of CD83+ dendritic cells. In some aspects of this embodiment, the activation of the antigen-presenting cells is characterized by an increase in the expression of CD80 and CD86 on dendritic cells. In some aspects, the compound of Formula (I), or a variant thereof, or pharmaceutical composition thereof, provides for the overall priming of an immune response (i.e., a vaccine) against a tumor or virus to boost / generate antiviral / tumor immunity.

[0177] In another embodiment, the presently disclosed subject matter is directed to a method for treating cancer, the method comprising administering to a subject in need thereof an effective amount of a compound of Formula (I), or a pharmaceutical composition thereof, as further described herein. The compound is understood to function by inhibiting Cbl-B in a manner that results in activated T cells capable of killing cancer cells, regardless of their origin in the body. In some aspects of this embodiment, the cancer comprises at least one cancer selected from the group consisting of colorectal cancer, melanoma, non-small cell lung cancer, ovarian cancer, breast cancer, pancreatic cancer, hematological tumors, and renal cell carcinoma. In some aspects of this embodiment, the cancer has elevated levels of T cell infiltration. In some aspects of this embodiment, the subject's cancer cells selectively have elevated expression of MHC class I antigen expression compared to before administration of the compound or composition.

[0178] In the methods described herein, the methods can further include administering a therapeutic or chemotherapeutic agent to the subject. For example, such an agent can be a PD-L1 / PD-1 inhibitor. In some aspects of this embodiment, the therapeutic or chemotherapeutic agent is administered to the subject simultaneously with the compound or composition. In some aspects of this embodiment, the therapeutic or chemotherapeutic agent is administered to the subject prior to administration of the compound or composition. In some aspects of this embodiment, the therapeutic or chemotherapeutic agent is administered to the subject after administration of the compound or composition.

[0179] As used herein, "enhancing an immune response" refers to improving any immunogenic response to an antigen. Non-limiting examples of improved immunogenic responses to an antigen include enhanced maturation or migration of dendritic cells, enhanced activation of T cells (e.g., CD4+ T cells, CDS T cells), enhanced proliferation of T cells (e.g., CD4+ T cells, CDS T cells), enhanced B cell proliferation, increased survival of T cells and / or B cells, improved antigen presentation by antigen-presenting cells (e.g., dendritic cells), improved antigen clearance, increased production of cytokines (e.g., interleukin-2) by T cells, enhanced resistance to prostaglandin E2-induced immunosuppression, and enhanced priming and / or cytolytic response of CDS T cells.

[0180] In some embodiments, the subject's CDS T cells exhibit enhanced priming, activation, proliferation, and / or cytolytic response compared to before administration of a compound of Formula (I), or a variant thereof, such as Formulas (IA), (IB), and (IC), or a pharmaceutically acceptable salt, prodrug, metabolite, or derivative thereof. In some embodiments, CDS T cell priming is characterized by increased CD44 expression and / or an enhanced cytolytic response on the CDS T cells. In some embodiments, CDS T cell activation is characterized by an increased frequency of y-IFN+ CDS T cells. In some embodiments, the CDS T cells are antigen-specific T cells.

[0181] In some embodiments, the subject's CD4+ T cells exhibit enhanced priming, activation, proliferation, and / or cytolytic response compared to before administration of a compound of Formula (I), or a variant thereof, such as Formulas (IA), (IB), and (IC), or a pharmaceutically acceptable salt, prodrug, metabolite, or derivative thereof. In some embodiments, priming of CD4+ T cells is characterized by increased CD44 expression and / or enhanced cytolytic response on the CD4+ T cells. In some embodiments, activation of CD4+ T cells is characterized by an increase in the frequency of y-IFN+ CD4+ T cells. In some embodiments, the CD4+ T cells are antigen-specific T cells.

[0182] Thus, the compounds of formula (I) disclosed herein, or pharmaceutically acceptable salts, prodrugs, metabolites, or derivatives thereof, are useful for treating T cell dysfunction disorders, which are disorders or conditions of T cells characterized by decreased responsiveness to antigenic stimulation.

[0183] Thus, the compounds disclosed herein can be used in the treatment of conditions where enhanced immunogenicity is desirable, for example, increasing tumor immunogenicity for the treatment of cancer.

[0184] "Immunogenicity" refers to the ability of a particular substance to provoke an immune response. Tumors are immunogenic, and enhancing tumor immunogenicity can aid in the clearance of tumor cells by the immune response. Viruses can also be immunogenic, and enhancing / activating immunogenicity can aid in the clearance of viral particles by the immune response.

[0185] "Tumor immunity" refers to the process by which tumors evade immune recognition and clearance. Thus, as a therapeutic concept, tumor immunity is "treated" when such evasion is attenuated and tumors are recognized and attacked by the immune system. Examples of tumor recognition include tumor binding, tumor shrinkage, and tumor clearance.

[0186] In some embodiments, the compound is administered to a subject at a dose between about 0.001 μg / kg and about 1000 mg / kg, including but not limited to about 0.001 μg / kg, about 0.01 μg / kg, about 0.05 μg / kg, about 0.1 μg / kg, about 0.5 μg / kg, about 1 μg / kg, about 10 μg / kg, about 25 μg / kg, about 50 μg / kg, about 100 μg / kg, about 250 μg / kg, about 500 μg / kg, about 1 mg / kg, about 5 mg / kg, about 10 mg / kg, about 25 mg / kg, about 50 mg / kg, about 100 mg / kg, and about 200 mg / kg. [Example]

[0187] The compounds of the present invention may be synthesized according to the following exemplary synthetic procedures. Unless otherwise indicated, the absolute configuration has been arbitrarily assigned to each enantiomer or diastereomer, and pairs (or more) of such stereoisomeric compounds have been synthesized or isolated. In cases where only one member of a stereoisomerically related pair is identified, the absolute stereochemistry of such final product has been arbitrarily assigned.

[0188] Example 1: Intermediate A Intermediate A (tert-butyl(1-methylcyclobutyl)((3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)carbamate) can be synthesized according to a three-step scheme (Figure 1).

[0189] Process 1 To a solution of 6-(hydroxymethyl)-4-(trifluoromethyl)isoindolin-1-one (3.50 g, 15.14 mmol) in DCM (75.7 mL) was added thionyl chloride (2.75 mL, 37.85 mmol). The reaction was stirred at rt for 2 days. The reaction was cooled to 0 °C and a few drops of MeOH were added. After 10 min, the reaction was diluted with saturated aqueous NaHCO3, extracted with DCM, dried over sodium sulfate, filtered, and evaporated to give 6-(chloromethyl)-4-(trifluoromethyl)isoindolin-1-one (3.705 g, 98% yield). The product was used directly in the next step. LCMS (ESI) m / z: 250.4 [M+H] + .

[0190] Step 2: To a solution of 1-methylcyclobutanamine hydrochloride (2.253 g, 18.53 mmol) in MeCN (37.1 mL) was added cesium carbonate (9.719 g, 29.65 mmol). The reaction was stirred at 60 °C for 5 minutes, after which 6-(chloromethyl)-4-(trifluoromethyl)isoindolin-1-one (1.850 g, 7.41 mmol) was added. The reaction was stirred at 60 °C for 16 hours. The reaction was cooled to rt, water was added, extracted with EtOAc, and the combined organic phases were dried over sodium sulfate, filtered, and evaporated. The residue was purified by chromatography on silica gel (0-10% MeOH in DCM) to give 6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one (1.230 g, 56% yield). LCMS(ESI)m / z:299.4[M+H] +

[0191] Step 3: To a solution of 6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one (0.64 g, 2.15 mmol) and di-tert-butyl dicarbonate (0.54 mL, 2.36 mmol) in DCM (7.2 mL) was added triethylamine (0.45 mL, 3.22 mmol). The reaction was stirred at rt for 16 h. The reaction was diluted with saturated aqueous NaHCO3, extracted with EtOAc, dried over sodium sulfate, filtered, and evaporated. The residue was purified by chromatography on silica gel (0-5% MeOH in DCM) to give tert-butyl (1-methylcyclobutyl)((3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)carbamate (Intermediate A; 745 mg, 87% yield). LCMS (ESI) m / z: 397.4 [M+H] + .

[0192] Example 2: Alternative Route to Intermediate A Intermediate A can also be synthesized by a four-step scheme (Scheme 2, Figure 2).

[0193] Process 1 To a stirred solution of methyl 2-(bromomethyl)-5-formyl-3-(trifluoromethyl)benzoate (12.0 g, 36.9 mmol) and (1-methylcyclobutyl)ammonium chloride (4.49 g, 36.9 mmol) in DCE (100 mL) was added triethylamine (5.15 mL, 36.9 mmol), followed by the addition of sodium triacetoxyborohydride (23.47 g, 110.74 mmol) in portions over 20 min. The suspension was stirred at rt for 16 h. The reaction was then quenched with saturated aqueous NaHCO and extracted with DCM (3 × 150 mL). The organics were combined, dried over sodium sulfate, filtered, and concentrated to give methyl 2-(bromomethyl)-5-(((1-methylcyclobutyl)amino)methyl)-3-(trifluoromethyl)benzoate (16.2 g, 111% yield) as an amber oil, which was used in the next step without further purification.

[0194] Process 2 To a solution of methyl 2-(bromomethyl)-5-(((1-methylcyclobutyl)amino)methyl)-3-(trifluoromethyl)benzoate (16.5 g, 31.4 mmol) in THF (150 mL) was added triethylamine (13.1 mL, 94.2 mmol), followed by di-tert-butyl dicarbonate (10.8 mL, 47.09 mmol). The reaction was stirred at rt for 18 h. Saturated aqueous NaHCO3 (150 mL) was added to the reaction, and the product was extracted with EtOAc (3 x 250 mL). The organic layers were combined, dried over sodium sulfate, filtered, and concentrated to give methyl 2-(bromomethyl)-5-(((tert-butoxycarbonyl)(1-methylcyclobutyl)amino)methyl)-3-(trifluoromethyl)benzoate (18.2 g, 117% yield), which was used in the next step without further purification.

[0195] Process 3 A solution (100 mL, 700 mmol) of methyl 2-(bromomethyl)-5-(((tert-butoxycarbonyl)(1-methylcyclobutyl)amino)methyl)-3-(trifluoromethyl)benzoate (18 g, 16.4 mmol) in ammonia (7 M in MeOH) was stirred at rt for 16 h. The reaction was concentrated, and the residue was purified by chromatography on silica gel (0-100% EtOAc in heptane). Because the product obtained was not sufficiently pure, a second purification was performed by chromatography on C18 silica gel (40-100% acetonitrile in ammonium formate buffer, pH=3.7). The appropriate fractions were concentrated, frozen, and lyophilized to give tert-butyl (1-methylcyclobutyl)((3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)carbamate (Intermediate A; 2.55 g, 39% yield). LCMS (ESI) m / z: 299.2 [M+H] + .

[0196] Example 3: Intermediate B Intermediate B (2,6-dichloro-4-(1-(4-methyl-4H-1,2,4-triazol-3-yl)-3-methylenecyclobutyl)pyridine) can be synthesized according to a five-step scheme (Scheme 3, Figure 3).

[0197] Step 1: 1-(2,6-dichloropyridin-4-yl)-3-methylenecyclobutanecarbonitrile 2,4,6-Trichloropyridine (7.5 g, 41.11 mmol) and 3-methylenecyclobutanecarbonitrile (4.02 g, 43.16 mmol) were dissolved in THF (82.2 mL). The mixture was cooled to -78 °C, and 1 M LiHMDS in THF (45.2 mL, 45.22 mmol) was added dropwise over 10 min. The reaction mixture was allowed to warm to 0 °C over 4–5 h. Upon completion, the reaction was quenched by the addition of a saturated aqueous solution of NH4Cl, extracted with DCM (3x), and the combined organic phases were washed with brine, dried over sodium sulfate, filtered, and concentrated. The crude product was purified by chromatography on silica gel (0–10% EtOAc in heptane) to give 1-(2,6-dichloropyridin-4-yl)-3-methylenecyclobutanecarbonitrile (4.92 g, 50% yield). LCMS(ESI)m / z:239.3, 241.2[M+H] +

[0198] Step 2: 1-(2,6-dichloropyridin-4-yl)-3-methylenecyclobutanecarboxylic acid To a stirred solution of 1-(2,6-dichloropyridin-4-yl)-3-methylenecyclobutanecarbonitrile (4.2 g, 17.57 mmol) in ethanol (80 mL) was added 1 M NaOH solution (87.8 mL, 87.83 mmol). The resulting reaction mixture was heated at 100 °C for 20 h. The reaction was cooled to rt, and most of the ethanol was removed. The mixture was slowly quenched by adding 1 M HCl solution until pH 4-5 and concentrated again. The crude residue was purified by chromatography on C18 silica gel (0 to 100% acetonitrile in ammonium formate buffer, pH = 3.8). The appropriate fractions were concentrated, frozen, and lyophilized to give 1-(2,6-dichloropyridin-4-yl)-3-methylenecyclobutanecarboxylic acid (3.4 g, 75% yield). LCMS(ESI)m / z:258.4, 260.4[M+H] + .

[0199] Step 3: 2-(1-(2,6-dichloropyridin-4-yl)-3-methylenecyclobutanecarbonyl)-N-methylhydrazinecarbothioamide A mixture of 1-(2,6-dichloropyridin-4-yl)-3-methylenecyclobutanecarboxylic acid (3.1 g, 12 mmol), N-methylhydrazinecarbothioamide (1.89 g, 18 mmol), HATU (6.84 g, 18 mmol), and DIPEA (6.3 mL, 36 mmol) was dissolved in DMF (60 mL) and stirred at rt for 2 h. The reaction mixture was quenched with a saturated aqueous solution of NH4Cl and extracted with CHCl3:IPA (9:1). The combined organic layers were dried over sodium sulfate, filtered, and concentrated to give 2-(1-(2,6-dichloropyridin-4-yl)-3-methylenecyclobutanecarbonyl)-N-methylhydrazinecarbothioamide (4.5 g, 109% yield), which was used in the next step without further purification. LCMS(ESI)m / z:345.3, 347.3[M+H] +

[0200] Step 4: 5-(1-(2,6-dichloropyridin-4-yl)-3-methylenecyclobutyl)-4-methyl-4H-1,2,4-triazole-3-thiol The product of the previous step (2-(1-(2,6-dichloropyridin-4-yl)-3-methylenecyclobutanecarbonyl)-N-methylhydrazinecarbothioamide, 4.14 g, 12 mmol) was dissolved in 1 M NaOH solution (60 mL, 60 mmol) and stirred at 50 °C for 5 h, then cooled to rt and acidified to pH 4 with 1 N HCl solution. The resulting mixture was extracted with CHCl3:IPA (9:1). The organics were combined, dried over sodium sulfate, filtered, and concentrated to give 5-(1-(2,6-dichloropyridin-4-yl)-3-methylenecyclobutyl)-4-methyl-4H-1,2,4-triazole-3-thiol (3.28 g, 84% yield), which was used in the next step without further purification. LCMS (ESI) m / z: 327.4, 329.4 [M+H] + .

[0201] Step 5: 2,6-dichloro-4-(1-(4-methyl-4H-1,2,4-triazol-3-yl)-3-methylenecyclobutyl)pyridine To 5-(1-(2,6-dichloropyridin-4-yl)-3-methylenecyclobutyl)-4-methyl-4H-1,2,4-triazole-3-thiol (3.27 g, 10 mmol) and sodium nitrite (3.45 g, 50 mmol) in THF (50 mL) / water (50 mL) was added 1 M solution of nitric acid (60 mL, 60 mmol). The resulting reaction mixture was stirred at 0 °C for 1 h. The reaction was then quenched by the addition of saturated aqueous NaHCO and extracted with a mixture of CHCl:IPA (9:1). The combined organic layers were washed with brine, dried over sodium sulfate, and concentrated. The crude product was purified by chromatography on silica gel (0-10% MeOH in DCM) to give 2,6-dichloro-4-(1-(4-methyl-4H-1,2,4-triazol-3-yl)-3-methylenecyclobutyl)pyridine (2.4 g, 81% yield). LCMS (ESI) m / z: 295.2, 297.2 [M+H] + .

[0202] Example 4: Intermediate C Intermediate C (2,6-dichloro-4-(6-(4-methyl-4H-1,2,4-triazol-3-yl)-2-oxaspiro[3.3]heptan-6-yl)pyridine) can be synthesized according to the five-step scheme shown in Figure 4 (Scheme 4).

[0203] Step 1: Ethyl 6-(2,6-dichloropyridin-4-yl)-2-oxaspiro[3.3]heptane-6-carboxylate 2,4,6-Trichloropyridine (500 mg, 2.74 mmol) and ethyl 2-oxaspiro[3.3]heptane-6-carboxylate (466.5 mg, 2.74 mmol) were dissolved in THF (30 mL) and cooled to −78 °C. A 1 M solution of LiHMDS in THF (3.3 mL, 3.29 mmol) was added dropwise over 10 min at −78 °C, and the reaction mixture was allowed to warm to 0 °C over 4–5 h. Upon completion, the reaction was quenched by the addition of a saturated aqueous solution of NH4Cl, extracted with DCM (3×), and the combined organic phases were washed with brine, dried over sodium sulfate, filtered, and concentrated. The crude product was purified by chromatography on silica gel (0-10 EtOAc in heptane) to give ethyl 6-(2,6-dichloropyridin-4-yl)-2-oxaspiro[3.3]heptane-6-carboxylate (320 mg, 37% yield). LCMS (ESI) m / z: 316.3 [M+H] + .

[0204] Step 2: 6-(2,6-dichloropyridin-4-yl)-2-oxaspiro[3.3]heptane-6-carboxylic acid Ethyl 6-(2,6-dichloropyridin-4-yl)-2-oxaspiro[3.3]heptane-6-carboxylate (1.4 g, 4.43 mmol) was dissolved in THF (10 mL). 2 M NaOH solution (11.07 mL, 22.14 mmol) was added, and the reaction mixture was stirred for 4 h. Upon completion, it was quenched by the addition of 0.5 M KHSO4 solution and 1 N HCl, extracted with IPA / CHCl3 (1:4), and the combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated to give 6-(2,6-dichloropyridin-4-yl)-2-oxaspiro[3.3]heptane-6-carboxylic acid (1.25 g, 98% yield), which was used in the next step without further purification. LCMS (ESI) m / z: 288.4 [M+H] + .

[0205] Step 3: 2-(6-(2,6-dichloropyridin-4-yl)-2-oxaspiro[3.3]heptane-6-carbonyl)-N-methylhydrazinecarbothioamide A mixture of 6-(2,6-dichloropyridin-4-yl)-2-oxaspiro[3.3]heptane-6-carboxylic acid (500 mg, 1.74 mmol), N-methylhydrazinecarbothioamide (237.2 mg, 2.26 mmol), HATU (989.8 mg, 2.6 mmol), and DIPEA (0.91 mL, 5.21 mmol) was dissolved in DMF (5 mL) and the reaction was stirred at room temperature for 2 h. The solvent was evaporated, and the crude was purified by chromatography on C18 silica gel (0-100% acetonitrile in ammonium bicarbonate buffer, pH = 10). The appropriate fractions were concentrated, frozen, and lyophilized to give 2-(6-(2,6-dichloropyridin-4-yl)-2-oxaspiro[3.3]heptane-6-carbonyl)-N-methylhydrazinecarbothioamide (155 mg, 24% yield). LCMS (ESI) m / z: 373.3 [M+H] +

[0206] Step 4: 5-(6-(2,6-dichloropyridin-4-yl)-2-oxaspiro[3.3]heptan-6-yl)-4-methyl-4H-1,2,4-triazole-3-thiol The product of the previous step (2-(6-(2,6-dichloropyridin-4-yl)-2-oxaspiro[3.3]heptane-6-carbonyl)-N-methylhydrazinecarbothioamide, 155 mg, 0.41 mmol) was dissolved in 1 M NaOH solution (5 mL, 5 mmol), and the mixture was stirred at 45 °C for 4 h. After completion, it was quenched by the addition of 0.5 M KHSO solution and 1 N HCl, extracted with IPA / CHCl (1:4), and the combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated to give 5-(6-(2,6-dichloropyridin-4-yl)-2-oxaspiro[3.3]heptane-6-yl)-4-methyl-4H-1,2,4-triazole-3-thiol (125 mg, 85% yield), which was used in the next step without further purification. LCMS(ESI)m / z:355.3, 357.3[M+H] +

[0207] Step 5: 2,6-dichloro-4-(6-(4-methyl-4H-1,2,4-triazol-3-yl)-2-oxaspiro[3.3]heptan-6-yl)pyridine To a solution of 5-(6-(2,6-dichloropyridin-4-yl)-2-oxaspiro[3.3]heptan-6-yl)-4-methyl-4H-1,2,4-triazole-3-thio (125 mg, 0.35 mmol) and NaNO (120.7 mg, 1.75 mmol) in THF (2 mL) / water (2 mL) at 0 °C was added 1 M HNO solution (2.1 mL, 2.1 mmol). The resulting reaction mixture was stirred at 0 °C for 1 h. After completion, it was quenched with saturated aqueous NaHCO and extracted with a mixture of CHCl:IPA (4:1). The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated to give intermediate D (2,6-dichloro-4-(6-(4-methyl-4H-1,2,4-triazol-3-yl)-2-oxaspiro[3.3]heptan-6-yl)pyridine, 105 mg, 92% yield). LCMS (ESI) m / z: 325.4 [M+H] + .

[0208] Example 5: Intermediate D Intermediate D (3-(3-bromobenzyl)-4-methyl-4H-1,2,4-triazole) can be synthesized according to Scheme 5 (Figure 5).

[0209] Step 1: (3-bromophenyl)(4-methyl-4H-1,2,4-triazol-3-yl)methanol To a solution of 4-methyl-1,2,4-triazole (250 mg, 3.009 mmol) in 1,2-dimethoxyethane (0.1 M) at −45° C. was added n-butyllithium (1.6 mol / L) in hexane (1 equiv., 3.009 mmol, 1.6 mol / L). The reaction was stirred at −45° C. for 30 minutes, at which point 3-bromobenzaldehyde (1 equiv., 3.009 mmol) in a small amount of DME was added. The reaction was immediately warmed to 0° C. and stirred for 1 hour, at which point it was quenched with saturated sodium bicarbonate solution, extracted three times with methylene chloride, dried over sodium sulfate, and concentrated. Purification by silica column chromatography (using a gradient of 0–10% MeOH in CHCl) afforded the desired product (359 mg, 1.33 mmol, 44% yield). 1 H NMR(400MHz,DMSO-d6)δ 8.41(s,1H), 7.57(dd,J=2.1, 1.1Hz,1H), 7.50(dtd,J=6.1,4.1,3.6,1.9Hz,1H ), 7.38-7.29(m,2H), 6.61(d,J=4.9Hz,1H), 6.03(d,J=4.6Hz,1H), 3.55(s,3H).

[0210] Step 2: 3-((3-bromophenyl)chloromethyl)-4-methyl-4H-1,2,4-triazole To a solution of (3-bromophenyl)-(4-methyl-1,2,4-triazol-3-yl)methanol (345 mg, 1.29 mmol) in dichloromethane (0.2 M) at 0° C. was added pyridine (5.0 equiv., 6.4339 mmol), followed by thionyl chloride (3 equiv., 3.8604 mmol), and the reaction was stirred at 0° C. for 2 hours. After 2 hours, the reaction was deemed complete and quenched by the addition of saturated sodium bicarbonate solution. The solution was then poured into saturated sodium bicarbonate solution and ice, extracted three times with methylene chloride, dried over sodium sulfate, concentrated, and purified by silica column chromatography using a methylene chloride / methanol gradient to give the desired product (Intermediate D, 263 mg, 0.918 mmol, 71% yield). 1H NMR(400MHz,DMSO-d6)δ 8.56(s,1H), 7.86(t,J=1.9Hz,1H), 7.72-7.56(m,2H), 7.42(t,J=7.9Hz,1H), 6.77(s,1H), 3.72(s,3H).

[0211] Step 3: 3-(3-bromobenzyl)-4-methyl-4H-1,2,4-triazole To a room temperature solution of 3-[(3-bromophenyl)-chloro-methyl]-4-methyl-1,2,4-triazole (60 mg, 0.20938 mmol) in acetic acid (0.1 M, 36.54 mmol) was added zinc (10 equiv., 2.0938 mmol). The reaction was stirred at room temperature for 2 hours, at which point the zinc was filtered and the filtrate was poured into saturated sodium bicarbonate solution. The solution was extracted three times with methylene chloride, dried over sodium sulfate, concentrated, and purified by silica column chromatography using a methylene chloride / methanol gradient to give the desired product (34 mg, 64% yield). 1 H NMR(400MHz,DMSO-d6)δ 8.38(s,1H), 7.47-7.43(m,2H), 7.29(dd,J=8.7, 7.5Hz,1H), 7.22(dt,J=7.7, 1.5Hz,1H), 4.16(s,2H), 3.51(s,3H).

[0212] Example 6: Alternative Route to Intermediate D Intermediate D can also be synthesized by a two-step scheme in Scheme 6 (Figure 6).

[0213] Step 1: 2-(3-bromophenyl)acetohydrazide To a solution of methyl 2-(3-bromophenyl)acetate (300 g, 1.31 mol) in MeOH (6.6 L) was added dropwise a solution of hydrazine hydrate (80%, 162 g, 2.6 mol) at room temperature. The mixture was then stirred overnight at 65° C. under N2. TLC analysis indicated that the reaction was complete. The mixture was concentrated under reduced pressure. The residue was washed with petroleum ether to give the desired crude product (310 g).

[0214] Step 2: 3-(3-bromobenzyl)-4-methyl-4H-1,2,4-triazole To a solution of 2-(3-bromophenyl)acetohydrazide (310 g, crude) in 1,4-dioxane (2.5 L) was added triethoxymethane (300.6 g, 2.0 mol) at room temperature. The mixture was stirred at 100° C. for 2 hours. The reaction was then cooled to room temperature, and AcOH (135 mL) and methylamine / MeOH (852 g, 9.0 mol) were added. The mixture was stirred at 100° C. for 2 hours. TLC indicated that approximately 40% of the starting material remained. The mixture was concentrated under reduced pressure. The residue was dissolved in 1,4-dioxane (2.5 L), and triethoxymethane 4 (300.6 g, 2.0 mol) was added at room temperature. The mixture was stirred at 100° C. for 2 hours. The reaction was then cooled to room temperature, and AcOH (135 mL) and methylamine / MeOH (852 g, 9.0 mol) were added. The mixture was stirred at 100° C. for 2 hours. TLC showed that the reaction was complete. The mixture was concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (DCM / MeOH 50 / 1) to give the desired product (117 g, 35% for two steps) as a white solid. LCMS: [M+H] += 254, 1 H NMR(400MHz,DMSO-d6)δ 8.39(s,1H), 7.45(m,2H), 7.33-7.20(m,2H), 4.17(s,2H), 3.52(s,3H).

[0215] Example 7: Intermediate E Intermediate E ((S)-6-((2-isopropyl-4-methylpiperazin-1-yl)methyl)-4-(trifluoromethyl)isoindolin-1-one) can be synthesized according to the scheme in Scheme 7 (Figure 7).

[0216] To a solution of methyl 2-(bromomethyl)-5-formyl-3-(trifluoromethyl)benzoate (1.64 g, 5.05 mmol) and (S)-3-isopropyl-1-methylpiperazine (718 mg, 5.05 mmol) in 1,2-dichloroethane (25 mL) was added sodium triacetoxyborohydride (3.21 g, 15.1 mmol). The reaction mixture was stirred for 18.5 hours, then quenched by the addition of saturated aqueous sodium bicarbonate and extracted with dichloromethane. The organic layer was dried over magnesium sulfate and concentrated to dryness. The crude benzylamine was dissolved in methanol (5 mL), and ammonia (18.0 mL, 7 M in MeOH, 126 mmol) was added. The reaction mixture was stirred for 21 hours and concentrated to dryness. The residue thus obtained was purified by flash column chromatography (0-10% MeOH in CH2Cl2) to give the desired product (1.15 g, 64% yield) as a white solid; 1 H NMR(400MHz,CDCl3)δ 8.06(s,1H), 7.75(s,1H), 6.69(br s,1H), 4.61(s,2H), 4.31(d,J=13.9Hz,1H), 3.27(d,J=13.9Hz,1H), 3.19(d,J=11.7Hz,1H), 3.10(d,J=11.4Hz,1H), 2.91-2.85(m,1H), 2.76-2.67(m,2H), 2.63(s,3H), 2.60-2.53(m,1H), 2.51-2.45(m,1H), 2.40-2.32(m,1H), 1.03(d,J=6.9Hz,3H), 0.97(d,J=6.9Hz,3H).

[0217] Example 8: Compounds 1 and 2 Compound 1 ((R)-2-(3-(cyclobutyl(hydroxy)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one) and compound 2 ((S)-2-(3-(cyclobutyl(hydroxy)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one) can be synthesized as follows, as shown in Scheme 8 in FIG. 8.

[0218] Intermediate 8.2 (Methyl 2-(3-bromophenyl)-2-cyclobutylacetate) In a round-bottom flask, potassium tert-butoxide (2.69 g, 24.01 mmol) was suspended in dry DMF (87.1 mL) at 0 °C under an argon atmosphere, and methyl 2-(3-bromophenyl)acetate (5 g, 21.83 mmol) was added. After stirring for 10 min, bromocyclobutane (2.26 mL, 24.01 mmol) was added, warmed to rt, and stirred for 2 h. Water (50 mL) was added, and the solution was extracted with DCM (2 × 100 mL). The combined organic layers were washed with saturated aqueous solutions of NH4Cl (100 mL) and water (100 mL), dried over magnesium sulfate, filtered, and concentrated. The crude product was purified by silica gel chromatography (hexane:EtOAc (9:1)) to give methyl 2-(3-bromophenyl)-2-cyclobutylacetate (3.2 g, 52% yield) as a colorless oil. LCMS(ESI)m / z:283.1, 285.1[M+H] + . 1 H NMR(400MHz,CDCl3):δ 7.43(t,J=1.6Hz,1H), 7.37(ddd,J=11.6,6.7,4.9Hz,1H), 7.23-7.19(m,1H), 7.17(t,J=7.6Hz,1H), 3.65( s,3H), 3.50(d,J=11.0Hz,1H), 3.02-2.85(m,1H), 2.23-2.12(m,1H), 1.89-1.73(m,4H), 1.63-1.56(m,1H)

[0219] Intermediate 8.3 (2-(3-bromophenyl)-2-cyclobutyl-2-hydroxyacetic acid) Cesium carbonate (230.1 mg, 0.71 mmol), triethyl phosphite (1.21 mL, 7.06 mmol), and methyl 2-(3-bromophenyl)-2-cyclobutylacetate (1 g, 3.53 mmol) were added to a 100 mL flask under an oxygen atmosphere. DMSO (20 mL) was added, and the mixture was stirred at rt under an oxygen atmosphere for 72 h. The solution was then diluted with water (100 mL), extracted with EtOAc (3 × 100 mL), dried over sodium sulfate, filtered, and concentrated. The crude product was purified by chromatography on silica gel to give methyl 2-(3-bromophenyl)-2-cyclobutyl-2-hydroxyacetate (250 mg, 24% yield). The aqueous layer was acidified to pH 5 with 1 M HCl solution and extracted with a mixture of CHCl3:IPA (9:1), and the combined organic phases were dried over sodium sulfate, filtered, and concentrated to give 2-(3-bromophenyl)-2-cyclobutyl-2-hydroxy-acetic acid (450 mg, 45% yield), which was used in the next step without further purification. LCMS (ESI) m / z: 283.3, 285.3 [M+H] + .

[0220] Intermediate 8.4 (2-(2-(3-bromophenyl)-2-cyclobutyl-2-hydroxyacetyl)-N-methylhydrazinecarbothioamide) A mixture of 2-(3-bromophenyl)-2-cyclobutyl-2-hydroxyacetic acid (550 mg, 1.93 mmol), N-methylhydrazinecarbothioamide (0.3 g, 2.89 mmol), HATU (1.1 g, 2.89 mmol), and DIPEA (1 mL, 5.79 mmol) was dissolved in DMF (19.3 mL) and stirred at rt for 20 h. The reaction mixture was quenched with a saturated aqueous solution of NH4Cl and extracted with CHCl3:IPA (9:1). The combined organic layers were dried over sodium sulfate, filtered, and concentrated. The crude residue was purified by chromatography on C18 silica gel (0–100% acetonitrile in ammonium bicarbonate buffer, pH = 10) to give 2-(2-(3-bromophenyl)-2-cyclobutyl-2-hydroxyacetyl)-N-methylhydrazinecarbothioamide (580 mg, 81% yield). LCMS(ESI)m / z:372.3, 374.2[M+H] +

[0221] Intermediate 8.5 ((3-Bromophenyl)(cyclobutyl)(5-mercapto-4-methyl-4H-1,2,4-triazol-3-yl)methanol) A solution of 2-(2-(3-bromophenyl)-2-cyclobutyl-2-hydroxyacetyl)-N-methylhydrazinecarbothioamide (580 mg, 1.56 mmol) in 1 M NaOH solution (4.9 mL, 4.86 mmol) was stirred at 50° C. for 20 h. The reaction mixture was acidified to pH 4 with 1 N HCl solution. The resulting mixture was extracted with CHCl:IPA (9:1). The combined organic layers were dried over sodium sulfate, filtered, and concentrated to give (3-bromophenyl)(cyclobutyl)(5-mercapto-4-methyl-4H-1,2,4-triazol-3-yl)methanol (490 mg, 89% yield), which was used in the next step without further purification. LCMS (ESI) m / z: 354.2, 356.2 [M+H] +

[0222] Intermediate 8.6 ((3-Bromophenyl)(cyclobutyl)(4-methyl-4H-1,2,4-triazol-3-yl)methanol) To a solution of (3-bromophenyl)(cyclobutyl)(5-mercapto-4-methyl-4H-1,2,4-triazol-3-yl)methanol (490 mg, 1.38 mmol) in DCM (10 mL) and acetic acid (2.5 mL) was added hydrogen peroxide 30% (0.57 mL, 5.53 mmol). The reaction mixture was stirred at rt for 1 h, then quenched with saturated aqueous NaHCO3 and extracted with DCM (3x). The combined organic layers were dried over sodium sulfate, filtered, and evaporated to give (3-bromophenyl)(cyclobutyl)(4-methyl-4H-1,2,4-triazol-3-yl)methanol (402 mg, 90% yield), which was used in the next step without further purification. LCMS (ESI) m / z: 322.4, 324.4 [M+H] +

[0223] Intermediate 8.7 (tert-butyl((2-(3-(cyclobutyl(hydroxy)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)(1-methylcyclobutyl)carbamate) To a screw-cap vial of (3-bromophenyl)(cyclobutyl)(4-methyl-4H-1,2,4-triazol-3-yl)methanol (100 mg, 0.31 mmol), tert-butyl(1-methylcyclobutyl)((3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)carbamate (Intermediate A, 160.8 mg, 0.40 mmol), XantPhos Pd G3 (29.4 mg, 0.03 mmol), and cesium carbonate (303.5 mg, 0.93 mmol) was added degassed tert-amyl alcohol (1.6 mL) under a nitrogen atmosphere. The reaction was heated at 110° C. for 20 h. The reaction mixture was cooled to rt, filtered through Celite, and concentrated. The crude product was purified by chromatography on silica gel (0-10% MeOH in DCM) to give tert-butyl ((2-(3-(cyclobutyl(hydroxy)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)(1-methylcyclobutyl)carbamate (80 mg, 40% yield). LCMS (ESI) m / z: 640.6 [M+H] +

[0224] Example 8: Compounds 1 and 2 To a stirred solution of tert-butyl ((2-(3-(cyclobutyl(hydroxy)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)(1-methylcyclobutyl)carbamate (80 mg, 0.13 mmol) in methanol (0.5 mL) was added 4 M HCl in dioxane (0.63 mL, 2.5 mmol) at rt. The reaction was concentrated, and the crude was purified by chromatography on C18 silica gel (acetonitrile in ammonium formate buffer, pH = 3.8). The appropriate fractions were concentrated, frozen, and lyophilized to give the desired product (28 mg, 42% yield) as a mixture of diastereoisomers.

[0225] The above racemate was further purified by chiral SFC (column = AS; column dimensions = 250 mm x 10 mm x 5 μm; flow rate = 10 mL / min; run time = 6 min; column temperature = 40°C) using 0.1% ammonium hydroxide-40% IPA-carbon dioxide to give: (R)-2-(3-(cyclobutyl(hydroxy)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one (peak 1) (compound 1; 8.2 mg, 12% yield). LCMS (ESI) m / z: 540.5 [M+H] + 1 H NMR(400MHz,DMSO-d6)δ 8.33(s,1H), 8.02(s,1H), 7.97(s,1H), 7.90(s,1H), 7.74(d,J=8.1Hz,1H), 7.36(t,J=8.0Hz,1H), 6.93(d,J=7.8Hz,1H), 6 .09(s,1H), 5.11(s,2H), 3.80(s,2H), 3.45(m,1H), 3.28(s,3H), 2.15-1.93(m,5H), 1.66(m,6H), 1.38(m,1H), 1.21(s,3H). (S)-2-(3-(cyclobutyl(hydroxy)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one (peak 2) (compound 2; 8.4 mg, 12% yield). LCMS (ESI) m / z: 540.5 [M+H] + 1 HNMR(400MHz,DMSO-d6)δ 8.33(s,1H), 8.02(s,1H), 7.97(s,1H), 7.91(s,1H), 7.74(dd,J=8.1, 1.5Hz,1H), 7.36(t,J=8.0Hz,1H), 6.93(d,J=7.8Hz,1H), 6 .09(s,1H), 5.13(s,2H), 3.80(s,2H), 3.46(m,1H), 3.28(s,3H), 2.19-1.90(m,5H), 1.77-1.52(m,6H), 1.38(m,1H), 1.21(s,3H).

[0226] Example 9: Compound 2 and Compound 3 Compound 3 (2-(6-ethoxy-4-((1s,3s)-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-yl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one) and compound 4 (2-(6-ethoxy-4-((1r,3r)-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-yl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one) can be synthesized according to Scheme 9 in FIG. 9 .

[0227] Intermediate 1: (2-chloro-6-ethoxy-4-(1-(4-methyl-4H-1,2,4-triazol-3-yl)-3-methylenecyclobutyl)pyridine) 2,6-Dichloro-4-(1-(4-methyl-4H-1,2,4-triazol-3-yl)-3-methylenecyclobutyl)pyridine (100 mg, 0.34 mmol) was dissolved in sodium ethoxide (21% wt in EtOH) (2.5 mL, 6.78 mmol) in a sealed tube. The resulting mixture was stirred at 80 °C for 25 min, then cooled to rt and concentrated. The crude mixture was purified by chromatography on silica gel (0 to 50% EtOAc in heptane) to give 2-chloro-6-ethoxy-4-(1-(4-methyl-4H-1,2,4-triazol-3-yl)-3-methylenecyclobutyl)pyridine (58.9 mg, 57% yield). LCMS (ESI) m / z: 305.4, 307.4 [M+H] + .

[0228] Intermediate 2: (tert-butyl((2-(6-ethoxy-4-(1-(4-methyl-4H-1,2,4-triazol-3-yl)-3-methylenecyclobutyl)pyridin-2-yl)-3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)(1-methylcyclobutyl)carbamate) A microwave vial equipped with a stir bar was charged with 2-chloro-6-ethoxy-4-(1-(4-methyl-4H-1,2,4-triazol-3-yl)-3-methylenecyclobutyl)pyridine (58.9 mg, 0.19 mmol), tert-butyl(1-methylcyclobutyl)((3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)carbamate (84.7 mg, 0.21 mmol), tris(dibenzylideneacetone)dipalladium(0) (7.1 mg, 0.01 mmol), Me4tButylXphos (9.3 mg, 0.02 mmol), flame-dried K3PO4 (82.1 mg, 0.39 mmol), and 4 Å MS (unweighed). The vial was then flushed with nitrogen for several minutes, and degassed tert-amyl alcohol (0.97 mL) was added via syringe. The vial was capped, and the reaction mixture was stirred at 110 °C for 18 h, then cooled to rt and adsorbed onto silica gel. The crude mixture was purified by chromatography on silica gel (0-100% EtOAc in 5 heptane, then 0-25% iPrOH / EtOAc) to give tert-butyl ((2-(6-ethoxy-4-(1-(4-methyl-4H-1,2,4-triazol-3-yl)-3-methylenecyclobutyl)pyridin-2-yl)-3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)(1-methylcyclobutyl)carbamate (48.5 mg, 38% yield). LCMS (ESI) m / z: 667.5 [M+H] + .

[0229] Intermediate 3: (tert-butyl((2-(6-ethoxy-4-(3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-yl)-3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)(1-methylcyclobutyl)carbamate) A solution of tert-butyl ((2-(6-ethoxy-4-(1-(4-methyl-4H-1,2,4-triazol-3-yl)-3-methylenecyclobutyl)pyridin-2-yl)-3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)(1-methylcyclobutyl)carbamate (48.5 mg, 0.07 mmol) in methanol (0.73 mL) was degassed by bubbling nitrogen through it, and then Pd / C 10% (7.74 mg, 0.01 mmol) was added. The mixture was saturated with hydrogen by bubbling hydrogen through the solution, and then stirred under 1 atmosphere of hydrogen at rt for 17 h. The reaction mixture was degassed again by bubbling nitrogen through it, filtered through a 45 μm PTFE filter, and evaporated to dryness to give tert-butyl ((2-(6-ethoxy-4-(3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-yl)-3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)(1-methylcyclobutyl)carbamate (46.4 mg, 95% yield), which was used in the next step without further purification. LCMS (ESI) m / z: 669.5 [M+H] +

[0230] Compound 3 and Compound 4 Trifluoroacetic acid (0.35 mL) was added to a solution of tert-butyl ((2-(6-ethoxy-4-(3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-yl)-3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)(1-methylcyclobutyl)carbamate (46.4 mg, 0.07 mmol) in DCM (0.35 mL), and the solution was stirred at rt for 1 h. The reaction mixture was diluted with toluene, concentrated to dryness, then basified with 1 N NaOH solution and extracted with a 4:1 mixture of CHCl3 / IPA (3x). The organics were combined, dried over sodium sulfate, filtered, and concentrated to give 39.8 mg of the desired product as a mixture of diastereoisomers.

[0231] The above racemate was further purified by chiral SFC using 0.1% ammonium hydroxide-40% IPA / carbon dioxide (column = IA; column dimensions = 250 mm x 10 mm x 5 μm; detection wavelength = 310 nm; flow rate = 10 mL / min; run time = 10 min; column temperature = 40°C) to give: 2-(6-ethoxy-4-((1s,3s)-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-yl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one (compound 3, peak 1, retention time = 5.71 min) (15.8 mg, 40% yield). LCMS (ESI) m / z: 569.5 [M+H] + 1 H NMR (400 MHz, DMSO-d6) δ 8.41(s,1H), 8.03(d,J=7.1Hz,2H), 7.88(d,J=1.1Hz,1H), 6.42(d,J=1.1H z,1H), 5.18(s,2H), 4.34(q, J=7.0Hz,2H), 3.81(s,2H), 3.26(s,3H), 3.13 -3.04(m,2H), 2.42-2.29(m,1H), 2.29-2.19(m,2H), 2.01-1.92(m,2H), 1. 76-1.61(m,4H), 1.36(t,J=7.0Hz,3H), 1.22(s,3H), 1.10(d,J=6.5Hz,3H). 2-(6-ethoxy-4-((1r,3r)-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-yl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one (compound 4, peak 2, retention time = 7.86 min) (4.8 mg, 12% yield). LCMS (ESI) m / z: 569.5 [M+H] + . 1H NMR(400MHz,DMSO-d6)δ 8.34(s,1H), 8.05-8.01(m,3H), 6.55(d,J=1.2Hz,1H), 5.19(s,2H), 4.35(q, J=7.1Hz,2H), 3.81(s,2H), 3.23(s,3H), 2.87-2. 75(m,2H), 2.60-2.54(m,3H), 2.01-1.92(m,2H), 1.77-1.62(m,4H), 1.36(t,J=7.0Hz,3H), 1.22(s,3H), 1.08(d,J=5.4Hz,3H).

[0232] Example 10: Compound 5 and Compound 6 Compound 5 (2-(6-(ethylamino)-4-((1s,3s)-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-yl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one) and compound 6 (2-(6-(ethylamino)-4-((1r,3r)-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-yl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one) can be synthesized according to Scheme 10 (Figure 10).

[0233] Intermediate 1: (tert-butyl ((2-(6-chloro-4-(1-(4-methyl-4H-1,2,4-triazol-3-yl)-3-methylenecyclobutyl)pyridin-2-yl)-3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)(1-methylcyclobutyl)carbamate) A microwave vial equipped with a stir bar was charged with 2,6-dichloro-4-(1-(4-methyl-4H-1,2,4-triazol-3-yl)-3-methylenecyclobutyl)pyridine (15 mg, 0.05 mmol), tert-butyl(1-methylcyclobutyl)((3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)carbamate (22.3 mg, 0.06 mmol), sodium trifluoroacetate (13.8 mg, 0.10 mmol), and XantPhos Pd G3 (4.8 mg, 0.01 mmol). The vial was flushed with nitrogen for several minutes, then degassed toluene (0.51 mL) was added via syringe, followed by DBU (30.4 μL, 0.20 mmol). The vial was capped, and the reaction mixture was stirred at 120 °C for 20 h. The reaction was cooled to rt and the solvent evaporated under a stream of air. The crude mixture was purified by chromatography on silica gel (0-6% MeOH in DCM) to give tert-butyl ((2-(6-chloro-4-(1-(4-methyl-4H-1,2,4-triazol-3-yl)-3-methylenecyclobutyl)pyridin-2-yl)-3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)(1-methylcyclobutyl)carbamate (23.8 mg, 71% yield), which was not completely clean, resulting in a 36% yield considering purity. This was used directly in the next step. LCMS (ESI) m / z: 657.4 [M+H] + .

[0234] Intermediate 2: (tert-butyl((2-(6-chloro-4-(3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-yl)-3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)(1-methylcyclobutyl)carbamate A solution of tert-butyl ((2-(6-chloro-4-(1-(4-methyl-4H-1,2,4-triazol-3-yl)-3-methylenecyclobutyl)pyridin-2-yl)-3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)(1-methylcyclobutyl)carbamate (117.3 mg, 0.18 mmol) in methanol (1.8 mL) was degassed by bubbling nitrogen through it, and then Pd / C 10% (19 mg, 0.02 mmol) was added. The mixture was saturated with hydrogen by bubbling through the solution, and then stirred under 1 atmosphere of hydrogen at rt for 28 h (completed after 16 h with additional Pd / C). The reaction mixture was degassed by bubbling nitrogen through it, filtered through a 45 μm PTFE filter, and evaporated to dryness. The crude mixture was purified by chromatography on silica gel (0-100% EtOAc in 5 heptane) to give tert-butyl ((2-(6-chloro-4-(3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-yl)-3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)(1-methylcyclobutyl)carbamate (69.8 mg, 56% yield). LCMS (ESI) m / z: 659.7 [M+H] + .

[0235] Intermediate 3: (tert-butyl((2-(6-(ethylamino)-4-(3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-yl)-3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)(1-methylcyclobutyl)carbamate) A microwave vial equipped with a stir bar was charged with tert-butyl ((2-(6-chloro-4-(3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-yl)-3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)(1-methylcyclobutyl)carbamate (104.7 mg, 0.16 mmol), cesium carbonate (103.5 mg, 0.32 mmol), and RuPhos Pd G4 (13.5 mg, 0.02 mmol). The vial was flushed with nitrogen for several minutes, then degassed THF (1.6 mL) was added via syringe, followed by ethylamine, 2 M in THF (0.12 mL, 0.24 mmol). The vial was capped and the reaction mixture was stirred at 120 °C for 17 h. The reaction was cooled to rt, and the solvent was evaporated under a stream of air. The crude residue was purified by chromatography on C18 silica gel (60-85% acetonitrile in ammonium formate buffer, pH = 3.8). The appropriate fractions were concentrated, frozen, and lyophilized to give tert-butyl ((2-(6-(ethylamino)-4-(3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-yl)-3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)(1-methylcyclobutyl)carbamate (69.7 mg, 66% yield). LCMS (ESI) m / z: 668.8 [M+H] + .

[0236] Compound 5 and Compound 6 Trifluoroacetic acid (0.52 mL) was added to a solution of tert-butyl ((2-(6-(ethylamino)-4-(3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-yl)-3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)(1-methylcyclobutyl)carbamate (69.7 mg, 0.10 mmol) in DCM (0.52 mL), and the solution was stirred at rt for 1 h. The reaction mixture was diluted with toluene, concentrated to dryness, then basified with 1 N NaOH solution and extracted with a 4:1 mixture of CHCl3 / IPA (3x). The organics were combined, dried over sodium sulfate, filtered, and concentrated to give 54.9 mg of the desired product as a mixture of diastereoisomers.

[0237] The above racemate was further purified by chiral SFC using 0.1% ammonium hydroxide-50% IPA / carbon dioxide (column=ID; column dimensions=250 mm×10 mm×5 μm; detection wavelength=320 nm; flow rate=10 mL / min; run time=14 min; column temperature=40° C.) to give: 2-(6-(ethylamino)-4-((1s,3s)-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-yl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one (compound 5, peak 1, retention time = 4.3 min) (23.5 mg, 40% yield). LCMS (ESI) m / z: 568.5 [M+H] + 1H NMR(400MHz,DMSO-d6)δ 8.40(s,1H), 8.01(s,1H), 7.99(s,1H), 7.57(s,1H), 6.68(t,J=5.1Hz,1H), 5 .98(s,1H), 5.13(s,2H), 3.80(s,2H), 3.30-3.20(m,5H), 3.06(t,J=9.6Hz,2 H), 2.33(dt,J=15.3, 7.7Hz,1H), 2.17(t,J=10.2Hz,2H), 2.03-1.90(m,2H), 1.77-1.60(m,4H), 1.22(s,3H), 1.14(t,J=7.2Hz,3H), 1.10(d,J=6.6Hz,3H). 2-(6-(ethylamino)-4-((1r,3r)-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-yl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one (compound 6, peak 2, retention time = 5.8 min) (7.1 mg, 12% yield). LCMS (ESI) m / z: 568.5 [M+H] + 1 H NMR(400MHz,DMSO-d6)δ 8.34(s,1H), 8.01(s,1H), 7.99(s,1H), 7.70(d,J=0.9Hz,1H), 6.68(t,J=5.3 Hz,1H), 6.12(d,J=0.9Hz,1H), 5.15(s,2H), 3.81(s,2H), 3.30-3.21(m,5H), 2.79-2.71(m,2H), 2.63-2.52(m,3H), 2.03-1.92(m,2H), 1.70(ddd,J=20.3, 10.1, 4.9Hz,4H), 1.23(s,3H), 1.15(t,J=7.1Hz,3H), 1.08(d,J=5.9Hz,3H).

[0238] Example 11: Compound 7 Compound 7 can be synthesized according to Scheme 11 (Figure 11).

[0239] Intermediate 1: (6-chloro-N-ethyl-4-(6-(4-methyl-4H-1,2,4-triazol-3-yl)-2-oxaspiro[3.3]heptan-6-yl)pyridin-2-amine) Ethylamine solution (1 mL, 19.14 mmol) was added to 2,6-dichloro-4-(6-(4-methyl-4H-1,2,4-triazol-3-yl)-2-oxaspiro[3.3]heptan-6-yl)pyridine (50 mg, 0.15 mmol) and the reaction was stirred at 80° C. for 16 hours. The reaction was concentrated and the crude residue was purified by chromatography on C18 silica gel (acetonitrile in ammonium formate buffer, pH=3.8). The appropriate fractions were concentrated, frozen, and lyophilized to give 6-chloro-N-ethyl-4-(6-(4-methyl-4H-1,2,4-triazol-3-yl)-2-oxaspiro[3.3]heptan-6-yl)pyridin-2-amine (42 mg, 82% yield). LCMS (ESI) m / z: 334.5 [M+H] + .

[0240] compound 7 A microwave vial equipped with a stir bar was charged with 6-chloro-N-ethyl-4-(6-(4-methyl-4H-1,2,4-triazol-3-yl)-2-oxaspiro[3.3]heptan-6-yl)pyridin-2-amine (35 mg, 0.10 mmol), tert-butyl(1-methylcyclobutyl)((3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)carbamate (45.9 mg, 0.12 mmol), tri(dibenzylideneacetone)dipalladium(0) (9.6 mg, 0.01 mmol), Me4tButylXphos (10.1 mg, 0.02 mmol), and flame-dried K3PO4 (44.5 mg, 0.21 mmol). The vial was then flushed with nitrogen for several minutes, and degassed t-AmOH (1 mL) was added via syringe. The vial was capped, and the reaction mixture was stirred at 110 °C for 16 h, then cooled to rt and adsorbed onto silica. The crude mixture was purified by chromatography on silica gel (5–30% MeOH in DCM) to give 17 mg of the Boc-protected intermediate. The intermediate was dissolved in DCM (2 mL), trifluoroacetic acid (1 mL) was added, and the mixture was stirred for 1 h. The solvent was evaporated, and the crude mixture was dissolved in MeOH (2 mL), saturated aqueous NaHCO3 was added, and the mixture was stirred for 10 min. The solvent was evaporated, and the crude was purified by chromatography on C18 silica gel (acetonitrile in 0.5% formic acid buffer). The appropriate fractions were concentrated, frozen, and lyophilized to give 2-(6-(ethylamino)-4-(6-(4-methyl-4H-1,2,4-triazol-3-yl)-2-oxaspiro[3.3]heptan-6-yl)pyridin-2-yl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one (8 mg, 13% yield). LCMS (ESI) m / z: 596.5 [M+H] + . 1H NMR(400MHz,DMSO-d6)δ 9.14(s,1H), 8.40(s,1H), 8.30-8.21(m,2H), 7.50(s,1H), 6.79-6.72(m,1H), 6.03(s,1H), 5.21(s,2H), 4.63(s,2H), 4.4 8(s,2H), 4.36-4.28(m,2H), 3.28-3.16(m,7H), 2.87-2.78(m,2H), 1.97-1.80(m,6H), 1.56(s,3H), 1.15(t,J=7.2Hz,3H).

[0241] Example 12: Compound 8 and Compound 9 Compound 8 (2-(6-(ethylamino)-4-((1s,3s)-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-yl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one) and compound 9 (2-(6-(ethylamino)-4-((1r,3r)-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-yl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one) can be synthesized according to Scheme 12 (Figure 12).

[0242] Intermediate 1: (3-(2,6-dichloropyridin-4-yl)-3-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutanone) NaIO (1.014 mg, 4.74 mmol) was added to a solution of 2,6-dichloro-4-(1-(4-methyl-4H-1,2,4-triazol-3-yl)-3-methylenecyclobutyl)pyridine (700 mg, 2.37 mmol) and RuCl (19.7 mg, 0.09 mmol) in 49 mL of a 6:1 mixture of MeCN:HO. The solution was stirred at room temperature for 5 h. The reaction mixture was quenched with a 10% aqueous solution of NaSO and extracted with CHCl:IPA (9:1). The organic layer was collected, washed with saturated aqueous NaCl, dried over sodium sulfate, filtered, and concentrated. The crude mixture was purified by chromatography on silica gel (0-15% MeOH in DCM) to give 3-(2,6-dichloropyridin-4-yl)-3-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutanone (254 mg, 36% yield) as a white solid. LCMS (ESI) m / z: 297.3, 299.3 [M+H] + .

[0243] Intermediate 2: (3-(2,6-dichloropyridin-4-yl)-3-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutanol) To a stirred solution of 3-(2,6-dichloropyridin-4-yl)-3-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutanone (250 mg, 0.84 mmol) in methanol (4.2 mL) was added sodium borohydride (38.2 mg, 1.01 mmol) at 0 °C. Upon completion, the reaction was quenched with saturated aqueous NH4Cl and extracted with CHCl3:IPA (9:1). The combined extracts were dried over sodium sulfate and concentrated to give 3-(2,6-dichloropyridin-4-yl)-3-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutanol (230 mg, 91% yield), which was used in the next step without further purification. LCMS (ESI) m / z: 299.3, 301.3 [M+H] + .

[0244] Intermediate 3: (2,6-dichloro-4-(3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridine) To a cooled solution of 3-(2,6-dichloropyridin-4-yl)-3-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutanol (180 mg, 0.60 mmol) in THF (0.5 mL) was added sodium hydride (48.1 mg, 1.2 mmol) at 0 °C. After stirring for 10 min at 0 °C, the mixture was warmed to rt and stirred for an additional 1 h. The reaction was cooled back to 0 °C, and methyl iodide (74.9 μL, 1.2 mmol) was added to the reaction mixture and stirred for 20 h. The solvent was evaporated, and the crude was purified by chromatography on C18 silica gel (0–50% acetonitrile in ammonium formate buffer, pH = 3.8). The appropriate fractions were concentrated, frozen, and lyophilized to give 2,6-dichloro-4-(3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridine (80 mg, 42% yield). LCMS (ESI) m / z: 313.3, 315.2 [M+H] + .

[0245] Intermediate 4: (6-chloro-N-cyclopentyl-4-(3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-amine) A mixture of 2,6-dichloro-4-(3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridine (80 mg, 0.26 mmol) and cyclopentylamine (0.25 mL, 2.55 mmol) in DMSO (1.3 mL) was heated to 120 °C for 4 h. The solvent was evaporated, and the crude was purified by chromatography on C18 silica gel (0 to 100% acetonitrile in ammonium formate buffer, pH = 3.8). The appropriate fractions were concentrated, frozen, and lyophilized to give 6-chloro-N-cyclopentyl-4-(3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-amine (80 mg, 875% yield). LCMS(ESI)m / z:362.3, 364.3[M+H] + .

[0246] Intermediate 5: (tert-butyl((2-(6-(cyclopentylamino)-4-(3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-yl)-3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)(1-methylcyclobutyl)carbamate) A microwave vial was charged with the resulting 6-chloro-N-cyclopentyl-4-(3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-amine (50 mg, 0.14 mmol), tert-butyl(1-methylcyclobutyl)((3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)carbamate (60.7 mg, 0.15 mmol), Me4tButylXphos (6.6 mg, 0.01 mmol), Pd2(dba)3 (6.3 mg, 0.01 mmol), and K3PO4 (88.0 mg, 0.41 mmol). After purging the vial with nitrogen, degassed anhydrous tert-amyl alcohol (1.6 mL) was added and the vial was sealed. The reaction mixture was stirred at 120 °C for 15 h. The solvent was evaporated, and the crude was purified by chromatography on C18 silica gel (0-100% acetonitrile in ammonium formate buffer, pH = 3.8). The appropriate fractions were concentrated, frozen, and lyophilized to give tert-butyl ((2-(6-(cyclopentylamino)-4-(3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-yl)-3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)(1-methylcyclobutyl)carbamate (90 mg, 90% yield) as a white solid. LCMS (ESI) m / z: 724.7 [M+H] + .

[0247] To a stirred solution of tert-butyl ((2-(6-(cyclopentylamino)-4-(3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-yl)-3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)(1-methylcyclobutyl)carbamate (90.5 mg, 0.13 mmol) in methanol (0.5 mL) was added a 4 M solution of HCl in dioxane (0.63 mL, 2.5 mmol). Upon completion, the reaction was concentrated and the crude product was purified by semi-prep. LCMS (70-90% gradient of acetonitrile in ammonium bicarbonate buffer, pH=10). The appropriate fractions were concentrated, frozen, and lyophilized to give 77 mg.

[0248] The above racemate was further purified by chiral SFC (column=ID; column dimensions=250 mm×10 mm×5 μm; flow rate=10 mL / min; run time=9 min; column temperature=40° C.) using 0.1% ammonium hydroxide-40% IPA / MeCN-carbon dioxide to give: 2-(6-(cyclopentylamino)-4-((1s,3s)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-yl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one (peak 1) (compound 8, 19 mg, 24%). LCMS (ESI) m / z: 624.5 [M+H] + 1 H NMR(400MHz,DMSO-d6)δ 8.41(s,1H), 8.02-7.94(m,2H), 7.52(d,J=1.1Hz,1H), 6.72(d,J=5.9Hz,1H), 5.98(s,1H), 5.12(s,2H), 4.06-3.96(m,1H), 3.84-3. 73(m,3H), 3.28-3.19(m,5H), 3.15(s,3H), 2.40-2.32(m,1H), 2.06-1.85(m,5H), 1.73-1.60(m,6H), 1.58-1.39(m,4H), 1.20(s,3H). 2-(6-(cyclopentylamino)-4-((1r,3r)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-yl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one (peak 2) (compound 9, 6 mg, 8%). LCMS (ESI) m / z: 624.5 [M+H] + 1 H NMR (400 MHz, DMSO-d6) δ 8.36(s,1H), 8.03-7.98(m,2H), 7.63(s,1H), 6.75(d,J=5.9Hz,1H), 6. 12(s,1H), 5.15(s,2H), 4.15-3.99(m,1H), 3.81(s,2H), 3.27(s,2H), 3. 17(s,3H), 2.98-2.89(m,2H), 2.81-2.78(m,2H), 2.08(d,J=8.7Hz,1H) , 2.02-1.81(m,4H), 1.76-1.62(m,6H), 1.60-1.41(m,5H), 1.23(s,3H).

[0249] Example 13: Compound 10 and Compound 11 Compounds 10 and 11 can be synthesized according to Scheme 13, FIG.

[0250] Intermediate 1: (3-((3-bromophenyl)(oxetan-3-yl)methyl)-4-methyl-4H-1,2,4-triazole) To a solution of 3-(3-bromobenzyl)-4-methyl-4H-1,2,4-triazole (100 mg, 0.397 mmol) in anhydrous 1,2-dimethoxyethane (1.3 mL) under nitrogen and at −10° C. was added lithium bis(trimethylsilyl)amide (0.6 mL, 1.0 M in THF, 0.6 mmol). The stirred mixture was allowed to warm to room temperature and stirring was continued for 48 h. Additional lithium bis(trimethylsilyl)amide (0.6 mL, 1.0 M in THF) was added and stirred for 1 h. The reaction was then quenched by the addition of saturated aqueous NH4Cl and extracted with CHCl2. The organic layer was dried over MgSO4, filtered, and concentrated. The crude mixture was purified by chromatography on silica gel (0 to 100% 80:15:2.5 CH2Cl2 / MeOH / NH4OH in heptane) to give 3-((3-bromophenyl)(oxetan-3-yl)methyl)-4-methyl-4H-1,2,4-triazole as a colorless liquid (43.6 mg, 36% yield); 1 H NMR(400MHz,CDCl3)δ 8.06(s,1H), 7.46-7.38(m,1H), 7.38-7.31(m,1H), 7.21(dd,J=7.8Hz,7.8Hz,1H), 7.19-7.07(m,1H), 5.06-4.99(m,1H), 4.73-4.61(m, 1H), 4.51-4.43(m,1H), 4.37(d,J=7.0Hz,7.0Hz,1H), 4.35-4.24(m,1H), 4.04-3.88(m,1H), 3.39(s,3H);LCMS(ESI)m / z:308, 310[M+H] + .

[0251] Compound 10 and Compound 11 3-((3-Bromophenyl)(oxetan-3-yl)methyl)-4-methyl-4H-1,2,4-triazole (43.6 mg, 0.141 mmol), (S)-6-((2-isopropyl-4-methylpiperazin-1-yl)methyl)-4-(trifluoromethyl)isoindolin-1-one (55.3 mg, 0.156 mmol), [(4,5-bis(diphenylphosphino)-9,9-dimethylxanthene)-2-(2′-amino-1,1′-biphenyl)]palladium(II) methanesulfonate (13.6 mg, 0.014 mmol), and cesium carbonate (138 mg, 0.424 mmol) were weighed into a vial. Anhydrous 2-methyl-2-butanol (0.7 mL) was added to the vessel under a stream of nitrogen gas, and the vial was sealed. The reaction mixture was stirred for 5 h at 100° C. After cooling to rt, the mixture was concentrated and purified by flash column chromatography (0-100% 80:15:2.5 CH2Cl2 / MeOH / NH4OH in CH2Cl2), HPLC, and chiral SFC to give: 6-(((S)-2-isopropyl-4-methylpiperazin-1-yl)methyl)-2-(3-((S)-(4-methyl-4H-1,2,4-triazol-3-yl)(oxetan-3-yl)methyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one (peak 1) (compound 10, 7.3 mg, 9%), and 6-(((S)-2-Isopropyl-4-methylpiperazin-1-yl)methyl)-2-(3-((R)-(4-methyl-4H-1,2,4-triazol-3-yl)(oxetan-3-yl)methyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one (Peak 2) (Compound 11, 6.7 mg, 8%); LCMS (ESI) m / z: 583.3 [M+H] + ; 1H NMR(500MHz,DMSO-d6)δ 8.36(s,1H), 7.98(s,1H), 7.91(s,2H), 7.82(dd,J=8.1, 2.1Hz,1H), 7.40(t,J=7.9Hz,1H) , 7.02(d,J=7.7Hz,1H), 5.17(s,2H), 4.81-4.71(m,2H), 4.54-4.43(m,2H), 4.32-4.26(m,1 H), 4.21(d,J=14.4Hz,1H), 3.94-3.82(m,1H), 3.43-3.32(m,5H), 2.69-2.54(m,2H), 2.32- 2.18(m,3H), 2.14(s,3H), 2.01-1.86(m,2H), 0.93(d,J=6.6Hz,3H), 0.88(d,J=6.7Hz,3H).

[0252] Example 14: Compound 12, Compound 13, Compound 14, and Compound 15 Compounds 12 to 15 can be synthesized according to Scheme 14 in FIG.

[0253] Intermediate 1: (3-((3-bromophenyl)(3-methoxycyclobutyl)methyl)-4-methyl-4H-1,2,4-triazole) To a solution of 3-(3-bromobenzyl)-4-methyl-4H-1,2,4-triazole (300 mg, 1.19 mmol) in anhydrous 1,2-dimethoxyethane (2.4 mL) under nitrogen and at 0° C. was added sodium bis(trimethylsilyl)amide (1.4 mL, 1.0 M in THF [untitrated], 1.4 mmol). After 1.5 h, the reaction was quenched by the addition of saturated aqueous NH4Cl and extracted with CHCl2. The organic layer was dried over MgSO4, filtered, and concentrated. The crude residue was purified by chromatography on silica gel (0-100% 3:1 iPrOH / MeOH in heptane) to give 3-((3-bromophenyl)(3-methoxycyclobutyl)methyl)-4-methyl-4H-1,2,4-triazole as a colorless liquid (210 mg, 53% yield); LCMS (ESI) m / z: 336, 338 [M+H] + .

[0254] Compound 12, Compound 13, Compound 14, and Compound 15 3-((3-bromophenyl)(3-methoxycyclobutyl)methyl)-4-methyl-4H-1,2,4-triazole (97.9 mg, 0.291 mmol), (S)-6-((2-isopropyl-4-methylpiperazin-1-yl)methyl)-4-(trifluoromethyl)isoindolin-1-one (114 mg, 0.320 mmol), [(4,5-bis(diphenylphosphino)-9,9-dimethylxanthene)-2-(2′-amino-1,1′-biphenyl)]palladium(II) methanesulfonate (27.9 mg, 0.0195 mmol), and cesium carbonate (285 mg, 0.874 mmol) were weighed into a vial. Anhydrous 2-methyl-2-butanol (1.5 mL) was charged to the vessel under a stream of nitrogen gas, and the vial was sealed. The reaction mixture was stirred for 18 h at 100° C. After cooling to rt, the mixture was concentrated and purified by flash column chromatography (0-100% 80:15:2.5 CH2Cl2 / MeOH / NH4OH in CH2Cl2), HPLC, and chiral SFC to give: 6-(((S)-2-isopropyl-4-methylpiperazin-1-yl)methyl)-2-(3-((S)-((1R,3S)-3-methoxycyclobutyl)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one (Peak 1) (Compound 12, 3.7 mg, 2%), 6-(((S)-2-isopropyl-4-methylpiperazin-1-yl)methyl)-2-(3-((S)-((1S,3S)-3-methoxycyclobutyl)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one (peak 2) (compound 13, 1511.8 mg, 7%), 6-(((S)-2-isopropyl-4-methylpiperazin-1-yl)methyl)-2-(3-((S)-((1S,3R)-3-methoxycyclobutyl)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one (compound 14, peak 3) and (5.7 mg, 3%), and 6-(((S)-2-isopropyl-4-methylpiperazin-1-yl)methyl)-2-(3-((S)-((1R,3S)-3-methoxycyclobutyl)(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-4-(trifluoromethyl)isoindolin-1-one (compound 15, peak 4) (11.9 mg, 7%); LCMS (ESI) m / z: 611.3 [M+H] + ; 1 H NMR(500MHz,DMSO-d6)δ 8.32(s,1H), 7.98(s,1H), 7.90(d,J=8.1Hz,2H), 7.77(d,J=8.2Hz,1H), 7.38(dd,J=7.9Hz,7.9Hz,1H ), 7.03(d,J=7.4Hz,1H), 5.16(s,2H), 4.27-4.15(m,2H), 3.71(p,J=7.4Hz,1H), 3.45-3.32(m,5H), 3. 09(s,3H), 2.78-2.66(m,1H), 2.66-2.56(m,2H), 2.45-2.33(m,1H), 2.31-2.17(m,3H), 2.14(s,3H), 2 .11-2.00(m,1H), 1.99-1.86(m,2H), 1.72-1.50(m,2H), 0.93(d,J=6.7Hz,3H), 0.88(d,J=6.7Hz,3H).

[0255] Example 15: Compound 16 Compound 16 can be synthesized according to Scheme 15 in FIG.

[0256] Intermediate 3: (1-(2,6-dichloropyridin-4-yl)-3,3-difluorocyclobutanecarbonitrile) To a solution of 2,4,6-trichloropyridine (5 g, 27.4 mmol) in tetrahydrofuran (80 mL) was added 3,3-difluorocyclobutanecarbonitrile (3.37 g, 28.8 mmol), followed by the addition of lithium bis(trimethylsilyl)amide (1.0 M in tetrahydrofuran, 30.2 mL, 30.2 mmol) over 10 minutes at −78° C. The mixture was stirred at 20° C. for 2 hours. The mixture was quenched with saturated aqueous ammonium chloride solution (30 mL) and then extracted with ethyl acetate (3×100 mL). The combined organic phases were washed with brine (50 mL), dried, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (mobile phase: ethyl acetate / petroleum ether, gradient 0% to 10%) to give 1-(2,6-dichloropyridin-4-yl)-3,3-difluorocyclobutanecarbonitrile (5.2 g, 72% yield) as a white solid. 1 H NMR(400MHz,CDCl3)δ 7.40(s,2H), 3.58-3.54(m,2H), 3.23-3.20(m,2H).

[0257] Intermediate 4: (1-(2,6-dichloropyridin-4-yl)-3,3-difluorocyclobutanecarboxylic acid) To a mixture of 1-(2,6-dichloropyridin-4-yl)-3,3-difluorocyclobutanecarbonitrile (4.5 g, 17.1 mmol) in ethanol (35 mL) and water (15 mL) was added sodium hydroxide (2.0 g, 51.3 mmol). The mixture was stirred at 80° C. for 2 hours. After cooling to 0° C., the mixture was adjusted to pH=5 with aqueous hydrochloric acid (1 M) and diluted with water (100 mL). The solution was extracted with dichloromethane (3×100 mL). The combined organic layers were washed with brine (40 mL), dried, and concentrated under reduced pressure to give crude 1-(2,6-dichloropyridin-4-yl)-3,3-difluorocyclobutanecarboxylic acid (4.5 g, 93% yield) as a yellow solid. LCMS [M+H] + =282.0 and 284.0.

[0258] Intermediate 5: (2-(1-(2,6-dichloropyridin-4-yl)-3,3-difluorocyclobutanecarbonyl)-N-methylhydrazinecarbothioamide To a mixture of 1-(2,6-dichloropyridin-4-yl)-3,3-difluorocyclobutanecarboxylic acid (4.5 g, 16.0 mmol), N-methylhydrazinecarbothioamide (2.5 g, 23.9 mmol), and N-ethyl-N-isopropylpropan-2-amine (5.5 g, 47.9 mmol) in N,N-dimethylformamide (50 mL) was added 2-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (9.1 g, 23.9 mmol). The mixture was stirred at 25 °C for 16 hours. The reaction mixture was diluted with water (100 mL) and then extracted with dichloromethane (3 × 100 mL). The combined organic layers were washed with brine (3 × 50 mL), dried, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (mobile phase: ethyl acetate / petroleum ether, gradient 0% to 50%) to give the crude product (4.1 g). The crude product was triturated with ethyl acetate (10 mL) to give 2-(1-(2,6-dichloropyridin-4-yl)-3,3-difluorocyclobutanecarbonyl)-N-methylhydrazinecarbothioamide (1.5 g, 26% yield) as a white solid. LCMS [M+H] + =369.0 and 371.0.

[0259] Intermediate 6: (5-(1-(2,6-dichloropyridin-4-yl)-3,3-difluorocyclobutyl)-4-methyl-4H-1,2,4-triazole-3-thiol A mixture of 2-(1-(2,6-dichloropyridin-4-yl)-3,3-difluorocyclobutanecarbonyl)-N-methylhydrazinecarbothioamide (1.3 g, 3.52 mmol) in aqueous sodium hydroxide (1 M, 28.9 mL, 28.9 mmol) was stirred at 25 °C. Stirred for 12 hours. After cooling to 0°C, the mixture was adjusted to pH = 5 by addition of aqueous hydrochloric acid (1 M) and filtered. The filter cake was washed with water (2 x 10 mL) and dried to give 5-(1-(2,6-dichloropyridin-4-yl)-3,3-difluorocyclobutyl)-4-methyl-4H-1,2,4-triazole-3-thiol (1.0 g, 81% yield) as a white solid. LCMS [M+H] + =351.1 and 353.0.

[0260] Intermediate 7: (2,6-dichloro-4-(3,3-difluoro-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridine To a solution of 5-(1-(2,6-dichloropyridin-4-yl)-3,3-difluorocyclobutyl)-4-methyl-4H-1,2,4-triazole-3-thiol (1.3 g, 3.7 mmol) in water (30 mL) and acetonitrile (10 mL) was added sodium nitrite (1.3 g, 18.5 mmol), followed by aqueous nitric acid (1 M, 18.5 mL, 18.5 mmol) at 0° C. The mixture was stirred at 20° C. for 5 hours and quenched with saturated sodium bicarbonate solution (50 mL). The resulting mixture was extracted with dichloromethane (3×50 mL). The combined organic layers were washed with brine (50 mL), dried, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (mobile phase: methanol / dichloromethane, gradient 0% to 5%) to give 2,6-dichloro-4-(3,3-difluoro-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridine (600 mg, 51% yield) as a brown oil. 1 H NMR(400MHz,CDCl3)δ 8.23(s,1H), 7.15(s,2H), 3.84-3.70(m,2H), 3.35(s,3H), 3.33-3.22(m,2H).LCMS[M+H] + =319.1 and 321.1.

[0261] Intermediate 9: (tert-butyl((2-(6-chloro-4-(3,3-difluoro-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-yl)-3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)(1-methylcyclobutyl)carbamate) To a solution of tert-butyl (1-methylcyclobutyl)((3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)carbamate (562 mg, 1.4 mmol) and 2,6-dichloro-4-(3,3-difluoro-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridine (450 mg, 1.4 mmol) in 1,4-dioxane (40 mL) was added potassium phosphate (599 mg, 2.8 mmol), (9,9-dimethyl-9H-xanthene-4,5-diyl)bis(diphenylphosphine) (82 mg, 0.14 mmol), and palladium(II) acetate (31.7 mg, 0.14 mmol). The mixture was stirred at 100° C. under nitrogen protection for 16 hours. After cooling, the mixture was diluted with dichloromethane (50 mL). The separated organic layer was washed with brine (20 mL), dried, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (mobile phase: methanol / dichloromethane, gradient 0% to 6%) to give tert-butyl ((2-(6-chloro-4-(3,3-difluoro-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-yl)-3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)(1-methylcyclobutyl)carbamate (900 mg, 94% yield) as a yellow solid. LCMS [M+H] + =681.3 and 683.3.

[0262] Intermediate 10: (tert-butyl((2-(6-cyclopropyl-4-(3,3-difluoro-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-yl)-3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)(1-methylcyclobutyl)carbamate) A mixture of tert-butyl ((2-(6-chloro-4-(3,3-difluoro-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-yl)-3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)(1-methylcyclobutyl)carbamate (150 mg, 0.22 mmol), cyclopropylboronic acid (37.8 mg, 0.44 mmol), [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (18.0 mg, 0.02 mmol), and cesium carbonate (215.3 mg, 0.66 mmol) in toluene (5 mL) and water (0.5 mL) was stirred at 110° C. for 16 hours under nitrogen protection. After cooling, the mixture was diluted with water (30 mL) and extracted with dichloromethane (3×20 mL). The combined organic layers were dried and concentrated under reduced pressure. The residue was purified by preparative TLC (solvent gradient: 10% methanol in dichloromethane) to give tert-butyl ((2-(6-cyclolo-4-(3,3-difluoro-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-yl)-3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)(1-methylcyclobutyl)carbamate (70.0 mg, 46% yield) as a yellow solid. LCMS [M+H] + =687.1.

[0263] compound 16 A mixture of tert-butyl ((2-(6-chloro-4-(3,3-difluoro-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-yl)-3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)(1-methylcyclobutyl)carbamate (60.0 mg, 0.09 mmol) and trifluoroacetic acid (0.03 mL, 0.4 mmol) in dichloromethane (1 mL) was stirred at 20° C. for 2 hours and concentrated under reduced pressure. The residue was purified by RP-HPLC (60% to 90% ACN / (0.05% NH3H2O ​​in water + 10 mM NH4HCO3)) to give 2-(6-cyclopropyl-4-(3,3-difluoro-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-yl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one (compound 16, 20.6 mg, 38% yield). 1 H NMR(400MHz, methanol-d4)δ 8.44(s,1H), 8.30(s,1H), 8.09(s,1H), 8.02(s,1H), 7.04(s,1H), 5.20(s,2H), 3.88(s,2H), 3.76-3.69(m,2H), 3 .48-3.44(m,2H), 3.42(s,3H), 2.13-2.08(m,3H), 1.91-1.80(m,4H), 1.39(s,3H), 1.08-1.01(m,4H).LCMS[M+H] + =587.1.

[0264] Example 16: Compound 17 Compound 17 can be synthesized according to Scheme 16 in FIG.

[0265] Intermediate 2: (tert-butyl((2-(4-(3,3-difluoro-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)-6-(ethylamino)pyridin-2-yl)-3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)(1-methylcyclobutyl)carbamate) A mixture of tert-butyl ((2-(6-chloro-4-(3,3-difluoro-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)pyridin-2-yl)-3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)(1-methylcyclobutyl)carbamate (200.0 mg, 0.29 mmol), Ruphos Pd G4 (24.5 mg, 0.03 mmol, CAS#: 1599466-85-9), ethanamine hydrochloride (28.2 mg, 0.35 mmol), and cesium carbonate (281.2 mg, 0.86 mmol) in tetrahydrofuran (6 mL) was stirred at 100° C. under nitrogen protection for 16 hours and concentrated under reduced pressure. The residue was purified by preparative TLC (solvent gradient: 10% methanol in dichloromethane) to give tert-butyl ((2-(4-(3,3-difluoro-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)-6-(ethylamino)pyridin-2-yl)-3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)(1-methylcyclobutyl)carbamate (70.0 mg, 35% yield) as a yellow solid. LCMS [M+H] + =690.0.

[0266] compound 17 A mixture of tert-butyl ((2-(4-(3,3-difluoro-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)-6-(ethylamino)pyridin-2-yl)-3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)(1-methylcyclobutyl)carbamate (70.0 mg, 0.10 mmol) and trifluoroacetic acid (0.6 mL, 8.19 mmol) in dichloromethane (5 mL) was stirred at 25° C. for 2 hours and concentrated under reduced pressure. The residue was purified by RP-HPLC (50 to 80% ACN / (0.05% NH3H2O ​​in water + 10 mM NH4HCO3)) to give 2-(4-(3,3-difluoro-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)-6-(ethylamino)pyridin-2-yl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one (30.0 mg, 50% yield). 1 H NMR(400MHz, methanol-d4)δ 8.43(s,1H), 8.07(s,1H), 8.00(s,1H), 7.69(s,1H), 6.11(d,J=1.2Hz,1H), 5.22(s,2H), 3.85(s,2H), 3.72-3.65(m,2H) ), 3.44(s,3H), 3.41-3.33(m,4H), 2.12-2.08(m,2H), 1.90-1.77(m,4H), 1.38(s,3H), 1.23(t,J=7.2Hz,3H).LCMS[M+H] + =590.3.

[0267] Example 18: Compound 18 Compound 18 can be synthesized according to Scheme 17 in FIG.

[0268] Intermediate 2: (3-(1-(3-bromophenyl)-3-methylenecyclobutyl)-4-methyl-4H-1,2,4-triazole) To a solution of 3-(3-bromobenzyl)-4-methyl-4H-1,2,4-triazole (500.0 mg, 1.98 mmol) in 1,2-dimethoxyethane (20 mL) was added 3-chloro-2-(chloromethyl)prop-1-ene (0.28 mL, 2.38 mmol) and lithium bis(trimethylsilyl)amide (1.0 M in tetrahydrofuran, 3.97 mL, 3.97 mmol) at −40° C. The mixture was stirred at −40° C. for 20 minutes, and then additional lithium bis(trimethylsilyl)amide (1.0 M in tetrahydrofuran, 3.97 mL, 3.97 mmol) was added at −40° C. The resulting mixture was stirred at 0° C. for an additional 1 hour and quenched with water (15 mL). The mixture was extracted with dichloromethane (3×30 mL). The combined organic phase was washed with brine (10 mL), dried, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (mobile phase: methanol / dichloromethane, gradient 0% to 10%) to give 3-(1-(3-bromophenyl)-3-methylenecyclobutyl)-4-methyl-4H-1,2,4-triazole (100.0 mg, 17% yield) as a white solid. 1 H NMR(400MHz,DMSO-d6)δ 8.40(s,1H), 7.51-7.45(m,1H), 7.38-7.29(m,2H), 7.21-7.19(m,1H), 4 .91(t,J=2.4Hz,2H), 3.70-3.59(m,2H), 3.31-3.29(m,2H), 3.21(s,3H).

[0269] Intermediate 3: (tert-butyl((2-(3-(1-(4-methyl-4H-1,2,4-triazol-3-yl)-3-methylenecyclobutyl)phenyl)-3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)(1-methylcyclobutyl)carbamate) In a glove box, 3-(1-(3-bromophenyl)-3-methylenecyclobutyl)-4-methyl-4H-1,2,4-triazole (30.0 mg, 0.10 mmol), tert-butyl(1-methylcyclobutyl)((3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)carbamate (43.2 mg, 0.11 mmol) were dissolved in 1,4-dioxane (2 mL). A mixture of (2-dicyclohexylphosphino-2',6'-diisopropoxy-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) methanesulfonate (8.3 mg, 0.01 mmol, CAS#: 1445085-77-7) was stirred at 100°C for 16 hours and concentrated under reduced pressure. The residue was purified by preparative TLC (solvent gradient: 10% methanol in dichloromethane) to give tert-butyl ((2-(3-(1-(4-methyl-4H-1,2,4-triazol-3-yl)-3-methylenecyclobutyl)phenyl)-3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)(1-methylcyclobutyl)carbamate (50.0 mg, 82% yield) as a yellow oil. LCMS [M+H] + =622.3.

[0270] compound 18 A mixture of tert-butyl ((2-(3-(1-(4-methyl-4H-1,2,4-triazol-3-yl)-3-methylenecyclobutyl)phenyl)-3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)(1-methylcyclobutyl)carbamate (50.0 mg, 0.08 mmol) and trifluoroacetic acid (0.5 mL, 6.49 mmol) in dichloromethane (5 mL) was stirred at 20° C. for 16 hours and concentrated under reduced pressure. The residue was purified by RP-HPLC (55% to 85% ACN / (0.05% NH3H2O+10 mM NH4HCO3 in water)) to give 2-(3-(1-(4-methyl-4H-1,2,4-triazol-3-yl)-3-methylenecyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one (compound 18, 12.0 mg, 29% yield). 1 H NMR (400 MHz, methanol-d4) δ 8.41(s,1H), 8.08(s,1H), 8.01(s,1H), 7.96(s,1H), 7.68(d,J=9.2Hz,1H ), 7.48(t,J=8.0Hz,1H), 7.16(d,J=6.8Hz,1H), 5.14(s,2H), 4.98(s,2H) , 3.88(s,2H), 3.77-3.72(m,2H), 3.49-3.46(m,2H), 3.39(s,3H), 2.15-2 .09(m,2H), 1.90-1.86(m,2H), 1.82-1.78(m,2H), 1.39(s,3H).LCMS[M+H] + =522.3.

[0271] Example 19: Compound 19 Compound 19 can be synthesized according to Scheme 18 in FIG.

[0272] Intermediate 2: (3-(3-bromophenyl)-3-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutanol) To a solution of 3-(3-bromobenzyl)-4-methyl-4H-1,2,4-triazole (500 mg, 1.98 mmol) in tetrahydrofuran (20 mL) were added epichlorohydrin (202 mg, 2.18 mmol) and isopropylmagnesium chloride (2.0 M in tetrahydrofuran, 3.97 mL, 7.94 mmol) at −40° C. The reaction mixture was stirred at −40° C. for 30 minutes and then at 20° C. for 16 hours. The mixture was quenched by the addition of water (30 mL) and extracted with dichloromethane (3×50 mL). The combined organic layers were washed with brine (50 mL), dried, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (mobile phase: methanol / dichloromethane, gradient 0% to 10%) to give 3-(3-bromophenyl)-3-(4-methyl-1,2,4-triazol-3-yl)cyclobutanol (300 mg, 49% yield). 1 H NMR(400MHz,DMSO-d6)δ 8.29(s,1H), 7.47-7.43(m,1H), 7.40(s,1H), 7.33(s,2H), 5.31(d,J=6.8Hz ,1H), 4.27-4.17(m,1H), 3.18(s,3H), 3.03-2.98(m,2H), 2.77-2.62(m,2H).

[0273] Intermediate 3: (tert-butyl((2-(3-(3-hydroxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)(1-methylcyclobutyl)carbamate) In a glovebox, a solution of 3-(3-bromophenyl)-3-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutanol (50.0 mg, 0.16 mmol), tert-butyl(1-methylcyclobutyl)((3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)carbamate (71.1 mg, 0.18 mmol) in 1,4-dioxane (2 mL) was added. A mixture of (2-dicyclohexylphosphino-2',6'-diisopropoxy-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) methanesulfonate (13.6 mg, 0.02 mmol, CAS#: 1445085-77-7) was stirred at 100°C for 16 hours and concentrated under reduced pressure. The residue was purified by preparative TLC (solvent gradient: 10% methanol in dichloromethane) to give tert-butyl ((2-(3-(3-hydroxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)(1-methylcyclobutyl)carbamate (40.0 mg, 39% yield) as a yellow oil. LCMS [M+H] + =626.3.

[0274] Intermediate 5: (tert-butyl((2-(3-(1-(4-methyl-4H-1,2,4-triazol-3-yl)-3-oxocyclobutyl)phenyl)-3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)(1-methylcyclobutyl)carbamate) To a solution of tert-butyl ((2-(3-(3-hydroxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)(1-methylcyclobutyl)carbamate (40.0 mg, 0.06 mmol) in dichloromethane (2 mL) was added Dess-Martin periodinane (54.2 mg, 0.13 mmol) at 0° C. The mixture was stirred at 25° C. for 16 h, diluted with dichloromethane (20 mL), washed with saturated sodium sulfite solution (3×10 mL), saturated sodium bicarbonate solution (10 mL), brine (10 mL), dried, and concentrated under reduced pressure. The residue was purified by preparative TLC (solvent gradient: 10% methanol in dichloromethane) to give tert-butyl ((2-(3-(1-(4-methyl-4H-1,2,4-triazol-3-yl)-3-oxocyclobutyl)phenyl)-3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)(1-methylcyclobutyl)carbamate (35 mg, 88% yield) as a white solid.

[0275] compound 19 A mixture of tert-butyl ((2-(3-(1-(4-methyl-4H-1,2,4-triazol-3-yl)-3-oxocyclobutyl)phenyl)-3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)(1-methylcyclobutyl)carbamate (50.0 mg, 0.08 mmol) and trifluoroacetic acid (0.5 mL, 6.49 mmol) in dichloromethane (5 mL) was stirred at 20° C. for 2 hours and concentrated under reduced pressure. The residue was purified by RP-HPLC (45% to 75% ACN / (0.05% NH3H2O+10 mM NH4HCO3 in water)) to give 2-(3-(1-(4-methyl-4H-1,2,4-triazol-3-yl)-3-oxocyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one (9.0 mg, 21% yield). 1H NMR(400MHz,CDCl3)δ 8.13(d,J=2.4Hz,2H), 8.10(s,1H), 7.93(s,1H), 7.54-7.45(m,2H), 7.13(d,J=7.6Hz,1H), 4.95(s,2H), 4.29-4.23(m, 2H), 3.91-3.82(m,4H), 3.43(s,3H), 2.25-2.00(m,2H), 2.00-1.92(m,2H), 1.82-1.80(m,2H), 1.38(s,3H).LCMS:[M+H] + =524.3.

[0276] Example 20: Compounds 20 and 21 Compounds 20 and 21 can be synthesized according to Scheme 19 (Figure 19).

[0277] A mixture of tert-butyl ((2-(3-(3-hydroxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)(1-methylcyclobutyl)carbamate (109 mg, 0.17 mmol) and trifluoroacetic acid (0.5 mL, 6.49 mmol) in dichloromethane (5 mL) was stirred at 20° C. for 2 hours and concentrated under reduced pressure. The residue was purified by RP-HPLC (45% to 75% ACN / (0.05% NH3H2O+10 mM NH4HCO3 in water)) to give ((2-(3-(3-hydroxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-3-6-((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one (50 mg, 55% yield).

[0278] The above racemate (46 mg, 0.09 mmol) was further purified by chiral SFC using 0.1% ammonium hydroxide-30% ethanol-carbon dioxide (column = Daicel ChiralPAK IG; column dimensions = 250 mm × 30 mm × 10 μm; detection wavelength = 220 nM; flow rate = 80 mL / min; run time = 4.0 min; column temperature = 25°C) to give: 2-(3-((1r,3r)-3-hydroxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one (peak 1, retention time = 2.552 min) (compound 20, 4.1 mg, 9% yield), 1 H NMR (400 MHz, methanol-d4) δ 8.29(s,1H), 8.07(s,1H), 8.04(t,J=8.0Hz,1H), 7.99(s,1H), 7.65(d,J =8.4Hz,1H), 7.46(t,J=8.0Hz,1H), 7.20(d,J=9.2Hz,1H), 5.13(s,2H), 4 .47-4.41(m,1H), 3.86(s,2H), 3.33(s,3H), 3.20-3.16(m,2H), 2.87-2.8 3(m,2H), 2.10-2.07(m,2H), 1.88-1.74(m,4H), 1.37(s,3H).LCMS:[M+H] + =526.3; and 2-(3-((1s,3s)-3-hydroxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one (peak 2, retention time = 2.808 min) (compound 21, 19.9 mg, 43% yield). 1 H NMR (400 MHz, methanol-d4) δ 1 H NMR(400MHz, methanol-d4)δ 8.36(s,1H), 8.07(s,1H), 7.99(s,1H), 7.87(s,1H), 7.65(d,J=8.0Hz,1H), 7.45(t,J=8.0Hz,1H), 7.06(d,J=7.6Hz,1H), 5.13(s,2H), 4 .27(t,J=7.2Hz,1H), 3.87(s,2H), 3.36-3.31(m,5H), 2.65-2.59(m,2H), 2.11-2.08(m,2H), 1.88-1.76(m,4H), 1.38(s,3H).LCMS:[M+H] + =526.3.

[0279] Example 21: Compound 22 Compound 22 can be synthesized according to Scheme 20 in FIG.

[0280] Intermediate 2: (3-((1s,3s)-1-(3-bromophenyl)-3-methoxycyclobutyl)-4-methyl-4H-1,2,4-triazole) To a solution of methyl (1s,3s)-3-(3-bromophenyl)-3-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutanol (300 mg, 0.97 mmol) in N,N-dimethylformamide (10 mL) was added sodium hydride (60%, 47 mg, 1.2 mmol) at 0° C. The mixture was stirred at 0° C. for 30 minutes, and then methyl iodide (0.09 mL, 1.46 mmol) was added. The resulting mixture was stirred at 25° C. for 16 hours. After cooling, the mixture was quenched by the addition of water (10 mL) and extracted with ethyl acetate (3×30 mL). The combined organic phases were washed with brine (2×10 mL), dried, and concentrated under reduced pressure. The residue was purified by preparative TLC (solvent gradient: 10% methanol in dichloromethane) to give 3-((1s,3s)-1-(3-bromophenyl)-3-methoxycyclobutyl)-4-methyl-4H-1,2,4-triazole (90 mg, 29% yield) as a colorless oil. LCMS [M+H] + =322.0.

[0281] Intermediate 3: (tert-butyl((2-(3-((1s,3s)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)(1-methylcyclobutyl)carbamate) In a glove box, 3-((1s,3s)-1-(3-bromophenyl)-3-methoxycyclobutyl)-4-methyl-4H-1,2,4-triazole (90.0 mg, 0.16 mmol), tert-butyl(1-methylcyclobutyl)((3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)carbamate (122 mg, A mixture of (2-dicyclohexylphosphino-2',6'-diisopropoxy-1,1'-biphenyl)[2-(2'-amino-1,1'biphenyl)]palladium(II) methanesulfonate (23.4 mg, 0.03 mmol, CAS#1445085-77-7) was stirred at 100°C for 16 hours and concentrated under reduced pressure. The residue was purified by preparative TLC (solvent gradient: 10% methanol in dichloromethane) to give tert-butyl ((2-(3-((1s,3s)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)(1-methylcyclobutyl)carbamate (30 mg, 17% yield) as a yellow oil. LCMS [M+H] + =640.0.

[0282] compound 22 A mixture of tert-butyl ((2-(3-((1s,3s)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)(1-methylcyclobutyl)carbamate (30.0 mg, 0.05 mmol) and trifluoroacetic acid (0.3 mL, 3.89 mmol) in dichloromethane (5 mL) was stirred at 20° C. for 2 hours and concentrated under reduced pressure. The residue was purified by RP-HPLC (50% to 80% ACN / (0.05% NH3H2O+10 mM NH4HCO3 in water)) to give 2-(3-((1s,3s)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one (9.0 mg, 21% yield). 1 H NMR (400 MHz, methanol-d4) δ 8.32(s,1H), 8.08(s,1H), 8.06(t,J=2.0Hz,1H), 8.01(s,1H), 7.70-7.67( m,1H), 7.49(t,J=8.0Hz,1H), 7.23-7.20(m,1H), 5.15(s,2H), 4.22-4.15( m,1H), 3.86(s,2H), 3.36(s,3H), 3.29(s,3H), 3.22-3.17(m,2H), 2.93-2. 83(m,2H), 2.15-2.04(m,2H), 1.91-1.76(m,4H), 1.38(s,3H).LCMS:[M+H] + =540.1.

[0283] Example 22: Compound 23 Compound 23 can be synthesized according to Scheme 21 (Figure 21).

[0284] Intermediate 2: (3-((1r,3r)-1-(3-bromophenyl)-3-methoxycyclobutyl)-4-methyl-4H-1,2,4-triazole) To a solution of methyl(1r,3r)-3-(3-bromophenyl)-3-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutanol (250 mg, 0.81 mmol) in N,N-dimethylformamide (10 mL) was added sodium hydride (60%, 38.9 mg, 0.97 mmol) at 0° C. The mixture was stirred at 0° C. for 30 minutes, and then methyl iodide (0.08 mL, 1.22 mmol) was added. The resulting mixture was stirred at 25° C. for 16 hours. After cooling, the mixture was quenched by the addition of water (10 mL) and extracted with ethyl acetate (3×30 mL). The combined organic phases were washed with brine (2×10 mL), dried, and concentrated under reduced pressure. The residue was purified by preparative TLC (solvent gradient: 10% methanol in dichloromethane) to give 3-((1r,3r)-1-(3-bromophenyl)-3-methoxycyclobutyl)-4-methyl-4H-1,2,4-triazole (170 mg, 65% yield) as a colorless oil. LCMS [M+H] + =322.0.

[0285] Intermediate 3: (tert-butyl((2-(3-((1r,3r)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)(1-methylcyclobutyl)carbamate) In a glovebox, a solution of 3-((1r,3r)-1-(3-bromophenyl)-3-methoxycyclobutyl)-4-methyl-4H-1,2,4-triazole (170 mg, 0.53 mmol), tert-butyl(1-methylcyclobutyl)((3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)carbamate (231 mg, 0.53 mmol) in 1,4-dioxane (5 mL) was prepared. A mixture of (2-dicyclohexylphosphino-2',6'-diisopropoxy-1,1'-biphenyl)[2-(2'-amino-1,1'biphenyl)]palladium(II) methanesulfonate (44.1 mg, 0.05 mmol, CAS#: 1445085-77-7) was stirred at 110°C for 16 hours and concentrated under reduced pressure. The residue was purified by preparative TLC (solvent gradient: 10% methanol in dichloromethane) to give tert-butyl ((2-(3-((1r,3r)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)(1-methylcyclobutyl)carbamate (150 mg, 44% yield) as a yellow oil. LCMS [M+H] + =640.0.

[0286] compound 23 A mixture of tert-butyl ((2-(3-((1r,3r)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)(1-methylcyclobutyl)carbamate (150 mg, 0.23 mmol) and trifluoroacetic acid (0.58 mL, 7.49 mmol) in dichloromethane (5 mL) was stirred at 20° C. for 2 hours and concentrated under reduced pressure. The residue was purified by RP-HPLC (50% to 80% ACN / (0.05% NH3H2O+10 mM NH4HCO3 in water)) to give 2-(3-((1r,3r)-3-methoxy-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one (compound 23, 9.0 mg, 21% yield). 1 H NMR(400MHz,DMSO-d6)δ 8.39(s,1H), 8.07(s,1H), 8.03(s,1H), 7.88(s,1H), 7.72(dd,J=1.2, 8.0Hz,1H), 7.42(t,J=8.0Hz, 1H), 6.96(d,J=7.6Hz,1H), 5.20(s,2H), 3.88-3.82(m,3H), 3.24(s,3H), 3.18(s,3H), 2.53-2.49(m 4H), 2.10-1.90(m,2H), 1.74-1.67(m,4H), 1.27(s,3H).LCMS:[M+H] + =540.4.

[0287] Example 23: Compounds 24 and 25 Compounds 24 and 25 can be synthesized according to Scheme 22 in FIG.

[0288] Intermediate 2: (3-(3-bromophenyl)-3-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl methanesulfonate) To a mixture of 3-(3-bromophenyl)-3-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutanol (1.00 g, 3.24 mmol) in dichloromethane (20 mL) was added triethylamine (2.26 mL, 16.2 mmol) and mesyl chloride (1.23 mL, 15.9 mmol) at 0 °C. The mixture was stirred at 25 °C for 3 hours and then quenched with saturated sodium bicarbonate solution (10 mL). The resulting mixture was extracted with dichloromethane (3 × 20 mL). The combined organic layers were washed with brine (50 mL), dried, and concentrated under reduced pressure to give 3-(3-bromophenyl)-3-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl methanesulfonate (1.20 g, 96% yield) as a yellow oil.

[0289] Intermediate 3: (3-(3-bromophenyl)-3-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutanecarbonitrile) To a solution of 3-(3-bromophenyl)-3-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl methanesulfonate (1.2 g, 3.11 mmol) in dimethyl sulfoxide (15 mL) were added potassium carbonate (2.15 g, 15.53 mmol) and potassium cyanide (1.16 g, 17.8 mmol), and the mixture was stirred at 120° C. for 16 hours and diluted with water (10 mL). The resulting mixture was extracted with dichloromethane (3×20 mL). The combined organic layers were washed with brine (20 mL), dried, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (mobile phase: methanol / dichloromethane, gradient 0% to 4%) to give 3-(3-bromophenyl)-3-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutanecarbonitrile (750 mg, 76% yield) as a yellow oil. LCMS [M+H] + =319.1 and 320.1.

[0290] Intermediate 4: (tert-butyl((2-(3-(3-cyano-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)(1-methylcyclobutyl)carbamate) To a solution of tert-butyl (1-methylcyclobutyl)((3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)carbamate (180 mg, 0.45 mmol) and 3-(3-bromophenyl)-3-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutanecarbonitrile (130 mg, 0.4 mmol) in 1,4-dioxane (5 mL) was added cesium carbonate (401 mg, 1.2 mmol) and (2-dicyclohexylphosphino-2',6'-diisopropoxy-1,1'-biphenyl)[2-(2'-amino-1,1'biphenyl)]palladium(II) methanesulfonate (34 mg, 0.04 mmol, CAS#: 1445085-77-7). The mixture was stirred at 110 °C for 16 h under nitrogen protection. After cooling, the mixture was diluted with dichloromethane (5 mL). The separated organic layer was washed with brine (5 mL), dried, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (mobile phase: methanol / dichloromethane, gradient 0% to 6%) to give tert-butyl ((2-(3-(3-cyano-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)(1-methylcyclobutyl)carbamate (150 mg, 58% yield) as a yellow solid. LCMS [M+H] + =635.3.

[0291] Compounds 24 and 25 A mixture of tert-butyl ((2-(3-(3-cyano-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)(1-methylcyclobutyl)carbamate (150 mg, 0.23 mmol) and trifluoroacetic acid (0.5 mL, 27.6 mmol) in dichloromethane (5 mL) was stirred at 20° C. for 2 hours and concentrated under reduced pressure. The residue was purified by RP-HPLC (60% to 90% ACN / (0.05% NH3H2O+10 mM NH4HCO3 in water)) to give 3-(4-methyl-4H-1,2,4-triazol-3-yl)-3-(3-(6-(((1-methylcyclobutyl)amino)methyl)-1-oxo-4-(trifluoromethyl)isoindolin-2-yl)phenyl)cyclobutanecarbonitrile (60 mg, 48% yield).

[0292] The above racemate (60 mg, 0.57 mmol) was further purified by chiral SFC using 0.1% ammonium hydroxide-30% ethanol-carbon dioxide (column = Daicel Chiralcel OD; column dimensions = 250 mm x 30 mm x 10 μm; detection wavelength = 220 nM; flow rate = 70 mL / min; run time = 4.0 min; column temperature = 25°C) to give: (1r,3r)-3-(4-methyl-4H-1,2,4-triazol-3-yl)-3-(3-(6-(((1-methylcyclobutyl)amino)methyl)-1-oxo-4-(trifluoromethyl)isoindolin-2-yl)phenyl)cyclobutanecarbonitrile (peak 2, retention time = 4.550 min) (39 mg, 69% yield). 1H NMR(400MHz,DMSO-d6)δ 8.43(s,1H), 8.26(s,1H), 8.21(s,1H), 7.86-7.82(m,2H), 7.51-7.46(m,1H), 7.08(d,J=8.0Hz,1H), 5.28(s,2H), 4.26(s ,2H), 3.43-3.38(m,3H), 3.23(s,3H), 3.08-3.01(m,2H), 2.38-2.32(m,3H), 1.90-1.83(m,4H), 1.52(s,3H).LCMS:[M+H] + =535.3. (1s,3s)-3-(4-methyl-4H-1,2,4-triazol-3-yl)-3-(3-(6-(((1-methylcyclobutyl)amino)methyl)-1-oxo-4-(trifluoromethyl)isoindolin-2-yl)phenyl)cyclobutanecarbonitrile (peak 1, retention time = 4.233 min) (2 mg, 4% yield). 1 H NMR(400MHz,DMSO-d6)δ 8.38(s,1H), 8.05(s,1H), 8.01(s,1H), 7.89(s,1H), 7.81(d,J=8.0Hz,1H), 7.47(t,J=8.0Hz,1H), 7.12(d,J=8.4Hz,1H), 5.20(s,2 H), 3.82(s,2H), 3.70-3.50(m,1H), 3.26(s,3H), 3.26-3.12(m,4H), 2.02-1.94(m,2H), 1.76-1.62(m,4H), 1.23(s,3H).LCMS:[M+H] + =535.3.

[0293] Example 24: Compounds 26 and 27 Compounds 26 and 27 (2-(3-((1s,3s)-3-hydroxy-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one) and (2-(3-((1r,3r)-3-hydroxy-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one) can be synthesized according to Scheme 23 (Figure 23).

[0294] Intermediate 2: (3-(3-bromophenyl)-3-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutanone To a solution of 3-(3-bromophenyl)-3-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutanol (4.0 g, 13.0 mmol) in ethyl acetate (100 mL) was added 2-iodoxybenzoic acid (10.9 g, 38.94 mmol) at 25 °C. The mixture was stirred at 80 °C for 16 hours and filtered. The filtrate was concentrated under reduced pressure, and the residue was purified by silica gel chromatography (mobile phase: methanol / dichloromethane, gradient 0% to 10%) to give 3-(3-bromophenyl)-3-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutanone (3.5 g, 88% yield) as a yellow solid. LCMS: [M+H] + =306.

[0295] Intermediate 3: (3-(3-bromophenyl)-1-methyl-3-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutanol To a solution of 3-(3-bromophenyl)-3-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutan-1-one (2.0 g, 6.53 mmol) in tetrahydrofuran (30 mL) was added methylmagnesium bromide (3 M in tetrahydrofuran, 8.71 mL, 26.13 mmol) at 0° C. The reaction mixture was stirred at 20° C. for 16 hours. The reaction was quenched with water (20 mL) and then extracted with dichloromethane (3×50 mL). The combined organic phases were washed with brine (50 mL), dried, and concentrated under reduced pressure. The resulting residue was purified by silica gel chromatography (mobile phase: methanol / dichloromethane, gradient 0% to 10%) to give 3-(3-bromophenyl)-1-methyl-3-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutanol (900 mg, 45% yield) as a yellow oil. LCMS: [M+H] + =324.0.

[0296] Intermediate 4: (tert-butyl((2-(3-(3-hydroxy-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)(1-methylcyclobutyl)carbamate In a glove box, a solution of 3-(3-bromophenyl)-1-methyl-3-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutan-1-ol (150 mg, 0.47 mmol), tert-butyl(1-methylcyclobutyl)((3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)carbamate (204 mg, 0.51 mmol), cesium carbonate (455 mg, 1.40 mmol), and (2-dicyclohexylphosphino-2',6'-diisopropoxy-1,1'-biphenyl)[2-(2'-amino-1,1'biphenyl)]palladium(II) methanesulfonate (38.9 mg, 0.05 mmol, CAS 0747-10-1) in 1,4-dioxane (4 mL) was added. The mixture (No.: 1445085-77-7) was stirred at 110°C for 16 hours and concentrated under reduced pressure. The residue was purified by preparative TLC (solvent gradient: 10% methanol in dichloromethane) to give tert-butyl ((2-(3-(3-hydroxy-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)(1-methylcyclobutyl)carbamate (130 mg, 44% yield) as a yellow solid. LCMS [M+H] + =640.1.

[0297] Compounds 26 and 27 To a mixture of tert-butyl ((2-(3-(3-hydroxy-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)(1-methylcyclobutyl)carbamate (130 mg, 0.20 mmol) in dichloromethane (5 mL) was added trifluoroacetic acid (0.5 mL, 6.49 mmol). The mixture was stirred at 20 °C for 2 h and concentrated under reduced pressure. The residue was purified by RP-HPLC (45% to 75% ACN / (0.05% NH3H2O ​​in water + 10 mM NH4HCO3)) to give the tentatively assigned: 2-(3-((1s,3s)-3-hydroxy-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one (peak 1) (5 mg, 5% yield). 1 H NMR(400MHz, methanol-d4)δ 8.39(s,1H), 8.13(s,1H), 8.05(s,1H), 7.90(s,1H), 7.69(d,J=6.8Hz,1H), 7.53-7.41(m,1H), 7.17(d,J=7.2Hz,1H), 5.17(s,2H), 4.02(s ,2H), 3.40(s,3H), 3.24-3.21(m,2H), 2.94(d,J=12.8Hz,2H), 2.25-2.19(m,2H), 1.97-1.84(m,4H), 1.47(s,3H), 1.29(s,3H).LCMS[M+H] + =540.2. 2-(3-((1r,3r)-3-hydroxy-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one (peak 2) (5 mg, 5% yield). 1 H NMR(400MHz, methanol-d4)δ 8.28(s,1H), 8.13(s,1H), 8.10(s,1H)8.02(s,1H), 7.69(d,J=8.0Hz,1H), 7.49(t,J=8.0Hz,1H), 7.33(d,J=7.6Hz,1H), 5.16(s,2H), 3.8 9(s,2H), 3.46(s,3H), 3.21-3.14(m,2H), 3.12-3.04(m,2H), 2.17-2.07(m,2H), 1.92-1.78(m,4H), 1.40(s,3H), 1.30(s,3H).LCMS[M+H] + =540.2.

[0298] Example 25: Compounds 28 and 29 Compound 28 (2-(3-((1r,3r)-3-methoxy-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one), and Compound 29 (2-(3-((1s,3s)-3-hydroxy-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one) can be synthesized according to Scheme 24 (Figure 24).

[0299] Intermediate 2: (3-(1-(3-bromophenyl)-3-methoxy-3-methylcyclobutyl)-4-methyl-4H-1,2,4-triazole To a solution of 3-(3-bromophenyl)-1-methyl-3-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutanol (300 mg, 0.93 mmol) in N,N-dimethylacetamide (5 mL) was added sodium hydride (60%, 44.7 mg, 1.12 mmol) at 0° C. The mixture was stirred for 1 h, and then methyl iodide (0.09 mL, 1.40 mmol) was added. The reaction mixture was stirred at 25° C. for an additional 16 h and quenched by the addition of water (5 mL). The solution was concentrated under reduced pressure, and the residue was purified by preparative TLC (solvent gradient: 10% methanol in dichloromethane) to give 3-(1-(3-bromophenyl)-3-methoxy-3-methylcyclobutyl)-4-methyl-4H-1,2,4-triazole (200 mg, 64% yield) as a yellow oil. LCMS[M+H] + =336.3.

[0300] Intermediate 3: (tert-butyl((2-(3-(3-methoxy-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)(1-methylcyclobutyl)carbamate In a glove box, 3-(1-(3-bromophenyl)-3-methoxy-3-methylenecyclobutyl)-4-methyl-4H-1,2,4-triazole (200 mg, 0.59 mmol), tert-butyl(1-methylcyclobutyl)((3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)carbamate (261 mg, 0.65 mmol), cesium carbonate (581 mg, 1.78 mmol), and (2-dicyclohexylphosphino-2',6'-diisopropoxy-1,1'-biphenyl)[2-(2'-amino-1,1'biphenyl)]palladium(II) methanesulfonate (49.8 mg, 0.06 mmol, CAS The mixture (No.: 1445085-77-7) was stirred at 110° C. for 16 hours and concentrated under reduced pressure. The residue was purified by preparative TLC (solvent gradient: 10% methanol in dichloromethane) to give tert-butyl ((2-(3-(3-methoxy-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)(1-methylcyclobutyl)carbamate (180 mg, 46% yield) as a yellow oil. LCMS [M+H] + =654.3.

[0301] Compounds 28 and 29 A mixture of tert-butyl ((2-(3-(3-methoxy-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)(1-methylcyclobutyl)carbamate (180 mg, 0.28 mmol) and trifluoroacetic acid (0.68 mL, 8.79 mmol) in dichloromethane (5 mL) was stirred at 20° C. for 2 hours and concentrated under reduced pressure. The residue was purified by RP-HPLC (50% to 80% ACN / (0.05% NH3H2O+10 mM NH4HCO3 in water)) to give 2-(3-(3-methoxy-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one (50 mg, 33% yield).

[0302] The above racemate (50 mg, 0.09 mmol) was purified by chiral SFC using 0.1% ammonium hydroxide-40% ethanol-carbon dioxide (column = Daicel Chiralcel AD; column dimensions = 250 mm × 30 mm × 10 μm; detection wavelength = 220 nM; flow rate = 70 mL / min; run time = 4.0 min; column temperature = 25°C) to give the tentatively assigned: 2-(3-((1s,3s)-3-methoxy-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one (peak 1, retention time = 1.653 min) (22.7 mg, 45% yield). 1H NMR (400 MHz, methanol-d4) δ 8.40(s,1H), 8.09(s,1H), 8.02(s,1H), 7.95(s,1H), 7.68(d,J=8.0Hz,1 H), 7.47(t,J=8.0Hz,1H), 7.11(d,J=8.8Hz,1H), 5.15(s,2H), 3.89(s,2 H), 3.40(s,3H), 3.23(s,3H), 3.13-3.09(m,2H), 2.98-2.94(m,2H), 2.1 7-2.10(m,2H), 1.92-1.78(m,4H), 1.40(s,3H), 1.30(s,3H).LCMS[M+H] + =554.3. 2-(3-((1r,3r)-3-methoxy-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one (peak 2, retention time = 2.243 min) (11.9 mg, 23% yield). 1 H NMR (400 MHz, methanol-d4) δ 8.29(s,1H), 8.11(s,1H), 8.09(s,1H), 8.02(s,1H), 7.68(d,J=9.2Hz,1 H), 7.49(t,J=8.0Hz,1H), 7.29(d,J=6.8Hz,1H), 5.16(s,2H), 3.88(s,2 H), 3.44(s,3H), 3.24-3.20(m,2H), 3.20(s,3H), 2.95-2.91(m,2H), 2.1 2-2.07(m,2H), 1.91-1.78(m,4H), 1.39(s,3H), 1.32(s,3H).LCMS[M+H] + =554.3.

[0303] Example 26: Compounds 30 and 31 Compound 30 (2-(3-((1s,3s)-3-fluoro-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one) and compound 31 (2-(3-((1r,3r)-3-fluoro-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one) can be synthesized according to Scheme 25 (Figure 25).

[0304] Intermediate 2: (3-(1-(3-bromophenyl)-3-fluoro-3-methylcyclobutyl)-4-methyl-4H-1,2,4-triazole To a solution of 3-(3-bromophenyl)-1-methyl-3-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutanol (500 mg, 1.62 mmol) in dichloromethane (10 mL) was added diethylaminosulfur trifluoride (0.64 mL, 4.87 mmol) at 0° C. The mixture was stirred under nitrogen at 25° C. for 16 hours and quenched by the addition of saturated aqueous ammonium chloride solution (20 mL). The resulting solution was extracted with dichloromethane (3×50 ml). The combined organic layers were washed with brine (50 mL), dried, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (mobile phase: methanol / dichloromethane, gradient 0% to 4%) to give 3-(1-(3-bromophenyl)-3-fluoro-3-methylcyclobutyl)-4-methyl-4H-1,2,4-triazole (430 mg, 82% yield) as a colorless oil.

[0305] Intermediate 3: (tert-butyl((2-(3-(3-fluoro-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)(1-methylcyclobutyl)carbamate In a glove box, a solution of 3-(1-(3-bromophenyl)-3-fluoro-3-methylcyclopropyl)-4-methyl-4H-1,2,4-triazole (350 mg, 1.08 mmol), tert-butyl(1-methylcyclobutyl)((3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)carbamate (473 mg, 1.19 mmol), cesium carbonate (879 mg, 2.7 mmol), and (2-dicyclohexylphosphino-2',6'-diisopropoxy-1,1'-biphenyl)[2-(2'-amino-1,1'biphenyl)]palladium(II) methanesulfonate (72.2 mg, 0.09 mmol, CAS 0747-48-1) in 1,4-dioxane (10 mL) was added. The mixture (No.: 1445085-77-7) was stirred at 110°C for 16 hours and concentrated under reduced pressure. The residue was purified by silica gel chromatography (mobile phase: methanol / dichloromethane, gradient 0% to 4%) to give tert-butyl ((2-(3-(3-fluoro-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)(1-methylcyclobutyl)carbamate (300 mg, 43% yield) as a yellow oil. LCMS [M+H] + =642.3.

[0306] Compounds 30 and 31 To a mixture of tert-butyl ((2-(3-(3-fluoro-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-3-oxo-7-(trifluoromethyl)isoindolin-5-yl)methyl)(1-methylcyclobutyl)carbamate (300 mg, 0.47 mmol) in dichloromethane (5 mL) was added trifluoroacetic acid (0.68 mL, 8.79 mmol). The mixture was stirred at 20° C. for 2 hours and concentrated under reduced pressure. The residue was purified by RP-HPLC (55% to 85% ACN / (0.05% NH3H2O+10 mM NH4HCO3 in water)) to give 2-(3-(3-methoxy-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one (80 mg, 21% yield).

[0307] The above racemate (80 mg, 0.15 mmol) was purified by chiral SFC using 0.1% ammonium hydroxide-35% ethanol-carbon dioxide (Column = Daicel Chiralcel AD; Column dimensions = 250 mm × 30 mm × 10 μm; Detection wavelength = 220 nM; Flow rate = 70 mL / min; Run time = 4.0 min; Column temperature = 25°C) to give: 2-(3-((1r,3r)-3-fluoro-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one (peak 1, retention time = 1.608 min) (25.2 mg, 32% yield). 1H NMR (400 MHz, methanol-d4) δ 8.41(s,1H), 8.14(s,1H), 8.07(s,1H), 7.96(s,1H), 7.68(d,J=8.4Hz, 1H), 7.51(t,J=8.0Hz,1H), 7.19(d,J=7.6Hz,1H), 5.19(s,2H), 4.07(s, 2H), 3.39(s,3H), 3.39-3.35(m,2H), 3.21-3.15(m,2H), 2.27-2.21(m, 2H), 2.01-1.88(m,4H), 1.51(s,3H), 1.43(d,J=22.4Hz,3H).LCMS[M+H] + =542.4. 2-(3-((1s,3s)-3-fluoro-3-methyl-1-(4-methyl-4H-1,2,4-triazol-3-yl)cyclobutyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one (peak 2, retention time = 2.244 min) (22.3 mg, 28% yield). 1 H NMR (400 MHz, methanol-d4) δ 8.31(s,1H), 8.13(s,1H), 8.10(s,1H), 8.06(s,1H), 7.70(d,J=8.4Hz, 1H), 7.51(t,J=8.0Hz,1H), 7.30(d,J=7.6Hz,1H), 5.19(s,2H), 4.02(s, 2H), 3.43(s,3H), 3.41-3.34(m,2H), 3.19-3.14(m,2H), 2.23-2.18(m, 2H), 1.98-1.88(m,4H), 1.48(s,3H), 1.45(d,J=20.4Hz,3H).LCMS[M+H] + =542.3.

[0308] Example 27: Compounds 32 and 33 Compound 32 (S)-2-(3-(azetidin-1-yl(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one and compound 33 (R)-2-(3-(azetidin-1-yl(4-methyl-4H-1,2,4-triazol-3-yl)methyl)phenyl)-6-(((1-methylcyclobutyl)amino)methyl)-4-(trifluoromethyl)isoindolin-1-one can be synthesized according to Scheme 26 (Figure 26).

[0309] Intermediate 2: ((3-bromophenyl)(4-methyl-4H-1,2,4-triazol-3-yl)methanol Under nitrogen, n-butyllithium (2.5 M in hexanes, 6.5 mL, 16.2 mmol) was added to a solution of 4-methyl-4H-1,2,4-triazole (1.35 g, 16.2 mmol) in 1,2-dimethoxyethane (100 mL) at −50° C. over 5 minutes. The resulting mixture was stirred at −50° C. for 1.5 hou...

Claims

1. Formula (I) [In the formula: Q is a 5-membered heteroaryl optionally substituted with one or more alkyl, cycloalkyl, hydroxyalkyl, or haloalkyl groups; Y 1 and Y 2 is independently CH, CF, or N; J is C(R 3 ) (R 4 ) where: R 3 , R 4 are independently: H, halogen, CN, OH, amino, and LR 2a and L is selected from O, NR 0 , CHR 0 , C(═O), or a bond; R 0 is H or alkyl; R 2a is selected from alkyl, alkenyl, alkynyl, alkylcarboxy, cyanoalkyl, aminoalkyl, hydroxyalkyl, haloalkyl, and a 3- to 14-membered ring moiety; R 3 and R 4 is not H; or R 3 and R 4 together with the carbon atom to which they are both attached form a 3- to 14-membered ring moiety; R 3 Or R 4 When R is alkyl, haloalkyl, or hydroxyalkyl, 3 Or R 4 is optionally substituted with a 3- to 14-membered ring moiety; R 3 Or R 4 is or is substituted by a 3- to 14-membered ring moiety, or R 3 and R 4 When taken together are a 3- to 14-membered ring moiety, the ring moiety is: selected from monocyclic rings, fused bicyclic ring systems, bridged bicyclic ring systems, and spirocyclic ring systems; The ring portion is: Halogen, CN, amino, oxo, carbenyl, OH, or L 0 R 2b and L 0 is CH 2 , C(=O), NH, O, S, S(=O), S(=O) 2 or a bond, R 2b is alkyl, cycloalkyl, heterocyclyl, alkenyl, alkoxy, hydroxyalkyl, haloalkyl, cyanoalkyl, and aminoalkyl; is saturated or contains 1 or 2 endocyclic double bonds or is aryl; is carbocyclic, heterocyclic, or heteroaryl; and When the ring moiety is heterocyclic or heteroaryl, it contains 1, 2, or 3 ring atoms independently selected from O, N, and S; R 5 is H, halo, or L 1 -R 10 is selected from L 1 -N(R 11 )-, -C(=O)N(R 11 ) -, O, S, carbonyl, or a bond; R 10 and R 11 is independently H, alkyl, cycloalkyl, alkenyl, alkynyl, aryl, heteroaryl, or heterocyclyl; R 10 and R 11 When any of the above is not H, R 10 Or R 11 is optionally substituted with one or more groups selected from halo, CN, amino, oxo, OH, alkoxy, alkyl, perhaloalkyl, haloalkyl, heterocyclyl, aryl, and heteroaryl, or R 10 and R 11 together form a cycloalkyl or heterocyclyl ring, a spirocyclic ring, a fused bicyclic ring, or a bridged bicyclic ring; R 10 and R 11taken together form a ring which may be substituted with one or more groups selected from halo, CN, amino, oxo, carbenyl, OH, alkoxy, alkyl, perhaloalkyl, or haloalkyl; R 1 is H, halo, haloalkyl, or cycloalkyl; Z is -L 2a N.R. 7 R 8 Or -L 2b CyN-R 7 is: CyN is a 3-8 membered cycloaminoalkyl ring; R 7 is attached to N; L 2a H -C(H)R 6a -, -C(=O)-, or a bond; L 2b is -O-, -N(R 6b )-, -C(H)R 6b -, -C(=O)-, or a bond; R 6a = H, alkyl, cycloalkyl, haloalkyl or hydroxyalkyl; R 6b = H or alkyl; R 7 and R 8 is independent of L 3 R 9 is: L 3 = -(C(H)R 10 ) n -, -(C(H)R 10 ) n O- or a bond, and n=1 or 2; R 10 is selected from H and alkyl; R 9is selected from H, alkyl, haloalkyl, perhaloalkyl, hydroxyalkyl, aminoalkyl, cycloalkyl, hydroxyalkyl, alkoxyalkyl, alkylalkanoate, heterocyclyl, spirocyclyl ring systems, fused ring systems, bicyclic ring systems, 5- or 6-membered aromatic heterocycles, or 3- to 10-membered fused aromatic heterocycles, and bridged bicyclic rings; Z=CyNR 7 or R 7 Or R 8 is a cycloalkyl, heterocyclyl, spirocyclyl, fused bicyclic, bridged bicyclic ring, 5- or 6-membered aromatic heterocycle, or 3- to 10-membered fused aromatic heterocyclic ring system, said ring or ring system or CyN is optionally substituted with one or more groups selected from sulfonyl, halo, hydroxyl, alkoxy, alkyl, cycloalkyl, alkoxyalkyl, carbenyl, alkenyl, hydroxyalkyl, cyano, carboxyalkyl, or haloalkyl; or R 7 and R 8 together with the nitrogen atom to which they are both attached form a 3-8 membered ring moiety selected from monocyclic rings, fused bicyclic rings, bridged bicyclic rings, and spirocyclic rings, the ring moiety being selected from: optionally substituted with one or more groups independently selected from sulfonyl, cyano, halo, hydroxyl, alkoxy, alkyl, cycloalkyl, alkoxyalkyl, alkenyl, hydroxyalkyl, oxo, carbenyl, carboxyalkyl, or haloalkyl; The ring portion is R 7 and R 8 may contain, in addition to the nitrogen atom to which is attached, one or more ring atoms selected from N, O, and S; However, Y 1 and Y 2 When both are CH, R 5 = H, R 1 =CF 3 and Q is 2-methyltriazol-1-yl: R 7 and R 8When both of them are taken together with the nitrogen atom to which they are attached to form a 3-substituted cyclohexaminyl, R 3 and R 4 taken together are not cyclobutyl, oxetan-4-yl, spiro[2.3]hexan-5-yl, or trisubstituted cyclobutyl, or J is not C(H)(trisubstituted cyclobutyl); R 7 and R 8 When both of them are taken together with the nitrogen atom to which they are attached to form a 3-substituted morpholinyl, R 3 and R 4 taken together are not 3-substituted cyclobutyl or spiro[2.3]hexan-5-yl, or J is not C(H)(3-substituted cyclobutyl). or an enantiomer, diastereomer, or a pharma- ceutically acceptable salt or solvate thereof.

2. R 5 The compound of claim 1 , wherein

3. R 5 3. The compound of claim 1 or 2, wherein is selected from: alkyl, alkoxy, alkylamino, cycloalkylamino, cycloalkyl, and cycloalkyloxy, any of which may be substituted with one or more groups independently selected from halo, alkyl, cyano, hydroxyl, amino, and alkoxy.

4. Y 1 = Y 2 4. The compound according to claim 1 , wherein:

5. Y 1 5. The compound according to claim 1 , wherein: =N.

6. R 1 =CF 3 6. The compound according to claim 1 , wherein

7. 7. The compound of any one of claims 1 to 6, wherein Q is 2-methyltriazol-1-yl or imidazolyl.

8. The compound of any one of claims 1 to 7, wherein Q is 2-methyltriazol-1-yl.

9. Z is -C(H)R 6 N.R. 7 R 8 is: R 6 is H or methyl; R 7 and R 8 The compound according to any one of claims 1 to 8, wherein: is taken together with the nitrogen atom to which they are both attached to form a piperidinyl or piperazinyl ring, which may be substituted with alkyl.

10. Z is -C(H)R 6 N.R. 7 R 9 is: R 6 is H or methyl; R 7 is H; R 8 The compound according to any one of claims 1 to 9, wherein is cyclobutyl optionally substituted with alkyl.

11. R 3 is H or OH, R 4 is selected from cyclobut-1-amino, 3-oxetanyl, cyclopropyloxy, cyclobutyloxy, and methoxy; R 4 11. The compound of claim 1, wherein: is optionally substituted with one or more groups selected from halo, alkyl, hydroxyl, and alkoxyl.

12. R 3 and R 4 together with the carbon atom to which they are both attached, 12. The compound of any one of claims 1 to 11, forming a 3-8 membered ring moiety selected from cyclobutyl, oxetanyl, cyclobutenyl, spiro[3.3]hept-2-yl, and 2-oxaspiro[3.]hept-6-yl, which ring moiety is optionally substituted with one or more groups independently selected from halo, carbenyl, oxo, hydroxyl, cyano, alkyl, and alkoxy.

13. R 3 and R 4 and the carbon atom to which they are both attached together form an oxetan-3-yl ring or a cyclobutyl ring.

14. R 3 and R 4 together with the carbon atom to which they are both attached, methyl, ethyl, methoxy, acetyl, chloro, fluoro, fluoromethyl, difluoromethoxy, trifluoromethoxy, methoxy-d 3 13. The compound of claim 1, wherein the cycloalkyl ring is substituted with one or more instances of cycloalkyl, cycloalkylmethyl, or cyano.

15. The following compounds of Table 1 herein: Compound 2; Compound 9; Compound 22; Compound 23; Compound 24; Compound 36; Compound 41; Compound 52; Compound 54; Compound 65; Compound 70; Compound 92; Compound 94; Compound 95; Compound 101; Compound 102; Compound 106; Compound 108; Compound 117; Compound 129; Compound 130; Compound 137; Compound 138; Compound 150; Compound 164; Compound 170; Compound 185; Compound 270; Compound 272; Compound 273; Compound 312; Compound 320; Compound 334; Compound 335; Compound 342; Compound 347; Compound 351; Compound 359; Compound 361; Compound 362; Compound 364; Compound 365; Compound 372; Compound 373; Compound 374; Compound 375; Compound 380; Compound 404; Compound 416; Compound 421; Compound 426; Compound 427; Compound 446; Compound 447; Compound 451; Compound 454; Compound 455; Compound 459 2. The compound of claim 1 selected from the group consisting of:

16. 20. A method of treating cancer, comprising administering to a subject in need thereof a compound of any one of claims 1 to 15.

17. 20. Use of a compound according to any one of claims 1 to 15 for the manufacture of a medicament for treating certain cancers.

Citation Information

Patent Citations

  • Substituted benzyl-triazole compounds for CBL-b inhibition, and further uses thereof

    WO2020264398A1

  • CBL inhibitors and compositions for expansion of immune cells

    WO2021061870A1